<!DOCTYPE html>
<html><head><meta charset="UTF-8">
<title>Earnings Call ë²ˆì—­</title>
<style>
    body { font-family: Arial; margin: 40px; background-color: #fdfdfd; }
    h1 { text-align: center; }
    h2 { margin-top: 50px; color: #003366; }
    h3 { color: #333; }
    table { border: 1px solid #ddd; width: 100%; border-collapse: collapse; }
    th { background: #f0f0f0; padding: 10px; border-bottom: 2px solid #ccc; }
    td { padding: 10px; border-bottom: 1px dotted #ccc; vertical-align: top; }
    p { line-height: 1.6; }
    hr { margin: 50px 0; border: none; border-top: 1px solid #ccc; }
    .back-button {
        display: inline-block;
        background-color: #5f5f5f;
        color: white;
        padding: 10px 16px;
        border-radius: 6px;
        text-decoration: none;
        font-weight: 500;
        box-shadow: 0 2px 6px rgba(0,0,0,0.1);
        margin-bottom: 30px;
    }
</style>
</head><body>
<a href="../../index.html" class="back-button">â†</a>
<h1>ğŸ“„ Earnings Call Transcript ë²ˆì—­ ê²°ê³¼</h1>

    <h2>ğŸ“Š Presentation</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td></td><td></td></tr>
<tr><td>Medtronic plc (MDT) Q2 2026 Earnings Call November 18, 2025 8:00 AM EST<br><br>Company Participants<br><br>Ryan Weispfenning - VP & Head of Investor Relations<br>Geoffrey Martha - Chairman of the Board & CEO<br>Thierry Pieton - Executive VP & CFO<br>Laura Mauri - Senior VP and Chief Scientific & Medical Officer<br><br>Conference Call Participants<br><br>Patrick Wood - Morgan Stanley, Research Division<br>Travis Steed - BofA Securities, Research Division<br>Vijay Kumar - Evercore ISI Institutional Equities, Research Division<br>Robert Marcus - JPMorgan Chase & Co, Research Division<br>Larry Biegelsen - Wells Fargo Securities, LLC, Research Division<br>Shagun Singh Chadha - RBC Capital Markets, Research Division<br>Pito Chickering - Deutsche Bank AG, Research Division<br><br>Presentation<br><br>Ryan Weispfenning<br>VP & Head of Investor Relations<br><br>Hello, everyone, and thanks for joining us today for our fiscal '26 second quarter video earnings webcast.</td><td>ë©”ë“œíŠ¸ë¡œë‹‰ plc (MDT) 2026 íšŒê³„ì—°ë„ 2ë¶„ê¸° ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œ 2025ë…„ 11ì›” 18ì¼ ì˜¤ì „ 8ì‹œ (ë¯¸êµ­ ë™ë¶€ í‘œì¤€ì‹œ)<br><br>íšŒì‚¬ ì°¸ì„ì<br><br>Ryan Weispfenning - íˆ¬ìì ê´€ê³„ ë¶€ì‚¬ì¥ ê²¸ ì±…ì„ì<br>Geoffrey Martha - ì´ì‚¬íšŒ ì˜ì¥ ê²¸ CEO<br>Thierry Pieton - ì „ë¬´ì´ì‚¬ ê²¸ CFO<br>Laura Mauri - ìˆ˜ì„ ë¶€ì‚¬ì¥ ê²¸ ìµœê³  ê³¼í•™ ë° ì˜ë£Œ ì±…ì„ì<br><br>ì»¨í¼ëŸ°ìŠ¤ ì½œ ì°¸ì„ ì• ë„ë¦¬ìŠ¤íŠ¸<br><br>Patrick Wood - Morgan Stanley, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Travis Steed - BofA Securities, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Vijay Kumar - Evercore ISI Institutional Equities, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Robert Marcus - JPMorgan Chase & Co, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Larry Biegelsen - Wells Fargo Securities, LLC, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Shagun Singh Chadha - RBC Capital Markets, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Pito Chickering - Deutsche Bank AG, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br><br>ë°œí‘œ<br><br>Ryan Weispfenning<br>íˆ¬ìì ê´€ê³„ ë¶€ì‚¬ì¥ ê²¸ ì±…ì„ì<br><br>ì•ˆë…•í•˜ì„¸ìš”, ì—¬ëŸ¬ë¶„. 2026 íšŒê³„ì—°ë„ 2ë¶„ê¸° ë¹„ë””ì˜¤ ì‹¤ì  ì›¹ìºìŠ¤íŠ¸ì— ì°¸ì—¬í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>I'm Ryan Weispfenning, Vice President and Head of Medtronic Investor Relations. Joining me here today are Geoff Martha, Chairman and Chief Executive Officer; and Thierry Pieton, Chief Financial Officer. Geoff and Thierry will provide comments on the results of our second quarter, which ended on October 24, 2025, and our outlook for the remainder of fiscal year '26. After our prepared remarks, we'll take questions from the sell-side analysts that cover the company. Today's program should last about an hour. Earlier this morning, we issued a press release discussing our results and containing several financial schedules.</td><td>ì €ëŠ” ë©”ë“œíŠ¸ë¡œë‹‰ íˆ¬ìì ê´€ê³„ ë‹´ë‹¹ ë¶€ì‚¬ì¥ ê²¸ ì±…ì„ìì¸ ë¼ì´ì–¸ ì™€ì´ìŠ¤í˜ë‹ì…ë‹ˆë‹¤. ì˜¤ëŠ˜ ì €ì™€ í•¨ê»˜ ì œí”„ ë§ˆì‚¬ íšŒì¥ ê²¸ ìµœê³ ê²½ì˜ìì™€ í‹°ì—ë¦¬ í”¼ì—í†µ ìµœê³ ì¬ë¬´ì±…ì„ìê°€ ì°¸ì„í–ˆìŠµë‹ˆë‹¤. ì œí”„ì™€ í‹°ì—ë¦¬ëŠ” 2025ë…„ 10ì›” 24ì¼ì— ì¢…ë£Œëœ 2ë¶„ê¸° ì‹¤ì ê³¼ 2026 íšŒê³„ì—°ë„ ë‚¨ì€ ê¸°ê°„ì— ëŒ€í•œ ì „ë§ì— ëŒ€í•´ ë§ì”€ë“œë¦´ ì˜ˆì •ì…ë‹ˆë‹¤. ì¤€ë¹„ëœ ë°œí‘œê°€ ëë‚œ í›„, ë‹¹ì‚¬ë¥¼ ë‹´ë‹¹í•˜ëŠ” ì…€ì‚¬ì´ë“œ ì• ë„ë¦¬ìŠ¤íŠ¸ë“¤ì˜ ì§ˆë¬¸ì„ ë°›ê² ìŠµë‹ˆë‹¤. ì˜¤ëŠ˜ í”„ë¡œê·¸ë¨ì€ ì•½ 1ì‹œê°„ ì •ë„ ì†Œìš”ë  ì˜ˆì •ì…ë‹ˆë‹¤. ì˜¤ëŠ˜ ì•„ì¹¨ ì¼ì° ë‹¹ì‚¬ëŠ” ì‹¤ì ì„ ë…¼ì˜í•˜ê³  ì—¬ëŸ¬ ì¬ë¬´ ì¼ì •í‘œë¥¼ í¬í•¨í•œ ë³´ë„ìë£Œë¥¼ ë°œí‘œí–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We also posted an earnings presentation that provides additional details on our performance. The presentation can be accessed in our earnings press release or on our website at investorrelations.medtronic.com. During today's program, many of the statements we make may be considered forward-looking statements, and actual results may differ materially from those projected in any forward-looking statement. Additional information concerning factors that could cause our actual results to differ is contained in our periodic reports and other filings that we make with the SEC, and we do not undertake to update any forward-looking statement.</td><td>ì‹¤ì  ë°œí‘œ í”„ë ˆì  í…Œì´ì…˜ë„ ê²Œì‹œí–ˆìœ¼ë©°, ì´ëŠ” ë‹¹ì‚¬ì˜ ì„±ê³¼ì— ëŒ€í•œ ì¶”ê°€ ì„¸ë¶€ ì •ë³´ë¥¼ ì œê³µí•©ë‹ˆë‹¤. í”„ë ˆì  í…Œì´ì…˜ì€ ì‹¤ì  ë³´ë„ìë£Œ ë˜ëŠ” ë‹¹ì‚¬ ì›¹ì‚¬ì´íŠ¸ investorrelations.medtronic.comì—ì„œ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì˜¤ëŠ˜ í”„ë¡œê·¸ë¨ ì¤‘ ë‹¹ì‚¬ê°€ í•˜ëŠ” ë§ì€ ë°œì–¸ë“¤ì€ ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ (forward-looking statements)ë¡œ ê°„ì£¼ë  ìˆ˜ ìˆìœ¼ë©°, ì‹¤ì œ ê²°ê³¼ëŠ” ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ ì—ì„œ ì˜ˆìƒí•œ ê²ƒê³¼ ì¤‘ëŒ€í•˜ê²Œ ë‹¤ë¥¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì‹¤ì œ ê²°ê³¼ê°€ ë‹¬ë¼ì§ˆ ìˆ˜ ìˆëŠ” ìš”ì¸ë“¤ì— ê´€í•œ ì¶”ê°€ ì •ë³´ëŠ” ë‹¹ì‚¬ê°€ SECì— ì œì¶œí•˜ëŠ” ì •ê¸° ë³´ê³ ì„œ ë° ê¸°íƒ€ ì„œë¥˜ì— í¬í•¨ë˜ì–´ ìˆìœ¼ë©°, ë‹¹ì‚¬ëŠ” ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ ì„ ì—…ë°ì´íŠ¸í•  ì˜ë¬´ë¥¼ ì§€ì§€ ì•ŠìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Unless we say otherwise, all comparisons are on a year-over-year basis, and revenue comparisons are made on an organic basis, which excludes the impact of foreign exchange, second quarter revenue in the current and prior year from our divestiture this quarter of the Dutch Obesity Clinic, also known as NOK, and second quarter revenue in the current and prior year reported as other. References to sequential revenue changes compared to the first quarter of fiscal '26 and are made on an as-reported basis. All share references are on a revenue and year-over-year basis and compare our second fiscal quarter to our competitors' third calendar quarter.</td><td>ë‹¬ë¦¬ ëª…ì‹œí•˜ì§€ ì•ŠëŠ” í•œ, ëª¨ë“  ë¹„êµëŠ” ì „ë…„ ë™ê¸° ëŒ€ë¹„ì´ë©°, ë§¤ì¶œ ë¹„êµëŠ” ìœ ê¸°ì  ê¸°ì¤€(organic basis)ìœ¼ë¡œ ì´ë£¨ì–´ì§‘ë‹ˆë‹¤. ì´ëŠ” ì™¸í™˜ ì˜í–¥, ê¸ˆë²ˆ ë¶„ê¸°ì— ë§¤ê°í•œ ë„¤ëœë€ë“œ ë¹„ë§Œ í´ë¦¬ë‹‰(Dutch Obesity Clinic, NOKë¡œë„ ì•Œë ¤ì§)ì˜ ë‹¹ê¸° ë° ì „ë…„ë„ 2ë¶„ê¸° ë§¤ì¶œ, ê·¸ë¦¬ê³  ê¸°íƒ€ í•­ëª©ìœ¼ë¡œ ë³´ê³ ëœ ë‹¹ê¸° ë° ì „ë…„ë„ 2ë¶„ê¸° ë§¤ì¶œì„ ì œì™¸í•œ ê²ƒì…ë‹ˆë‹¤. ìˆœì°¨ì  ë§¤ì¶œ ë³€ë™ì€ íšŒê³„ì—°ë„ 26ë…„ 1ë¶„ê¸° ëŒ€ë¹„ì´ë©° ë³´ê³  ê¸°ì¤€(as-reported basis)ìœ¼ë¡œ ì‘ì„±ë˜ì—ˆìŠµë‹ˆë‹¤. ëª¨ë“  ì ìœ ìœ¨ ì–¸ê¸‰ì€ ë§¤ì¶œ ê¸°ì¤€ ì „ë…„ ë™ê¸° ëŒ€ë¹„ì´ë©°, ë‹¹ì‚¬ì˜ íšŒê³„ì—°ë„ 2ë¶„ê¸°ë¥¼ ê²½ìŸì‚¬ì˜ ì—­ë…„ ê¸°ì¤€ 3ë¶„ê¸°ì™€ ë¹„êµí•œ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Reconciliations of all non-GAAP financial measures can be found in our earnings press release or on our website at investorrelations.medtronic.com. And finally, our EPS guidance does not include any charges or gains that would be reported as non-GAAP adjustments to earnings during the fiscal year. With that, over to you, Geoff. Geoffrey Martha<br>Chairman of the Board & CEO<br><br>Okay. Thanks, Ryan, and hello, everyone. Last quarter, I told you that Medtronic is on the cusp of an acceleration in our financial results and our strategy. Well, today, I'm pleased to share that because of our organization's relentless focus, that acceleration is indeed underway. We delivered a strong second quarter.</td><td>ëª¨ë“  ë¹„-GAAP ì¬ë¬´ ì§€í‘œì˜ ì¡°ì • ë‚´ì—­ì€ ë‹¹ì‚¬ì˜ ì‹¤ì  ë³´ë„ìë£Œ ë˜ëŠ” ì›¹ì‚¬ì´íŠ¸ investorrelations.medtronic.comì—ì„œ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ, ë‹¹ì‚¬ì˜ ì£¼ë‹¹ìˆœì´ìµ(EPS) ê°€ì´ë˜ìŠ¤ì—ëŠ” íšŒê³„ì—°ë„ ì¤‘ ë¹„-GAAP ì¡°ì • í•­ëª©ìœ¼ë¡œ ë³´ê³ ë  ë¹„ìš©ì´ë‚˜ ì´ìµì´ í¬í•¨ë˜ì–´ ìˆì§€ ì•ŠìŠµë‹ˆë‹¤. ê·¸ëŸ¼ Geoffì—ê²Œ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.<br><br>Geoffrey Martha<br>ì´ì‚¬íšŒ ì˜ì¥ ê²¸ ìµœê³ ê²½ì˜ì<br><br>ë„¤, ê°ì‚¬í•©ë‹ˆë‹¤, Ryan. ê·¸ë¦¬ê³  ì—¬ëŸ¬ë¶„ ì•ˆë…•í•˜ì‹­ë‹ˆê¹Œ. ì§€ë‚œ ë¶„ê¸°ì— ì €ëŠ” Medtronicì´ ì¬ë¬´ ì‹¤ì ê³¼ ì „ëµ ì¸¡ë©´ì—ì„œ ê°€ì†í™”ì˜ ì „í™˜ì ì— ìˆë‹¤ê³  ë§ì”€ë“œë ¸ìŠµë‹ˆë‹¤. ì˜¤ëŠ˜ ì €ëŠ” ìš°ë¦¬ ì¡°ì§ì˜ ëŠì„ì—†ëŠ” ì§‘ì¤‘ ë•ë¶„ì— ê·¸ ê°€ì†í™”ê°€ ì‹¤ì œë¡œ ì§„í–‰ ì¤‘ì„ì„ ê¸°ì˜ê²Œ ê³µìœ í•˜ê³ ì í•©ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ê°•ë ¥í•œ 2ë¶„ê¸° ì‹¤ì ì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Both our revenue and EPS beat expectations. Looking across our business, procedure volumes and end markets are robust, and we're bringing Medtronic's full capabilities to bear as we launch innovative technologies and execute ahead of plan in some of the most attractive and fast-growing end markets in med-tech. We're glad to be able to raise our revenue growth and EPS guidance for the full year on the back of this building progress. This quarter, we accelerated our growth with significant contributions from our cardiac ablations business as promised. Looking ahead, there's even more that Medtronic is capable of.</td><td>ìš°ë¦¬ì˜ ë§¤ì¶œê³¼ ì£¼ë‹¹ìˆœì´ìµ ëª¨ë‘ ì‹œì¥ ì˜ˆìƒì¹˜ë¥¼ ìƒíšŒí–ˆìŠµë‹ˆë‹¤. ì‚¬ì—… ì „ë°˜ì„ ì‚´í´ë³´ë©´, ì‹œìˆ  ê±´ìˆ˜ì™€ ìµœì¢… ì‹œì¥ì´ ê²¬ì¡°í•˜ë©°, ìš°ë¦¬ëŠ” ë©”ë“œí…Œí¬ ì—…ê³„ì—ì„œ ê°€ì¥ ë§¤ë ¥ì ì´ê³  ë¹ ë¥´ê²Œ ì„±ì¥í•˜ëŠ” ì‹œì¥ì—ì„œ í˜ì‹ ì ì¸ ê¸°ìˆ ì„ ì¶œì‹œí•˜ê³  ê³„íšë³´ë‹¤ ì•ì„œ ì‹¤í–‰í•˜ë©´ì„œ ë©”ë“œíŠ¸ë¡œë‹‰ì˜ ëª¨ë“  ì—­ëŸ‰ì„ ì´ë™ì›í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì§„ì „ì„ ë°”íƒ•ìœ¼ë¡œ ì—°ê°„ ë§¤ì¶œ ì„±ì¥ë¥ ê³¼ ì£¼ë‹¹ìˆœì´ìµ ê°€ì´ë˜ìŠ¤ë¥¼ ìƒí–¥ ì¡°ì •í•  ìˆ˜ ìˆê²Œ ë˜ì–´ ê¸°ì©ë‹ˆë‹¤. ì´ë²ˆ ë¶„ê¸°ì—ëŠ” ì•½ì†í•œ ëŒ€ë¡œ ì‹¬ì¥ ì ˆì œìˆ  ì‚¬ì—…ì˜ ìƒë‹¹í•œ ê¸°ì—¬ë¡œ ì„±ì¥ì„ ê°€ì†í™”í–ˆìŠµë‹ˆë‹¤. ì•ìœ¼ë¡œ ë©”ë“œíŠ¸ë¡œë‹‰ì´ í•  ìˆ˜ ìˆëŠ” ì¼ì€ í›¨ì”¬ ë” ë§ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We're positioning ourselves for even greater acceleration in revenue growth in the back half of the year and beyond. And our momentum is fueled by our enterprise growth drivers, including our PFA franchise for Afib, Symplicity for hypertension, Hugo and soft tissue robotics and Altaviva for incontinence. Look, these are game changers, and they'll power our trajectory. And at this pivotal inflection point in our growth journey, we recognize the need to capitalize on the incredible market opportunities before us. So we've scaled manufacturing to support our acceleration. And this quarter, we took the opportunity to increase OpEx investments to support our revenue growth momentum.</td><td>ìš°ë¦¬ëŠ” í•˜ë°˜ê¸°ì™€ ê·¸ ì´í›„ ë”ìš± ê°•ë ¥í•œ ë§¤ì¶œ ì„±ì¥ ê°€ì†í™”ë¥¼ ìœ„í•œ ì…ì§€ë¥¼ êµ¬ì¶•í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ìš°ë¦¬ì˜ ëª¨ë©˜í…€ì€ ì‹¬ë°©ì„¸ë™ ì¹˜ë£Œë¥¼ ìœ„í•œ PFA í”„ëœì°¨ì´ì¦ˆ, ê³ í˜ˆì•• ì¹˜ë£Œë¥¼ ìœ„í•œ Symplicity, ì—°ì¡°ì§ ë¡œë´‡ìˆ˜ìˆ ì„ ìœ„í•œ Hugo, ê·¸ë¦¬ê³  ìš”ì‹¤ê¸ˆ ì¹˜ë£Œë¥¼ ìœ„í•œ Altavivaë¥¼ í¬í•¨í•œ ê¸°ì—… ì„±ì¥ ë™ë ¥ì— ì˜í•´ ì¶”ì§„ë˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ê²ƒë“¤ì€ ê²Œì„ ì²´ì¸ì €ì´ë©°, ìš°ë¦¬ì˜ ì„±ì¥ ê¶¤ë„ë¥¼ ì´ëŒì–´ê°ˆ ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ìš°ë¦¬ ì„±ì¥ ì—¬ì •ì˜ ì´ ì¤‘ìš”í•œ ë³€ê³¡ì ì—ì„œ, ìš°ë¦¬ëŠ” ëˆˆì•ì— ìˆëŠ” ë†€ë¼ìš´ ì‹œì¥ ê¸°íšŒë¥¼ í™œìš©í•  í•„ìš”ì„±ì„ ì¸ì‹í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ìš°ë¦¬ëŠ” ê°€ì†í™”ë¥¼ ë’·ë°›ì¹¨í•˜ê¸° ìœ„í•´ ì œì¡° ì—­ëŸ‰ì„ í™•ëŒ€í–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ë²ˆ ë¶„ê¸°ì— ìš°ë¦¬ëŠ” ë§¤ì¶œ ì„±ì¥ ëª¨ë©˜í…€ì„ ì§€ì›í•˜ê¸° ìœ„í•´ ìš´ì˜ë¹„ íˆ¬ìë¥¼ ëŠ˜ë¦´ ê¸°íšŒë¥¼ ê°€ì¡ŒìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We did all this while still delivering outsized EPS growth relative to our guidance. Overall, we've shifted to a growth mindset. Besides our organic programs, we're focused on pursuing tuck-in M&A and executing strategic portfolio management. Now let's get into the details on our enterprise growth drivers. One of them powered our growth acceleration this quarter. And together, all of them will fuel our total company revenue growth in the quarters ahead. In cardiac ablation, our PFA franchise is generating just a ton of momentum. We grew 71%, which is a strong acceleration from last quarter's nearly 50% CAS growth.</td><td>ì´ ëª¨ë“  ê²ƒì„ ë‹¬ì„±í•˜ë©´ì„œë„ ê°€ì´ë˜ìŠ¤ ëŒ€ë¹„ ë†’ì€ EPS ì„±ì¥ì„ ì‹¤í˜„í–ˆìŠµë‹ˆë‹¤. ì „ë°˜ì ìœ¼ë¡œ ìš°ë¦¬ëŠ” ì„±ì¥ ë§ˆì¸ë“œë¡œ ì „í™˜í–ˆìŠµë‹ˆë‹¤. ìœ ê¸°ì  í”„ë¡œê·¸ë¨ ì™¸ì—ë„ ì†Œê·œëª¨ M&A ì¶”ì§„ê³¼ ì „ëµì  í¬íŠ¸í´ë¦¬ì˜¤ ê´€ë¦¬ ì‹¤í–‰ì— ì§‘ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ì œ ìš°ë¦¬ì˜ ê¸°ì—… ì„±ì¥ ë™ë ¥ì— ëŒ€í•œ ì„¸ë¶€ ì‚¬í•­ì„ ì‚´í´ë³´ê² ìŠµë‹ˆë‹¤. ê·¸ ì¤‘ í•˜ë‚˜ê°€ ì´ë²ˆ ë¶„ê¸° ì„±ì¥ ê°€ì†í™”ë¥¼ ê²¬ì¸í–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ë“¤ ëª¨ë‘ê°€ í–¥í›„ ë¶„ê¸°ì— ì „ì‚¬ ë§¤ì¶œ ì„±ì¥ì„ ì´‰ì§„í•  ê²ƒì…ë‹ˆë‹¤. ì‹¬ì¥ ì ˆì œìˆ  ë¶„ì•¼ì—ì„œ ìš°ë¦¬ì˜ PFA í”„ëœì°¨ì´ì¦ˆëŠ” ì—„ì²­ë‚œ ëª¨ë©˜í…€ì„ ë§Œë“¤ì–´ë‚´ê³  ìˆìŠµë‹ˆë‹¤. ì§€ë‚œ ë¶„ê¸° ê±°ì˜ 50%ì— ë‹¬í–ˆë˜ CAS ì„±ì¥ë¥ ì—ì„œ í¬ê²Œ ê°€ì†í™”ë˜ì–´ 71% ì„±ì¥í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>This is the highest growth rate of any company in this large and fast-growing space. We're winning share as our PFA franchise grew over 300% in the U.S. as well as in international markets. This was based on the strength of our Affera mapping system and our Sphere-9 dual energy and high-density mapping catheter. Look, physicians tell us that they appreciate not only the shorter procedure times that they're seeing with Affera, but increasingly, they're calling out its outstanding durability as well. And demand continues to be extremely high as we hear repeatedly from customers that they want to purchase additional Affera systems to expand into even more of their labs.</td><td>ì´ëŠ” ì´ í¬ê³  ë¹ ë¥´ê²Œ ì„±ì¥í•˜ëŠ” ì‹œì¥ì—ì„œ ì–´ë–¤ ê¸°ì—…ë³´ë‹¤ë„ ê°€ì¥ ë†’ì€ ì„±ì¥ë¥ ì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ë¯¸êµ­ê³¼ í•´ì™¸ ì‹œì¥ ëª¨ë‘ì—ì„œ PFA í”„ëœì°¨ì´ì¦ˆê°€ 300% ì´ìƒ ì„±ì¥í•˜ë©´ì„œ ì‹œì¥ ì ìœ ìœ¨ì„ í™•ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” Affera ë§¤í•‘ ì‹œìŠ¤í…œê³¼ Sphere-9 ì´ì¤‘ ì—ë„ˆì§€ ê³ ë°€ë„ ë§¤í•‘ ì¹´í…Œí„°ì˜ ê°•ì ì— ê¸°ë°˜í•œ ê²ƒì…ë‹ˆë‹¤. ì˜ì‚¬ë“¤ì€ Afferaë¥¼ í†µí•´ ì‹œìˆ  ì‹œê°„ì´ ë‹¨ì¶•ë˜ëŠ” ê²ƒë¿ë§Œ ì•„ë‹ˆë¼, ì ì  ë” ë›°ì–´ë‚œ ë‚´êµ¬ì„±ì„ ë†’ì´ í‰ê°€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê³ ê°ë“¤ë¡œë¶€í„° ë” ë§ì€ ì—°êµ¬ì‹¤ì— í™•ëŒ€í•˜ê¸° ìœ„í•´ ì¶”ê°€ Affera ì‹œìŠ¤í…œì„ êµ¬ë§¤í•˜ê³  ì‹¶ë‹¤ëŠ” ìš”ì²­ì„ ë°˜ë³µì ìœ¼ë¡œ ë°›ê³  ìˆì–´ ìˆ˜ìš”ê°€ ë§¤ìš° ë†’ì€ ìƒí™©ì…ë‹ˆë‹¤.</td></tr>
<tr><td>And in the vast majority of instances, when a new Affera system goes into a lab, we take the majority of the AF procedure share in that lab. Our plants have scaled, as I mentioned earlier, to meet the challenge, and our mapping hiring is going really well. And as a result, we've doubled our installed base of Affera mapping systems during the quarter. And given the economics of this business with capital and consumables, our mapping system sales are a strong leading indicator of future revenue growth and margin expansion. So we're still in the early parts of this rollout, and we expect revenue acceleration to continue with an even higher CAS growth in Q3.</td><td>ê·¸ë¦¬ê³  ëŒ€ë¶€ë¶„ì˜ ê²½ìš°, ìƒˆë¡œìš´ Affera ì‹œìŠ¤í…œì´ ì—°êµ¬ì‹¤ì— ë„ì…ë˜ë©´, ìš°ë¦¬ëŠ” í•´ë‹¹ ì—°êµ¬ì‹¤ì—ì„œ ì‹¬ë°©ì„¸ë™ ì‹œìˆ  ì ìœ ìœ¨ì˜ ëŒ€ë¶€ë¶„ì„ ì°¨ì§€í•˜ê²Œ ë©ë‹ˆë‹¤. ì•ì„œ ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼ ìš°ë¦¬ ê³µì¥ë“¤ì€ ì´ëŸ¬í•œ ë„ì „ê³¼ì œë¥¼ ì¶©ì¡±í•˜ê¸° ìœ„í•´ ìƒì‚°ê·œëª¨ë¥¼ í™•ëŒ€í–ˆìœ¼ë©°, ë§¤í•‘ ë¶€ë¬¸ ì±„ìš©ë„ ë§¤ìš° ìˆœì¡°ë¡­ê²Œ ì§„í–‰ë˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ ê²°ê³¼, ë‹¹ ë¶„ê¸° ë™ì•ˆ Affera ë§¤í•‘ ì‹œìŠ¤í…œì˜ ì„¤ì¹˜ ê¸°ë°˜ì„ ë‘ ë°°ë¡œ ëŠ˜ë ¸ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì¥ë¹„ì™€ ì†Œëª¨í’ˆìœ¼ë¡œ êµ¬ì„±ëœ ì´ ì‚¬ì—…ì˜ ê²½ì œì„±ì„ ê³ ë ¤í•  ë•Œ, ë§¤í•‘ ì‹œìŠ¤í…œ íŒë§¤ëŠ” í–¥í›„ ë§¤ì¶œ ì„±ì¥ê³¼ ë§ˆì§„ í™•ëŒ€ì˜ ê°•ë ¥í•œ ì„ í–‰ì§€í‘œì…ë‹ˆë‹¤. ë”°ë¼ì„œ ìš°ë¦¬ëŠ” ì—¬ì „íˆ ì´ ì¶œì‹œì˜ ì´ˆê¸° ë‹¨ê³„ì— ìˆìœ¼ë©°, 3ë¶„ê¸°ì—ëŠ” í›¨ì”¬ ë” ë†’ì€ ì¼ì •í†µí™”ê¸°ì¤€(CAS) ì„±ì¥ê³¼ í•¨ê»˜ ë§¤ì¶œ ê°€ì†í™”ê°€ ì§€ì†ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤.</td></tr>
<tr><td>We remain on track to double the revenue of this business soon, adding an incremental $1 billion off the $1 billion FY '25 base. Look, and we're not stopping there. With our pipeline, we're bringing Affera technology to the single-shot segment with Sphere-360. EPs tell us that 360 is the most anticipated PFA catheter out there given the strength of its early clinical data. We've submitted the IDE to the FDA to get approval for our U.S. pivotal trial, which we're expecting to start in Q3. So the EP ablation space is now over $12 billion. It's growing mid-20s.</td><td>ìš°ë¦¬ëŠ” 25íšŒê³„ì—°ë„ 10ì–µ ë‹¬ëŸ¬ ê¸°ì¤€ì—ì„œ ì¶”ê°€ë¡œ 10ì–µ ë‹¬ëŸ¬ë¥¼ ë”í•´ ì´ ì‚¬ì—…ì˜ ë§¤ì¶œì„ ê³§ ë‘ ë°°ë¡œ ëŠ˜ë¦¬ê² ë‹¤ëŠ” ëª©í‘œë¥¼ ìˆœì¡°ë¡­ê²Œ ì§„í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì—¬ê¸°ì„œ ë©ˆì¶”ì§€ ì•Šì„ ê²ƒì…ë‹ˆë‹¤. ìš°ë¦¬ì˜ íŒŒì´í”„ë¼ì¸ì„ í†µí•´ Sphere-360ìœ¼ë¡œ ë‹¨ì¼ ì‹œìˆ (single-shot) ë¶€ë¬¸ì— Affera ê¸°ìˆ ì„ ë„ì…í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì „ê¸°ìƒë¦¬í•™ ì „ë¬¸ì˜ë“¤ì€ ì´ˆê¸° ì„ìƒ ë°ì´í„°ì˜ ìš°ìˆ˜ì„±ì„ ê³ ë ¤í•  ë•Œ 360ì´ ê°€ì¥ ê¸°ëŒ€ë˜ëŠ” PFA ì¹´í…Œí„°ë¼ê³  ë§í•©ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ë¯¸êµ­ í”¼ë²— ì„ìƒì‹œí—˜ ìŠ¹ì¸ì„ ë°›ê¸° ìœ„í•´ FDAì— IDE(ì„ìƒì‹œí—˜ê³„íšìŠ¹ì¸ì‹ ì²­)ë¥¼ ì œì¶œí–ˆìœ¼ë©°, 3ë¶„ê¸°ì— ì‹œì‘í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì „ê¸°ìƒë¦¬í•™ ì ˆì œìˆ (EP ablation) ì‹œì¥ì€ í˜„ì¬ 120ì–µ ë‹¬ëŸ¬ë¥¼ ë„˜ì–´ì„°ìœ¼ë©°, 20% ì¤‘ë°˜ëŒ€ì˜ ì„±ì¥ë¥ ì„ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And with our low double-digit share and the high demand I just talked about for the current portfolio and our pipeline, we see a long runway to gain significant share and add meaningful growth to Medtronic. Now on top of that growth, we're launching as the clear market leader in 2 very large end markets, our Symplicity procedure for hypertension and Altaviva for incontinence. And we're excited to have received the final Medicare NCD for Symplicity 3 weeks ago. So now in addition to a broad label from the FDA, we have an excellent coverage outcome from CMS.</td><td>ê·¸ë¦¬ê³  ìš°ë¦¬ì˜ ë‚®ì€ ë‘ ìë¦¿ìˆ˜ ì ìœ ìœ¨ê³¼ ë°©ê¸ˆ ë§ì”€ë“œë¦° í˜„ì¬ í¬íŠ¸í´ë¦¬ì˜¤ ë° íŒŒì´í”„ë¼ì¸ì— ëŒ€í•œ ë†’ì€ ìˆ˜ìš”ë¥¼ ê³ ë ¤í•  ë•Œ, ìƒë‹¹í•œ ì ìœ ìœ¨ì„ í™•ë³´í•˜ê³  ë©”ë“œíŠ¸ë¡œë‹‰ì— ì˜ë¯¸ ìˆëŠ” ì„±ì¥ì„ ë”í•  ìˆ˜ ìˆëŠ” ê¸´ í™œì£¼ë¡œê°€ ìˆë‹¤ê³  ë´…ë‹ˆë‹¤. ì´ëŸ¬í•œ ì„±ì¥ì— ë”í•´, ìš°ë¦¬ëŠ” ë‘ ê°œì˜ ë§¤ìš° í° ìµœì¢… ì‹œì¥ì—ì„œ ëª…í™•í•œ ì‹œì¥ ë¦¬ë”ë¡œì„œ ì œí’ˆì„ ì¶œì‹œí•˜ê³  ìˆìŠµë‹ˆë‹¤. ê³ í˜ˆì•• ì¹˜ë£Œë¥¼ ìœ„í•œ Symplicity ì‹œìˆ ê³¼ ìš”ì‹¤ê¸ˆ ì¹˜ë£Œë¥¼ ìœ„í•œ Altavivaì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  3ì£¼ ì „ Symplicityì— ëŒ€í•œ ìµœì¢… Medicare NCD(National Coverage Determination, ì „êµ­ ë³´í—˜ì ìš© ê²°ì •)ë¥¼ ë°›ê²Œ ë˜ì–´ ê¸°ì©ë‹ˆë‹¤. ë”°ë¼ì„œ ì´ì œ FDAë¡œë¶€í„° ë°›ì€ ê´‘ë²”ìœ„í•œ ì ì‘ì¦ì— ë”í•´, CMS(Centers for Medicare & Medicaid Services, ë©”ë””ì¼€ì–´Â·ë©”ë””ì¼€ì´ë“œ ì„œë¹„ìŠ¤ì„¼í„°)ë¡œë¶€í„° ìš°ìˆ˜í•œ ë³´í—˜ì ìš© ê²°ê³¼ë¥¼ ì–»ê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>The final NCD enables broad access and removes certain patient pathway barriers that were in the original proposal, including reducing in-person visits, removing a kidney function exclusion and cutting in half the time requirement for adherence to meds. It also highlights patient quality of life as an important consideration. So the NCD gives physicians many avenues to bring Symplicity to patients. Additionally, we are currently the only company to meet the full NCD criteria with an approved continued evidence development plan.</td><td>ë§ˆì§€ë§‰ NCDëŠ” ê´‘ë²”ìœ„í•œ ì ‘ê·¼ì„±ì„ ê°€ëŠ¥í•˜ê²Œ í•˜ë©°, ì´ˆê¸° ì œì•ˆì„œì— ìˆë˜ íŠ¹ì • í™˜ì ê²½ë¡œ ì¥ë²½ë“¤ì„ ì œê±°í–ˆìŠµë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” ëŒ€ë©´ ë°©ë¬¸ íšŸìˆ˜ ê°ì¶•, ì‹ ì¥ ê¸°ëŠ¥ ì œì™¸ ì¡°í•­ ì‚­ì œ, ê·¸ë¦¬ê³  ì•½ë¬¼ ìˆœì‘ë„ ìš”êµ¬ ê¸°ê°„ì„ ì ˆë°˜ìœ¼ë¡œ ë‹¨ì¶•í•˜ëŠ” ë‚´ìš©ì´ í¬í•¨ë©ë‹ˆë‹¤. ë˜í•œ í™˜ìì˜ ì‚¶ì˜ ì§ˆì„ ì¤‘ìš”í•œ ê³ ë ¤ì‚¬í•­ìœ¼ë¡œ ê°•ì¡°í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì´ë²ˆ NCDëŠ” ì˜ì‚¬ë“¤ì´ Symplicityë¥¼ í™˜ìë“¤ì—ê²Œ ì œê³µí•  ìˆ˜ ìˆëŠ” ë‹¤ì–‘í•œ ê²½ë¡œë¥¼ ì œì‹œí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì¶”ê°€ë¡œ, ìš°ë¦¬ëŠ” í˜„ì¬ ìŠ¹ì¸ëœ ì§€ì†ì  ê·¼ê±° ê°œë°œ ê³„íš(continued evidence development plan)ì„ í†µí•´ ì „ì²´ NCD ê¸°ì¤€ì„ ì¶©ì¡±í•˜ëŠ” ìœ ì¼í•œ íšŒì‚¬ì…ë‹ˆë‹¤.</td></tr>
<tr><td>And on the commercial payer front, we picked up significant momentum with wins during the quarter, including HCSC, Regence, and several Blue Cross Blue Shield plans that collectively cover 30 million lives. Shifting to efficacy. Medtronic is the runaway leader with Ardian clinical data, and we continue to add to it. Only Symplicity RF Ardian has consistently shown sustained and improving blood pressure reductions in the long term. This is definitively unique to us, as we've not seen this with the ultrasound devices. This sets the standard that all other devices must now meet.</td><td>ê·¸ë¦¬ê³  ë¯¼ê°„ ë³´í—˜ì‚¬ ì¸¡ë©´ì—ì„œëŠ” ì´ë²ˆ ë¶„ê¸° ì¤‘ HCSC, Regence, ê·¸ë¦¬ê³  ì´ 3ì²œë§Œ ëª…ì˜ ê°€ì…ìë¥¼ ë³´ìœ í•œ ì—¬ëŸ¬ Blue Cross Blue Shield í”Œëœë“¤ì„ í™•ë³´í•˜ë©° ìƒë‹¹í•œ ëª¨ë©˜í…€ì„ ì–»ì—ˆìŠµë‹ˆë‹¤. íš¨ëŠ¥ ì¸¡ë©´ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ë©”ë“œíŠ¸ë¡œë‹‰ì€ Ardian ì„ìƒ ë°ì´í„°ì—ì„œ ì••ë„ì ì¸ ì„ ë‘ì£¼ìì´ë©°, ê³„ì†í•´ì„œ ë°ì´í„°ë¥¼ ì¶”ê°€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì˜¤ì§ Symplicity RF Ardianë§Œì´ ì¥ê¸°ì ìœ¼ë¡œ ì§€ì†ì ì´ê³  ê°œì„ ë˜ëŠ” í˜ˆì•• ê°ì†Œ íš¨ê³¼ë¥¼ ì¼ê´€ë˜ê²Œ ë³´ì—¬ì£¼ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ì´ˆìŒíŒŒ ê¸°ê¸°ë“¤ì—ì„œëŠ” ë³¼ ìˆ˜ ì—†ì—ˆë˜ ê²ƒìœ¼ë¡œ, ëª…ë°±íˆ ìš°ë¦¬ë§Œì˜ ê³ ìœ í•œ íŠ¹ì§•ì…ë‹ˆë‹¤. ì´ê²ƒì´ ë‹¤ë¥¸ ëª¨ë“  ê¸°ê¸°ë“¤ì´ ì´ì œ ì¶©ì¡±í•´ì•¼ í•  ê¸°ì¤€ì„ ì„¤ì •í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And last month at TCT, we shared 3-year data from our ON MED trial that continued to show the procedure is effective over the long term. Patients who underwent the Symplicity procedure experienced an 18.5 point average drop in systolic blood pressure. We also completed enrollment in our SPYRAL AFFIRM trial, which aims to expand Symplicity into high-risk subgroups, including people with isolated systolic hypertension. The first data from a subset of this trial was also shown at TCT with very strong results. We're using these results in ongoing discussions with the FDA.</td><td>ê·¸ë¦¬ê³  ì§€ë‚œë‹¬ TCTì—ì„œ ìš°ë¦¬ëŠ” ON MED ì„ìƒì‹œí—˜ì˜ 3ë…„ ë°ì´í„°ë¥¼ ê³µìœ í–ˆìœ¼ë©°, ì´ëŠ” ì‹œìˆ ì´ ì¥ê¸°ì ìœ¼ë¡œ íš¨ê³¼ì ì„ì„ ì§€ì†ì ìœ¼ë¡œ ë³´ì—¬ì£¼ì—ˆìŠµë‹ˆë‹¤. Symplicity ì‹œìˆ ì„ ë°›ì€ í™˜ìë“¤ì€ ìˆ˜ì¶•ê¸° í˜ˆì••ì´ í‰ê·  18.5í¬ì¸íŠ¸ ê°ì†Œí•˜ëŠ” ê²ƒì„ ê²½í—˜í–ˆìŠµë‹ˆë‹¤. ë˜í•œ ìš°ë¦¬ëŠ” SPYRAL AFFIRM ì„ìƒì‹œí—˜ì˜ ë“±ë¡ì„ ì™„ë£Œí–ˆëŠ”ë°, ì´ëŠ” ê³ ë¦½ì„± ìˆ˜ì¶•ê¸° ê³ í˜ˆì•• í™˜ìë¥¼ í¬í•¨í•œ ê³ ìœ„í—˜ í•˜ìœ„ê·¸ë£¹ìœ¼ë¡œ Symplicityë¥¼ í™•ëŒ€í•˜ëŠ” ê²ƒì„ ëª©í‘œë¡œ í•©ë‹ˆë‹¤. ì´ ì„ìƒì‹œí—˜ì˜ ì¼ë¶€ í•˜ìœ„ê·¸ë£¹ì—ì„œ ë‚˜ì˜¨ ì²« ë²ˆì§¸ ë°ì´í„°ë„ TCTì—ì„œ ë°œí‘œë˜ì—ˆìœ¼ë©° ë§¤ìš° ê°•ë ¥í•œ ê²°ê³¼ë¥¼ ë³´ì˜€ìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì´ëŸ¬í•œ ê²°ê³¼ë“¤ì„ FDAì™€ì˜ ì§€ì†ì ì¸ ë…¼ì˜ì— í™œìš©í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>So Symplicity represents a massive multibillion-dollar opportunity for Medtronic with an addressable market of 18 million people in the U.S. with uncontrolled hypertension. And now with a broad NCD in place and commercial payers coming online faster than anticipated, this isn't a question of if or even how big, it's a question of how fast. Now we have not incorporated much Symplicity revenue into our back half guidance, but we are sprinting after this opportunity. We have supply. We've ramped up physician training and market development activities with many hospitals initiating Symplicity programs across the country. And now we're increasing our consumer awareness programs.</td><td>ë”°ë¼ì„œ SymplicityëŠ” ë¯¸êµ­ ë‚´ ì¡°ì ˆë˜ì§€ ì•ŠëŠ” ê³ í˜ˆì•• í™˜ì 1,800ë§Œ ëª…ì´ë¼ëŠ” addressable market(ì ì¬ ì‹œì¥)ì„ ë³´ìœ í•˜ê³  ìˆì–´ Medtronicì—ê²Œ ìˆ˜ì‹­ì–µ ë‹¬ëŸ¬ ê·œëª¨ì˜ ë§‰ëŒ€í•œ ê¸°íšŒë¥¼ ì˜ë¯¸í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ì œ ê´‘ë²”ìœ„í•œ NCD(National Coverage Determination, ì „êµ­ ë³´í—˜ ì ìš© ê²°ì •)ê°€ ì‹œí–‰ë˜ê³  commercial payer(ë¯¼ê°„ ë³´í—˜ì‚¬)ë“¤ì´ ì˜ˆìƒë³´ë‹¤ ë¹ ë¥´ê²Œ ì°¸ì—¬í•˜ê³  ìˆëŠ” ìƒí™©ì—ì„œ, ì´ê²ƒì€ ê°€ëŠ¥ì„± ì—¬ë¶€ë‚˜ ê·œëª¨ì˜ ë¬¸ì œê°€ ì•„ë‹ˆë¼ ì–¼ë§ˆë‚˜ ë¹ ë¥´ê²Œ ì„±ì¥í•  ê²ƒì¸ê°€ì˜ ë¬¸ì œì…ë‹ˆë‹¤. <br><br>í˜„ì¬ ì €í¬ëŠ” í•˜ë°˜ê¸° guidance(ì‹¤ì  ì „ë§)ì— Symplicity ë§¤ì¶œì„ ë§ì´ ë°˜ì˜í•˜ì§€ ì•Šì•˜ì§€ë§Œ, ì´ ê¸°íšŒë¥¼ ì ê·¹ì ìœ¼ë¡œ ì¶”ì§„í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê³µê¸‰ ë¬¼ëŸ‰ì„ í™•ë³´í–ˆìœ¼ë©°, ì „êµ­ì˜ ë§ì€ ë³‘ì›ë“¤ì´ Symplicity í”„ë¡œê·¸ë¨ì„ ì‹œì‘í•˜ë©´ì„œ ì˜ì‚¬ êµìœ¡ê³¼ ì‹œì¥ ê°œë°œ í™œë™ì„ í™•ëŒ€í–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ì œ ì†Œë¹„ì ì¸ì§€ë„ ì œê³  í”„ë¡œê·¸ë¨ë„ ê°•í™”í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And as a result, we expect our revenue to pick up in the back half of the fiscal year and ramp over the next few quarters and meaningfully contribute to Medtronic for years to come. Now shifting to Altaviva. We're seeing very positive signs in the first several weeks of the U.S. launch. Physician training programs are oversubscribed, and we're expanding training capacity to meet this demand. Physicians are stacking cases, and early media coverage has driven a surge in consumer search activity. Altaviva is a simple option to treat urinary urges and involuntary leaks, which affect 16 million people in the U.S.</td><td>ê·¸ ê²°ê³¼, ìš°ë¦¬ëŠ” íšŒê³„ì—°ë„ í•˜ë°˜ê¸°ì— ë§¤ì¶œì´ ì¦ê°€í•˜ê³  í–¥í›„ ëª‡ ë¶„ê¸°ì— ê±¸ì³ í™•ëŒ€ë˜ì–´ ì•ìœ¼ë¡œ ìˆ˜ë…„ê°„ ë©”ë“œíŠ¸ë¡œë‹‰ì— ì˜ë¯¸ ìˆëŠ” ê¸°ì—¬ë¥¼ í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ì´ì œ ì•Œíƒ€ë¹„ë°”(Altaviva)ë¡œ ì´ì•¼ê¸°ë¥¼ ì˜®ê¸°ê² ìŠµë‹ˆë‹¤. ë¯¸êµ­ ì¶œì‹œ ì²« ëª‡ ì£¼ ë™ì•ˆ ë§¤ìš° ê¸ì •ì ì¸ ì‹ í˜¸ë“¤ì´ ë‚˜íƒ€ë‚˜ê³  ìˆìŠµë‹ˆë‹¤. ì˜ì‚¬ êµìœ¡ í”„ë¡œê·¸ë¨ì€ ì •ì› ì´ˆê³¼ ì‹ ì²­ì„ ë°›ê³  ìˆìœ¼ë©°, ì´ëŸ¬í•œ ìˆ˜ìš”ë¥¼ ì¶©ì¡±í•˜ê¸° ìœ„í•´ êµìœ¡ ì—­ëŸ‰ì„ í™•ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì˜ì‚¬ë“¤ì´ ì‹œìˆ  ì¼€ì´ìŠ¤ë¥¼ ì—°ì†ìœ¼ë¡œ ì˜ˆì•½í•˜ê³  ìˆìœ¼ë©°, ì´ˆê¸° ì–¸ë¡  ë³´ë„ëŠ” ì†Œë¹„ì ê²€ìƒ‰ í™œë™ì˜ ê¸‰ì¦ì„ ì´ëŒì–´ëƒˆìŠµë‹ˆë‹¤. ì•Œíƒ€ë¹„ë°”ëŠ” ë¯¸êµ­ ë‚´ 1,600ë§Œ ëª…ì—ê²Œ ì˜í–¥ì„ ë¯¸ì¹˜ëŠ” ìš”ì ˆë°•(urinary urges)ê³¼ ë¶ˆìˆ˜ì˜ì  ìš”ì‹¤ê¸ˆ(involuntary leaks)ì„ ì¹˜ë£Œí•˜ëŠ” ê°„ë‹¨í•œ ì˜µì…˜ì…ë‹ˆë‹¤.</td></tr>
<tr><td>This small device is inserted just below the skin, but above the fascia near the ankle. The procedure is minimally invasive, doesn't require sedation, and the patient goes home with a therapy activated. So they're not waiting for follow-up appointments to feel the results. The device is only recharged once or twice a year, eliminating the need for daily at-home charging equipment, and it has a 15-year battery. So we believe Altaviva will add meaningful growth to our public health business, and be a Medtronic growth driver again for years to come. And more importantly, it is meaningful for patients. This is our first patient in South Carolina, who is dancing to Jingle Bell Rock.</td><td>ì´ ì†Œí˜• ê¸°ê¸°ëŠ” ë°œëª© ê·¼ì²˜ í”¼ë¶€ ë°”ë¡œ ì•„ë˜, ê·¼ë§‰ ìœ„ì— ì‚½ì…ë©ë‹ˆë‹¤. ì‹œìˆ ì€ ìµœì†Œ ì¹¨ìŠµì ì´ë©° ì§„ì •ì œê°€ í•„ìš”í•˜ì§€ ì•Šê³ , í™˜ìëŠ” ì¹˜ë£Œê°€ í™œì„±í™”ëœ ìƒíƒœë¡œ ê·€ê°€í•©ë‹ˆë‹¤. ë”°ë¼ì„œ ê²°ê³¼ë¥¼ ëŠë¼ê¸° ìœ„í•´ ì¶”í›„ ì§„ë£Œ ì˜ˆì•½ì„ ê¸°ë‹¤ë¦´ í•„ìš”ê°€ ì—†ìŠµë‹ˆë‹¤. ì´ ê¸°ê¸°ëŠ” ì—° 1~2íšŒë§Œ ì¶©ì „í•˜ë©´ ë˜ì–´ ë§¤ì¼ ê°€ì •ì—ì„œ ì¶©ì „ ì¥ë¹„ë¥¼ ì‚¬ìš©í•  í•„ìš”ê°€ ì—†ìœ¼ë©°, 15ë…„ ë°°í„°ë¦¬ ìˆ˜ëª…ì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ìš°ë¦¬ëŠ” Altavivaê°€ ê³µì¤‘ë³´ê±´ ì‚¬ì—…ì— ì˜ë¯¸ ìˆëŠ” ì„±ì¥ì„ ë”í•˜ê³ , í–¥í›„ ìˆ˜ë…„ê°„ ë‹¤ì‹œ Medtronicì˜ ì„±ì¥ ë™ë ¥ì´ ë  ê²ƒìœ¼ë¡œ ë¯¿ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë” ì¤‘ìš”í•œ ê²ƒì€ í™˜ìë“¤ì—ê²Œ ì˜ë¯¸ê°€ ìˆë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ì´ë¶„ì€ ì‚¬ìš°ìŠ¤ìºë¡¤ë¼ì´ë‚˜ì˜ ì²« ë²ˆì§¸ í™˜ìë¡œ, Jingle Bell Rockì— ë§ì¶° ì¶¤ì„ ì¶”ê³  ê³„ì‹­ë‹ˆë‹¤.</td></tr>
<tr><td>It's getting to be that time of the year, and it's a wonderful video. In addition to these enterprise growth drivers, we're seeing improvements in many of our other businesses as we execute on new product introductions, getting products to market ahead of schedule and ensuring strong commercial follow-through. So with that, I'm going to turn it over to Thierry to cover the details of our business performance, financials and our guidance. Thierry Pieton<br>Executive VP & CFO<br><br>Thanks, Geoff. Hi, everyone. I appreciate everyone joining us today. So I'll start with our Cardiovascular portfolio, where we grew 9%.</td><td>ì´ì œ ê·¸ëŸ° ì‹œê¸°ê°€ ë‹¤ê°€ì˜¤ê³  ìˆìœ¼ë©°, ì •ë§ ë©‹ì§„ ì˜ìƒì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ê¸°ì—… ì„±ì¥ ë™ë ¥ ì™¸ì—ë„, ìš°ë¦¬ëŠ” ì‹ ì œí’ˆ ì¶œì‹œë¥¼ ì‹¤í–‰í•˜ê³ , ì œí’ˆì„ ì˜ˆì •ë³´ë‹¤ ì•ì„œ ì‹œì¥ì— ì¶œì‹œí•˜ë©°, ê°•ë ¥í•œ ìƒì—…ì  í›„ì† ì¡°ì¹˜ë¥¼ ë³´ì¥í•¨ìœ¼ë¡œì¨ ë‹¤ë¥¸ ë§ì€ ì‚¬ì—… ë¶€ë¬¸ì—ì„œë„ ê°œì„ ì„ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ëŸ¼ ì´ì œ Thierryì—ê²Œ ë„˜ê²¨ì„œ ìš°ë¦¬ì˜ ì‚¬ì—… ì‹¤ì , ì¬ë¬´ ìƒí™© ë° ê°€ì´ë˜ìŠ¤ì— ëŒ€í•œ ì„¸ë¶€ ì‚¬í•­ì„ ë‹¤ë£¨ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤.<br><br>Thierry Pieton<br>ì „ë¬´ì´ì‚¬ ê²¸ CFO<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, Geoff. ì•ˆë…•í•˜ì„¸ìš”, ì—¬ëŸ¬ë¶„. ì˜¤ëŠ˜ ì°¸ì„í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ê·¸ëŸ¼ 9% ì„±ì¥í•œ ì‹¬í˜ˆê´€ í¬íŠ¸í´ë¦¬ì˜¤ë¶€í„° ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>This was our strongest growth in over a decade, excluding the easy comparisons we had after the pandemic. The growth acceleration was driven by our building momentum in CAS, which Geoff walked you through. And it's worth noting that PFA is now 75% of our cardiac ablation revenue. Our PFA growth significantly offset the 40% declines we had in cryo and 90% of our remaining cryo revenue is in markets outside of the U.S. And look, it wasn't just CAS. The rest of our Cardiovascular portfolio grew a combined mid-single digits. Cardiac Rhythm Management grew 5% with 18% growth in Micra leadless pacemakers, and nearly 80% growth in AURORA EV-ICDs.</td><td>ì´ëŠ” íŒ¬ë°ë¯¹ ì´í›„ ì‰¬ìš´ ë¹„êµ ê¸°ì €ë¥¼ ì œì™¸í•˜ê³  10ë…„ ì´ìƒ ë§Œì— ê°€ì¥ ê°•ë ¥í•œ ì„±ì¥ì´ì—ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì„±ì¥ ê°€ì†ì€ Geoffê°€ ì„¤ëª…ë“œë¦° CAS(ì‹¬ì¥ ì ˆì œìˆ ) ë¶€ë¬¸ì˜ ëª¨ë©˜í…€ êµ¬ì¶•ì— ì˜í•´ ì£¼ë„ë˜ì—ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  PFA(í„ìŠ¤ í•„ë“œ ì ˆì œìˆ )ê°€ í˜„ì¬ ì‹¬ì¥ ì ˆì œìˆ  ë§¤ì¶œì˜ 75%ë¥¼ ì°¨ì§€í•˜ê³  ìˆë‹¤ëŠ” ì ì€ ì£¼ëª©í•  ë§Œí•©ë‹ˆë‹¤. PFAì˜ ì„±ì¥ì€ ëƒ‰ë™ ì ˆì œìˆ (cryo)ì˜ 40% ê°ì†Œë¶„ì„ ìƒë‹¹ ë¶€ë¶„ ìƒì‡„í–ˆìœ¼ë©°, ëƒ‰ë™ ì ˆì œìˆ  ì”ì—¬ ë§¤ì¶œì˜ 90%ëŠ” ë¯¸êµ­ ì™¸ ì‹œì¥ì—ì„œ ë°œìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë³´ì‹œë‹¤ì‹œí”¼, CASë§Œì´ ì•„ë‹ˆì—ˆìŠµë‹ˆë‹¤. ë‚˜ë¨¸ì§€ ì‹¬í˜ˆê´€ í¬íŠ¸í´ë¦¬ì˜¤ëŠ” ì „ì²´ì ìœ¼ë¡œ ì¤‘ê°„ í•œ ìë¦¿ìˆ˜ ì„±ì¥ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì‹¬ì¥ ë¦¬ë“¬ ê´€ë¦¬(Cardiac Rhythm Management) ë¶€ë¬¸ì€ 5% ì„±ì¥í–ˆìœ¼ë©°, ì´ ì¤‘ Micra ë¬´ì„  ì‹¬ë°•ì¡°ìœ¨ê¸°ëŠ” 18% ì„±ì¥, AURORA EV-ICDëŠ” ê±°ì˜ 80% ì„±ì¥ì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>In Structural Heart, we grew 7% on the strength of the Evolut TAVR platform. In Peripheral Vascular, we grew low single digits, and we expect growth to improve as we continue to launch the Neuroguard IEP carotid stent and begin the launch of our Liberant mechanical thrombectomy system. Next, in our Neuroscience portfolio, our growth returned to mid-single digits as expected, with growth of 4%. In Cranial & Spinal Technologies, we grew 5%. That included 8% growth in Core Spine, both globally and in the U.S., and 5% in Neurosurgery capital equipment.</td><td>êµ¬ì¡°ì  ì‹¬ì¥ ë¶„ì•¼ì—ì„œëŠ” Evolut TAVR í”Œë«í¼ì˜ ê°•ì„¸ì— í˜ì…ì–´ 7% ì„±ì¥í–ˆìŠµë‹ˆë‹¤. ë§ì´ˆí˜ˆê´€ ë¶„ì•¼ì—ì„œëŠ” ì €ë‹¨ìœ„ í•œìë¦¿ìˆ˜ ì„±ì¥ì„ ê¸°ë¡í–ˆìœ¼ë©°, Neuroguard IEP ê²½ë™ë§¥ ìŠ¤í…íŠ¸ì˜ ì§€ì†ì ì¸ ì¶œì‹œì™€ Liberant ê¸°ê³„ì  í˜ˆì „ì œê±° ì‹œìŠ¤í…œì˜ ì¶œì‹œ ê°œì‹œì— ë”°ë¼ ì„±ì¥ì„¸ê°€ ê°œì„ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ë‹¤ìŒìœ¼ë¡œ, ì‹ ê²½ê³¼í•™ í¬íŠ¸í´ë¦¬ì˜¤ì—ì„œëŠ” ì˜ˆìƒëŒ€ë¡œ ì„±ì¥ë¥ ì´ ì¤‘ë‹¨ìœ„ í•œìë¦¿ìˆ˜ë¡œ íšŒë³µë˜ì–´ 4% ì„±ì¥í–ˆìŠµë‹ˆë‹¤. ë‘ê°œê³¨ ë° ì²™ì¶” ê¸°ìˆ  ë¶„ì•¼ì—ì„œëŠ” 5% ì„±ì¥í–ˆìŠµë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” ì „ ì„¸ê³„ì ìœ¼ë¡œ ê·¸ë¦¬ê³  ë¯¸êµ­ì—ì„œ ëª¨ë‘ 8% ì„±ì¥í•œ í•µì‹¬ ì²™ì¶” ë¶€ë¬¸ê³¼ ì‹ ê²½ì™¸ê³¼ ìë³¸ ì¥ë¹„ ë¶€ë¬¸ì˜ 5% ì„±ì¥ì´ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Our spine AiBLE ecosystem, which includes AI-enabled preoperative planning software, and enabling capital equipment, including robotics, navigation, imaging and powered surgical instruments continues to attract strong spine surgeon adoption and drive meaningful share gains. And this is enabling strong pull-through of our Core Spine hardware. Our Specialty Therapies businesses had flat results in Q2, an expected improvement from last quarter, driven by ENT and Neurovascular. We have clear line of sight to continued improvement in Specialty Therapies next quarter as we accelerate growth in both Neurovascular and Pelvic Health.</td><td>ìš°ë¦¬ì˜ ì²™ì¶” AiBLE ìƒíƒœê³„ëŠ” AI ê¸°ë°˜ ìˆ˜ìˆ  ì „ ê³„íš ì†Œí”„íŠ¸ì›¨ì–´ì™€ ë¡œë´‡ê³µí•™, ë„¤ë¹„ê²Œì´ì…˜, ì˜ìƒì¥ë¹„, ì „ë™ ìˆ˜ìˆ ê¸°êµ¬ë¥¼ í¬í•¨í•œ í•µì‹¬ ìë³¸ì¥ë¹„ë¡œ êµ¬ì„±ë˜ì–´ ìˆìœ¼ë©°, ì²™ì¶”ì™¸ê³¼ ì˜ì‚¬ë“¤ì˜ ê°•ë ¥í•œ ë„ì…ì„ ì´ëŒì–´ë‚´ê³  ì˜ë¯¸ ìˆëŠ” ì‹œì¥ì ìœ ìœ¨ í™•ëŒ€ë¥¼ ê²¬ì¸í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ìš°ë¦¬ì˜ í•µì‹¬ ì²™ì¶” í•˜ë“œì›¨ì–´ì˜ ê°•ë ¥í•œ ë™ë°˜ ë§¤ì¶œ ì„±ì¥ì„ ê°€ëŠ¥í•˜ê²Œ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ì˜ ì „ë¬¸ ì¹˜ë£Œ(Specialty Therapies) ì‚¬ì—…ë¶€ëŠ” 2ë¶„ê¸°ì— ë³´í•©ì„¸ë¥¼ ê¸°ë¡í–ˆìœ¼ë©°, ì´ëŠ” ì´ë¹„ì¸í›„ê³¼ì™€ ì‹ ê²½í˜ˆê´€ ë¶€ë¬¸ì— í˜ì…ì–´ ì§€ë‚œ ë¶„ê¸° ëŒ€ë¹„ ì˜ˆìƒëœ ê°œì„ ì„ ë³´ì—¬ì£¼ì—ˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì‹ ê²½í˜ˆê´€ê³¼ ê³¨ë°˜ ê±´ê°• ë¶€ë¬¸ ëª¨ë‘ì—ì„œ ì„±ì¥ì„ ê°€ì†í™”í•˜ë©´ì„œ ë‹¤ìŒ ë¶„ê¸° ì „ë¬¸ ì¹˜ë£Œ ë¶€ë¬¸ì˜ ì§€ì†ì ì¸ ê°œì„ ì— ëŒ€í•œ ëª…í™•í•œ ì „ë§ì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>In Neurovascular, growth will improve as we anniversary the vast majority of China VBP in January. We also expect an increasing growth contribution from the Neuroguard carotid stent launch, which is being sold by both our Peripheral Vascular and Neurovascular businesses. In Pelvic Health, we expect growth to accelerate on the Altaviva launch that Geoff outlined. In Neuromodulation, we grew 7%. Both Pain Stim and Brain Modulation grew high single digits as we continue the rollout of our Inceptiv SCS and BrainSense ADBS systems.</td><td>ì‹ ê²½í˜ˆê´€ ë¶€ë¬¸ì—ì„œëŠ” 1ì›”ì— ì¤‘êµ­ VBP(Volume-Based Procurement, ëŒ€ëŸ‰êµ¬ë§¤)ì˜ ëŒ€ë¶€ë¶„ì´ ê¸°ì €íš¨ê³¼ë¥¼ ë§ì´í•˜ë©´ì„œ ì„±ì¥ë¥ ì´ ê°œì„ ë  ê²ƒì…ë‹ˆë‹¤. ë˜í•œ ë§ì´ˆí˜ˆê´€ ì‚¬ì—…ë¶€ì™€ ì‹ ê²½í˜ˆê´€ ì‚¬ì—…ë¶€ ëª¨ë‘ì—ì„œ íŒë§¤í•˜ê³  ìˆëŠ” Neuroguard ê²½ë™ë§¥ ìŠ¤í…íŠ¸ ì¶œì‹œë¡œ ì¸í•œ ì„±ì¥ ê¸°ì—¬ë„ê°€ ì¦ê°€í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ê³¨ë°˜ê±´ê°• ë¶€ë¬¸ì—ì„œëŠ” Geoffê°€ ì„¤ëª…í•œ Altaviva ì¶œì‹œë¡œ ì„±ì¥ì´ ê°€ì†í™”ë  ê²ƒìœ¼ë¡œ ì „ë§ë©ë‹ˆë‹¤. ì‹ ê²½ì¡°ì ˆ ë¶€ë¬¸ì€ 7% ì„±ì¥í–ˆìŠµë‹ˆë‹¤. Inceptiv SCSì™€ BrainSense ADBS ì‹œìŠ¤í…œì˜ ì¶œì‹œë¥¼ ì§€ì†í•˜ë©´ì„œ í†µì¦ìê·¹ì¹˜ë£Œì™€ ë‡Œì¡°ì ˆ ë¶€ë¬¸ ëª¨ë‘ ë†’ì€ í•œ ìë¦¿ìˆ˜ ì„±ì¥ë¥ ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>The market continues to appreciate our differentiated fully closed-loop technology with responsive real-time therapy adjustments that's available in both of these products. Next, our MedSurg portfolio grew 1% as expected. Our Surgical business also grew 1%, impacted, as we anticipated, by the timing of certain tenders in emerging markets and the ongoing but stable market pressures from bariatric surgery and the shift to robotics. We expect a slight rebound in surgical in the back half. And over time, we expect growth to continue to improve as we enter new markets with Hugo.</td><td>ì‹œì¥ì€ ì´ ë‘ ì œí’ˆ ëª¨ë‘ì—ì„œ ì œê³µë˜ëŠ” ì‹¤ì‹œê°„ ì¹˜ë£Œ ì¡°ì •ì´ ê°€ëŠ¥í•œ ë‹¹ì‚¬ì˜ ì°¨ë³„í™”ëœ ì™„ì „ íì‡„ ë£¨í”„(fully closed-loop) ê¸°ìˆ ì„ ì§€ì†ì ìœ¼ë¡œ ë†’ì´ í‰ê°€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë‹¤ìŒìœ¼ë¡œ, MedSurg í¬íŠ¸í´ë¦¬ì˜¤ëŠ” ì˜ˆìƒëŒ€ë¡œ 1% ì„±ì¥í–ˆìŠµë‹ˆë‹¤. ë‹¹ì‚¬ì˜ Surgical ì‚¬ì—… ì—­ì‹œ 1% ì„±ì¥í–ˆëŠ”ë°, ì´ëŠ” ì˜ˆìƒí–ˆë˜ ëŒ€ë¡œ ì‹ í¥ì‹œì¥ì˜ íŠ¹ì • ì…ì°° ì‹œê¸°ì™€ ë¹„ë§Œìˆ˜ìˆ  ë° ë¡œë´‡ìˆ˜ìˆ ë¡œì˜ ì „í™˜ìœ¼ë¡œ ì¸í•œ ì§€ì†ì ì´ì§€ë§Œ ì•ˆì •ì ì¸ ì‹œì¥ ì••ë ¥ì˜ ì˜í–¥ì„ ë°›ì•˜ìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” í•˜ë°˜ê¸°ì— surgical ë¶€ë¬¸ì˜ ì†Œí­ ë°˜ë“±ì„ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì‹œê°„ì´ ì§€ë‚¨ì— ë”°ë¼ Hugoë¥¼ í†µí•´ ìƒˆë¡œìš´ ì‹œì¥ì— ì§„ì…í•˜ë©´ì„œ ì„±ì¥ì´ ì§€ì†ì ìœ¼ë¡œ ê°œì„ ë  ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•©ë‹ˆë‹¤.</td></tr>
<tr><td>In the back half of this fiscal year, we expect the FDA to approve Hugo with a urology indication and we'll start our entrance in the U.S. We also continue to make progress on expanding indications. During the quarter, we presented our Enable Hernia repair study, which met its safety and effectiveness endpoints. And we kicked off our Embrace Gynecology U.S. pivotal study last month. This builds on the momentum from the positive results of our international gyn study, which we shared at SRS in July. Given our experience in international markets, we've developed a clear understanding of the differentiated features that will make our robotics program successful.</td><td>ì˜¬í•´ íšŒê³„ì—°ë„ í•˜ë°˜ê¸°ì—ëŠ” FDAê°€ ë¹„ë‡¨ê¸°ê³¼ ì ì‘ì¦ìœ¼ë¡œ Hugoë¥¼ ìŠ¹ì¸í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ë©°, ë¯¸êµ­ ì‹œì¥ ì§„ì…ì„ ì‹œì‘í•  ê²ƒì…ë‹ˆë‹¤. ë˜í•œ ì ì‘ì¦ í™•ëŒ€ì—ì„œë„ ì§€ì†ì ìœ¼ë¡œ ì§„ì „ì„ ì´ë£¨ê³  ìˆìŠµë‹ˆë‹¤. ì´ë²ˆ ë¶„ê¸° ë™ì•ˆ ì•ˆì „ì„± ë° ìœ íš¨ì„± í‰ê°€ë³€ìˆ˜ë¥¼ ì¶©ì¡±í•œ Enable íƒˆì¥ ë³µì› ì—°êµ¬ ê²°ê³¼ë¥¼ ë°œí‘œí–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì§€ë‚œë‹¬ Embrace ë¶€ì¸ê³¼ ë¯¸êµ­ í”¼ë²— ì—°êµ¬ë¥¼ ì‹œì‘í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì§€ë‚œ 7ì›” SRSì—ì„œ ê³µìœ í•œ êµ­ì œ ë¶€ì¸ê³¼ ì—°êµ¬ì˜ ê¸ì •ì  ê²°ê³¼ì— ê¸°ë°˜í•œ ê²ƒì…ë‹ˆë‹¤. í•´ì™¸ ì‹œì¥ì—ì„œì˜ ê²½í—˜ì„ í†µí•´, ìš°ë¦¬ëŠ” ë¡œë´‡ í”„ë¡œê·¸ë¨ì„ ì„±ê³µìœ¼ë¡œ ì´ëŒ ì°¨ë³„í™”ëœ íŠ¹ì§•ë“¤ì— ëŒ€í•œ ëª…í™•í•œ ì´í•´ë¥¼ êµ¬ì¶•í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>This includes Hugo's modularity and open console. It also includes continuously adding advanced technologies such as our ICG imaging and instrumentation like LigaSure RAS. Our Touch Surgery digital ecosystem is a force multiplier for robotics and for laparoscopic surgery. Adoption is building momentum and bringing AI into operating rooms in over 30 countries. Beyond the features, we're also leveraging our deep partnerships with customers through our training, support and through our service. We look forward to robotics becoming a more meaningful growth driver over time. Next, our Endoscopy business grew 8%.</td><td>ì´ëŠ” Hugoì˜ ëª¨ë“ˆì„±ê³¼ ê°œë°©í˜• ì½˜ì†”ì„ í¬í•¨í•©ë‹ˆë‹¤. ë˜í•œ ICG ì˜ìƒ ê¸°ìˆ ê³¼ LigaSure RASì™€ ê°™ì€ ê¸°ê¸° ë“± ì²¨ë‹¨ ê¸°ìˆ ì„ ì§€ì†ì ìœ¼ë¡œ ì¶”ê°€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ì˜ Touch Surgery ë””ì§€í„¸ ìƒíƒœê³„ëŠ” ë¡œë´‡ ìˆ˜ìˆ ê³¼ ë³µê°•ê²½ ìˆ˜ìˆ ì˜ í˜ì„ ë°°ê°€ì‹œí‚¤ëŠ” ì—­í• ì„ í•©ë‹ˆë‹¤. ë„ì…ì´ íƒ„ë ¥ì„ ë°›ê³  ìˆìœ¼ë©° 30ê°œêµ­ ì´ìƒì˜ ìˆ˜ìˆ ì‹¤ì— AIë¥¼ ë„ì…í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ê¸°ëŠ¥ë“¤ ì™¸ì—ë„, ìš°ë¦¬ëŠ” êµìœ¡, ì§€ì› ë° ì„œë¹„ìŠ¤ë¥¼ í†µí•´ ê³ ê°ë“¤ê³¼ì˜ ê¹Šì€ íŒŒíŠ¸ë„ˆì‹­ì„ í™œìš©í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ë¡œë´‡ ìˆ˜ìˆ ì´ ì‹œê°„ì´ ì§€ë‚¨ì— ë”°ë¼ ë”ìš± ì˜ë¯¸ ìˆëŠ” ì„±ì¥ ë™ë ¥ì´ ë  ê²ƒì„ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë‹¤ìŒìœ¼ë¡œ, ìš°ë¦¬ì˜ ë‚´ì‹œê²½ ì‚¬ì—…ì€ 8% ì„±ì¥í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>This was driven by double-digit growth in our esophageal products as well as in GI Genius, our AI-powered solution used to detect polyps during colonoscopies. Wrapping up our business performance, our Diabetes business or MiniMed, as it will be called post separation, grew high single digits. We had particular strength in international markets, which grew 11%. As expected, the U.S. was lower this quarter, in large part due to a decline in new orders as customers anticipated the launch of our new sensors. As we've started accepting orders, we're seeing this pent-up demand materialize. There's a lot of excitement behind both the Simplera Sync and Instinct sensors.</td><td>ì´ëŠ” ì‹ë„ ì œí’ˆì˜ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ê³¼ ëŒ€ì¥ë‚´ì‹œê²½ ì¤‘ ìš©ì¢… ê²€ì¶œì— ì‚¬ìš©ë˜ëŠ” AI ê¸°ë°˜ ì†”ë£¨ì…˜ì¸ GI Geniusì˜ ì„±ì¥ì— í˜ì…ì€ ê²ƒì…ë‹ˆë‹¤. ì‚¬ì—… ì‹¤ì ì„ ë§ˆë¬´ë¦¬í•˜ë©°, ë‹¹ë‡¨ë³‘ ì‚¬ì—…ë¶€ ë˜ëŠ” ë¶„ì‚¬ í›„ MiniMedë¼ê³  ë¶ˆë¦´ ì‚¬ì—…ë¶€ëŠ” ë†’ì€ í•œ ìë¦¿ìˆ˜ ì„±ì¥ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. íŠ¹íˆ í•´ì™¸ ì‹œì¥ì—ì„œ ê°•ì„¸ë¥¼ ë³´ì˜€ìœ¼ë©° 11% ì„±ì¥í–ˆìŠµë‹ˆë‹¤. ì˜ˆìƒëŒ€ë¡œ ë¯¸êµ­ ì‹œì¥ì€ ì´ë²ˆ ë¶„ê¸°ì— ê°ì†Œí–ˆëŠ”ë°, ì´ëŠ” ì£¼ë¡œ ê³ ê°ë“¤ì´ ì‹ ì œí’ˆ ì„¼ì„œ ì¶œì‹œë¥¼ ê¸°ë‹¤ë¦¬ë©´ì„œ ì‹ ê·œ ì£¼ë¬¸ì´ ê°ì†Œí–ˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ì£¼ë¬¸ ì ‘ìˆ˜ë¥¼ ì‹œì‘í•˜ë©´ì„œ ì´ëŸ¬í•œ ì–µëˆŒë¦° ìˆ˜ìš”ê°€ ì‹¤í˜„ë˜ê³  ìˆìŠµë‹ˆë‹¤. Simplera Syncì™€ Instinct ì„¼ì„œ ëª¨ë‘ì— ëŒ€í•œ ê¸°ëŒ€ê°€ ë§¤ìš° í½ë‹ˆë‹¤.</td></tr>
<tr><td>Look, with the Simplera Sync, we continue to ramp manufacturing volume to support its European launch. As that ramp continues, we plan to roll it out more broadly to U.S. consumers later this fiscal year. And ahead of that, we started accepting orders during the quarter. With the Instinct sensor, we started taking preorders in the U.S. during the last month of the quarter, and we expect to begin shipping in late November. We accumulated more than 35,000 U.S. customer orders for Simplera Sync and preorders for Instinct. Around 25% of these orders are from new pump users or our Medtronic pump users who are not using our CGM.</td><td>Simplera Syncì˜ ê²½ìš°, ìœ ëŸ½ ì¶œì‹œë¥¼ ì§€ì›í•˜ê¸° ìœ„í•´ ìƒì‚°ëŸ‰ì„ ì§€ì†ì ìœ¼ë¡œ í™•ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ìƒì‚° í™•ëŒ€ê°€ ê³„ì†ë¨ì— ë”°ë¼, ê¸ˆë…„ë„ í›„ë°˜ì— ë¯¸êµ­ ì†Œë¹„ìë“¤ì—ê²Œ ë”ìš± ê´‘ë²”ìœ„í•˜ê²Œ ì¶œì‹œí•  ê³„íšì…ë‹ˆë‹¤. ê·¸ì— ì•ì„œ ë¶„ê¸° ì¤‘ì— ì£¼ë¬¸ ì ‘ìˆ˜ë¥¼ ì‹œì‘í–ˆìŠµë‹ˆë‹¤. Instinct ì„¼ì„œì˜ ê²½ìš°, ë¶„ê¸° ë§ˆì§€ë§‰ ë‹¬ì— ë¯¸êµ­ì—ì„œ ì‚¬ì „ ì£¼ë¬¸ì„ ë°›ê¸° ì‹œì‘í–ˆìœ¼ë©°, 11ì›” ë§ì— ì¶œí•˜ë¥¼ ì‹œì‘í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. Simplera Sync ì£¼ë¬¸ê³¼ Instinct ì‚¬ì „ ì£¼ë¬¸ì„ í•©ì³ ë¯¸êµ­ ê³ ê°ìœ¼ë¡œë¶€í„° 35,000ê±´ ì´ìƒì„ í™•ë³´í–ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì£¼ë¬¸ ì¤‘ ì•½ 25%ëŠ” ì‹ ê·œ íŒí”„ ì‚¬ìš©ìì´ê±°ë‚˜ ë‹¹ì‚¬ì˜ CGMì„ ì‚¬ìš©í•˜ì§€ ì•ŠëŠ” Medtronic íŒí”„ ì‚¬ìš©ìë“¤ë¡œë¶€í„° ë‚˜ì˜¨ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>The rest of these orders are current customers in our installed base upgrading to the new sensors. We also saw over 9,000 HCPs in the U.S. who are new Medtronic prescribers. Look, for those of you who follow this space, you know how big a deal these numbers are and the impact they're expected to have on increasing our installed base. We expect the demand for our new sensors to accelerate our U.S. growth in the back half of the fiscal year. Our Diabetes business is in a strong innovation cycle. We've had a lot of great news in the last few months as our teams execute on the pipeline.</td><td>ë‚˜ë¨¸ì§€ ì£¼ë¬¸ë“¤ì€ ì‹ ê·œ ì„¼ì„œë¡œ ì—…ê·¸ë ˆì´ë“œí•˜ëŠ” ê¸°ì¡´ ê³ ê° ê¸°ë°˜ì—ì„œ ë‚˜ì˜¨ ê²ƒì…ë‹ˆë‹¤. ë˜í•œ ë¯¸êµ­ì—ì„œ 9,000ëª… ì´ìƒì˜ ì˜ë£Œì§„ì´ Medtronicì˜ ì‹ ê·œ ì²˜ë°©ìê°€ ë˜ì—ˆìŠµë‹ˆë‹¤. ì´ ë¶„ì•¼ë¥¼ ì£¼ëª©í•˜ì‹œëŠ” ë¶„ë“¤ì€ ì´ëŸ¬í•œ ìˆ˜ì¹˜ê°€ ì–¼ë§ˆë‚˜ ì¤‘ìš”í•œì§€, ê·¸ë¦¬ê³  ì´ê²ƒì´ ìš°ë¦¬ì˜ ì„¤ì¹˜ ê¸°ë°˜ í™•ëŒ€ì— ë¯¸ì¹  ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ëŠ” ì˜í–¥ì„ ì˜ ì•„ì‹¤ ê²ƒì…ë‹ˆë‹¤. ì‹ ê·œ ì„¼ì„œì— ëŒ€í•œ ìˆ˜ìš”ê°€ íšŒê³„ì—°ë„ í•˜ë°˜ê¸° ë¯¸êµ­ ë‚´ ì„±ì¥ì„ ê°€ì†í™”í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ë‹¹ì‚¬ì˜ ë‹¹ë‡¨ë³‘ ì‚¬ì—…ë¶€ëŠ” ê°•ë ¥í•œ í˜ì‹  ì‚¬ì´í´ì— ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ íŒ€ì´ íŒŒì´í”„ë¼ì¸ì„ ì‹¤í–‰í•˜ë©´ì„œ ì§€ë‚œ ëª‡ ë‹¬ê°„ ë§ì€ ì¢‹ì€ ì†Œì‹ë“¤ì´ ìˆì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>In July, the 780G system received CE Mark for 3 expanded indications, including for type 2 for children as young as age 2 and during pregnancy. In September, the U.S. FDA also approved 780G for people with type 2 diabetes. And they cleared our SmartGuard algorithm that enabled integration with the Instinct sensor. Earlier this month, we received FDA approval to start the U.S. pivotal for Vivera, our third-generation algorithm. We also continue to make progress with our new AID systems, MiniMed Flex and MiniMed Fit. We remain on track to submit Flex, our next-generation durable pump, to the U.S. FDA. And with Fit, our AID patch system, we intend to submit to the U.S.</td><td>7ì›”ì— 780G ì‹œìŠ¤í…œì€ ë§Œ 2ì„¸ ì´ìƒ ì†Œì•„ 2í˜• ë‹¹ë‡¨ë³‘ í™˜ì ë° ì„ì‹  ì¤‘ ì‚¬ìš©ì„ í¬í•¨í•œ 3ê°€ì§€ í™•ëŒ€ ì ì‘ì¦ì— ëŒ€í•´ CE ë§ˆí¬ë¥¼ íšë“í–ˆìŠµë‹ˆë‹¤. 9ì›”ì—ëŠ” ë¯¸êµ­ FDAë„ 2í˜• ë‹¹ë‡¨ë³‘ í™˜ìë¥¼ ëŒ€ìƒìœ¼ë¡œ 780Gë¥¼ ìŠ¹ì¸í–ˆìŠµë‹ˆë‹¤. ë˜í•œ Instinct ì„¼ì„œì™€ì˜ í†µí•©ì„ ê°€ëŠ¥í•˜ê²Œ í•˜ëŠ” SmartGuard ì•Œê³ ë¦¬ì¦˜ì— ëŒ€í•œ í—ˆê°€ë¥¼ ë°›ì•˜ìŠµë‹ˆë‹¤. ì´ë‹¬ ì´ˆì—ëŠ” 3ì„¸ëŒ€ ì•Œê³ ë¦¬ì¦˜ì¸ Viveraì˜ ë¯¸êµ­ ì„ìƒì‹œí—˜ì„ ì‹œì‘í•  ìˆ˜ ìˆëŠ” FDA ìŠ¹ì¸ì„ ë°›ì•˜ìŠµë‹ˆë‹¤. ë˜í•œ ìƒˆë¡œìš´ AID ì‹œìŠ¤í…œì¸ MiniMed Flexì™€ MiniMed Fitì—ì„œë„ ì§€ì†ì ìœ¼ë¡œ ì§„ì „ì„ ì´ë£¨ê³  ìˆìŠµë‹ˆë‹¤. ì°¨ì„¸ëŒ€ ë‚´êµ¬ì„± íŒí”„ì¸ Flexë¥¼ ë¯¸êµ­ FDAì— ì œì¶œí•  ê³„íšëŒ€ë¡œ ì§„í–‰ ì¤‘ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  AID íŒ¨ì¹˜ ì‹œìŠ¤í…œì¸ FitëŠ” ë¯¸êµ­ì— ì œì¶œí•  ì˜ˆì •ì…ë‹ˆë‹¤.</td></tr>
<tr><td>FDA by the fall of next year. Look, finally, our planned separation of MiniMed is on track. Our preferred path continues to be a 2-step IPO and split. We continue to expect the separation to be complete by the end of calendar year '26. So we have a lot of momentum with diabetes given the order inflection and progress on the pipeline and separation. And you're hearing today that this momentum acceleration extends across the enterprise as we advance our pipeline and deliver growth. Now turning to the financials. The second quarter revenue of $9 billion grew 6.6% reported and 5.5% organic. That's an acceleration from last quarter and 75 basis points ahead of the midpoint of our guidance.</td><td>FDA ìŠ¹ì¸ì„ ë‚´ë…„ ê°€ì„ê¹Œì§€ ë°›ì„ ê³„íšì…ë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ, MiniMed ë¶„ë¦¬ ê³„íšì€ ìˆœì¡°ë¡­ê²Œ ì§„í–‰ë˜ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ê°€ ì„ í˜¸í•˜ëŠ” ë°©ì‹ì€ 2ë‹¨ê³„ IPOì™€ ë¶„í• ì´ë©°, 2026ë…„ ë§ê¹Œì§€ ë¶„ë¦¬ë¥¼ ì™„ë£Œí•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ë‹¹ë‡¨ ì‚¬ì—…ë¶€ëŠ” ì£¼ë¬¸ ì¦ê°€ì„¸ì™€ íŒŒì´í”„ë¼ì¸ ì§„ì „, ê·¸ë¦¬ê³  ë¶„ë¦¬ ì‘ì—…ìœ¼ë¡œ í° ëª¨ë©˜í…€ì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì˜¤ëŠ˜ ì—¬ëŸ¬ë¶„ê»˜ì„œ ë“¤ìœ¼ì‹œëŠ” ê²ƒì²˜ëŸ¼, ì´ëŸ¬í•œ ëª¨ë©˜í…€ ê°€ì†í™”ëŠ” ìš°ë¦¬ê°€ íŒŒì´í”„ë¼ì¸ì„ ì§„ì „ì‹œí‚¤ê³  ì„±ì¥ì„ ë‹¬ì„±í•˜ë©´ì„œ ì „ì‚¬ì ìœ¼ë¡œ í™•ëŒ€ë˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ì´ì œ ì¬ë¬´ ì‹¤ì ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. 2ë¶„ê¸° ë§¤ì¶œì€ 90ì–µ ë‹¬ëŸ¬ë¡œ ë³´ê³  ê¸°ì¤€ 6.6%, ìœ ê¸°ì  ê¸°ì¤€ 5.5% ì„±ì¥í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì§€ë‚œ ë¶„ê¸° ëŒ€ë¹„ ê°€ì†í™”ëœ ìˆ˜ì¹˜ì´ë©°, ìš°ë¦¬ ê°€ì´ë˜ìŠ¤ ì¤‘ê°„ê°’ë³´ë‹¤ 75bp ë†’ì€ ìˆ˜ì¤€ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Our revenue from a geographic perspective was balanced with double-digit growth in Japan and mid-single-digit growth in the U.S., in Western Europe and China. In China, we're driving growth even as we go through ongoing but very manageable volume-based procurement in a few businesses. Our adjusted gross margin was 65.9%, up 70 basis points year-over-year. Similar to last quarter, I'll walk you through the main components. So we got 30 basis points again from pricing as well as 40 basis points from our COGS efficiency programs, net of inflation. Importantly, margin headwinds from ramping up our manufacturing capacity on Affera are now behind us.</td><td>ì§€ì—­ë³„ ë§¤ì¶œì€ ê· í˜•ì„ ì´ë£¨ì—ˆìœ¼ë©°, ì¼ë³¸ì—ì„œ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì„, ë¯¸êµ­, ì„œìœ ëŸ½, ì¤‘êµ­ì—ì„œ ì¤‘ë°˜ëŒ€ í•œ ìë¦¿ìˆ˜ ì„±ì¥ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì¤‘êµ­ì˜ ê²½ìš°, ì¼ë¶€ ì‚¬ì—…ë¶€ë¬¸ì—ì„œ ì§„í–‰ ì¤‘ì´ì§€ë§Œ ì¶©ë¶„íˆ ê´€ë¦¬ ê°€ëŠ¥í•œ ìˆ˜ì¤€ì˜ volume-based procurement(ëŒ€ëŸ‰ êµ¬ë§¤ ì…ì°°ì œ)ë¥¼ ê²ªê³  ìˆëŠ” ê°€ìš´ë°ì„œë„ ì„±ì¥ì„ ê²¬ì¸í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì¡°ì • ë§¤ì¶œì´ì´ìµë¥ ì€ 65.9%ë¡œ ì „ë…„ ëŒ€ë¹„ 70bp(ë² ì´ì‹œìŠ¤í¬ì¸íŠ¸) ìƒìŠ¹í–ˆìŠµë‹ˆë‹¤. ì§€ë‚œ ë¶„ê¸°ì™€ ë§ˆì°¬ê°€ì§€ë¡œ ì£¼ìš” êµ¬ì„± ìš”ì†Œë¥¼ ì„¤ëª…ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ê°€ê²© ì±…ì •ì—ì„œ ë‹¤ì‹œ 30bpë¥¼ ì–»ì—ˆìœ¼ë©°, ì¸í”Œë ˆì´ì…˜ì„ ì°¨ê°í•œ COGS(ë§¤ì¶œì›ê°€) íš¨ìœ¨í™” í”„ë¡œê·¸ë¨ì—ì„œ 40bpë¥¼ ì–»ì—ˆìŠµë‹ˆë‹¤. ì¤‘ìš”í•œ ì ì€ Afferaì˜ ìƒì‚° ëŠ¥ë ¥ í™•ëŒ€ë¡œ ì¸í•œ ë§ˆì§„ ì—­í’ì´ ì´ì œ í•´ì†Œë˜ì—ˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>So together, we drove a 70 basis point operational improvement in gross margin in the quarter. This was offset by business mix, which represented a headwind of 80 basis points, split roughly equally between Cardiac Ablation and Diabetes. As I noted last quarter, CAS is impacted by the mix of lower-margin capital to higher-margin catheters, and Diabetes is early in its manufacturing ramp-up of Simplera. Over time, we expect both of these to improve as we scale our CAS business and separate the Diabetes business. Next, tariffs were a 20 basis points headwind. And finally, FX was about 100 basis points tailwind.</td><td>ì´ëŸ¬í•œ ë…¸ë ¥ë“¤ì„ í†µí•´ ë‹¹ ë¶„ê¸° ë§¤ì¶œì´ì´ìµë¥ ì—ì„œ 70bpì˜ ìš´ì˜ìƒ ê°œì„ ì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ë‹¤ë§Œ ì´ëŠ” ì‚¬ì—… ë¯¹ìŠ¤ë¡œ ì¸í•´ ìƒì‡„ë˜ì—ˆëŠ”ë°, ì´ëŠ” 80bpì˜ ì—­í’ìœ¼ë¡œ ì‘ìš©í–ˆìœ¼ë©°, Cardiac Ablationê³¼ Diabetes ì‚¬ì—…ë¶€ì—ì„œ ê±°ì˜ ê· ë“±í•˜ê²Œ ë‚˜íƒ€ë‚¬ìŠµë‹ˆë‹¤. ì§€ë‚œ ë¶„ê¸°ì— ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´, CASëŠ” ì €ë§ˆì§„ ì¥ë¹„ ëŒ€ë¹„ ê³ ë§ˆì§„ ì¹´í…Œí„°ì˜ ë¯¹ìŠ¤ ì˜í–¥ì„ ë°›ê³  ìˆìœ¼ë©°, Diabetes ì‚¬ì—…ë¶€ëŠ” Simpleraì˜ ìƒì‚° í™•ëŒ€ ì´ˆê¸° ë‹¨ê³„ì— ìˆìŠµë‹ˆë‹¤. ì‹œê°„ì´ ì§€ë‚¨ì— ë”°ë¼ CAS ì‚¬ì—…ì„ í™•ëŒ€í•˜ê³  Diabetes ì‚¬ì—…ë¶€ë¥¼ ë¶„ë¦¬í•˜ë©´ì„œ ì´ ë‘ ë¶€ë¬¸ ëª¨ë‘ ê°œì„ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ë‹¤ìŒìœ¼ë¡œ, ê´€ì„¸ê°€ 20bpì˜ ì—­í’ìœ¼ë¡œ ì‘ìš©í–ˆìŠµë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ, ì™¸í™˜ì€ ì•½ 100bpì˜ ìˆœí’ íš¨ê³¼ë¥¼ ë³´ì˜€ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Adjusted R&D was 8.4% of revenue and increased 8.9%, which is 230 basis points ahead of reported revenue growth. We've increased R&D investments in our core right-to-win franchises, where we've identified opportunities to accelerate top line growth and improve our share in the near, mid and long term. SG&A was 32.7% of revenue, up 20 basis points versus last year. As Geoff mentioned, we proactively took the opportunity to increase spending to accelerate our PFA and RDN launches in light of the considerable market demand and compelling near- and medium-term outlooks. At the same time, we delivered disciplined leverage on G&A with growth at under half the rate of our revenue growth.</td><td>ì¡°ì • R&DëŠ” ë§¤ì¶œì˜ 8.4%ë¡œ 8.9% ì¦ê°€í–ˆìœ¼ë©°, ì´ëŠ” ë³´ê³ ëœ ë§¤ì¶œ ì„±ì¥ë¥ ë³´ë‹¤ 230bp ì•ì„œëŠ” ìˆ˜ì¹˜ì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ë‹¨ê¸°, ì¤‘ê¸° ë° ì¥ê¸°ì ìœ¼ë¡œ ë§¤ì¶œ ì„±ì¥ì„ ê°€ì†í™”í•˜ê³  ì‹œì¥ ì ìœ ìœ¨ì„ ê°œì„ í•  ìˆ˜ ìˆëŠ” ê¸°íšŒë¥¼ í™•ì¸í•œ í•µì‹¬ ê²½ìŸë ¥ í”„ëœì°¨ì´ì¦ˆì— R&D íˆ¬ìë¥¼ í™•ëŒ€í–ˆìŠµë‹ˆë‹¤. SG&AëŠ” ë§¤ì¶œì˜ 32.7%ë¡œ ì „ë…„ ëŒ€ë¹„ 20bp ì¦ê°€í–ˆìŠµë‹ˆë‹¤. Geoffê°€ ì–¸ê¸‰í–ˆë“¯ì´, ìš°ë¦¬ëŠ” ìƒë‹¹í•œ ì‹œì¥ ìˆ˜ìš”ì™€ ë§¤ë ¥ì ì¸ ë‹¨ê¸° ë° ì¤‘ê¸° ì „ë§ì„ ê³ ë ¤í•˜ì—¬ PFAì™€ RDN ì¶œì‹œë¥¼ ê°€ì†í™”í•˜ê¸° ìœ„í•´ ì„ ì œì ìœ¼ë¡œ ì§€ì¶œì„ ëŠ˜ë¦¬ëŠ” ê¸°íšŒë¥¼ í™œìš©í–ˆìŠµë‹ˆë‹¤. ë™ì‹œì— ìš°ë¦¬ëŠ” ë§¤ì¶œ ì„±ì¥ë¥ ì˜ ì ˆë°˜ ë¯¸ë§Œ ìˆ˜ì¤€ìœ¼ë¡œ G&Aë¥¼ ì„±ì¥ì‹œí‚¤ë©° ê·œìœ¨ ìˆëŠ” ë ˆë²„ë¦¬ì§€ë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Our adjusted op profit was $2.2 billion, an increase of 6%. This resulted in an adjusted operating margin of 24.1%, down 20 basis points year-over-year, but an increase of 50 basis points sequentially. Our adjusted tax rate was 16.4%. Q2 tax expense was lower than expected, which is largely due to timing and which we expect to offset in the fourth quarter. All in all, adjusted EPS was $1.36, an increase of 8% and $0.05 above the midpoint of our guidance. Now let's cover our guidance. Given our outperformance in the first half of the year as well as the confidence we have in our revenue growth acceleration, we're raising our full year revenue guidance today.</td><td>ì¡°ì • ì˜ì—…ì´ìµì€ 22ì–µ ë‹¬ëŸ¬ë¡œ 6% ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ì´ì— ë”°ë¼ ì¡°ì • ì˜ì—…ì´ìµë¥ ì€ 24.1%ë¥¼ ê¸°ë¡í–ˆìœ¼ë©°, ì´ëŠ” ì „ë…„ ë™ê¸° ëŒ€ë¹„ 20bp ê°ì†Œí–ˆì§€ë§Œ ì „ë¶„ê¸° ëŒ€ë¹„ë¡œëŠ” 50bp ì¦ê°€í•œ ìˆ˜ì¹˜ì…ë‹ˆë‹¤. ì¡°ì • ì„¸ìœ¨ì€ 16.4%ì˜€ìŠµë‹ˆë‹¤. 2ë¶„ê¸° ì„¸ê¸ˆ ë¹„ìš©ì€ ì˜ˆìƒë³´ë‹¤ ë‚®ì•˜ëŠ”ë°, ì´ëŠ” ì£¼ë¡œ íƒ€ì´ë° ìš”ì¸ì— ê¸°ì¸í•œ ê²ƒìœ¼ë¡œ 4ë¶„ê¸°ì— ìƒì‡„ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ì¢…í•©ì ìœ¼ë¡œ ì¡°ì • ì£¼ë‹¹ìˆœì´ìµ(EPS)ì€ 1.36ë‹¬ëŸ¬ë¡œ 8% ì¦ê°€í–ˆìœ¼ë©°, ê°€ì´ë˜ìŠ¤ ì¤‘ê°„ê°’ ëŒ€ë¹„ 0.05ë‹¬ëŸ¬ ìƒíšŒí–ˆìŠµë‹ˆë‹¤. <br><br>ì´ì œ ê°€ì´ë˜ìŠ¤ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ìƒë°˜ê¸° ìš°ìˆ˜í•œ ì‹¤ì ê³¼ ë§¤ì¶œ ì„±ì¥ ê°€ì†í™”ì— ëŒ€í•œ í™•ì‹ ì„ ë°”íƒ•ìœ¼ë¡œ, ì˜¤ëŠ˜ ì—°ê°„ ë§¤ì¶œ ê°€ì´ë˜ìŠ¤ë¥¼ ìƒí–¥ ì¡°ì •í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Year-to-date, we've delivered 5.2% organic growth, and we expect this to further accelerate in the back half of the year. As a result, we now expect fiscal '26 revenue growth of approximately 5.5%, a 50 basis point increase from the prior guidance. In the third quarter, we're also expecting approximately 5.5% growth and Q4 will be even stronger. Based on recent rates, we now see an FX tailwind to fiscal '26 revenue of $625 million to $725 million, including $150 million to $200 million tailwind in the third quarter. Moving down the P&L.</td><td>ì—°ì´ˆ ëŒ€ë¹„ í˜„ì¬ê¹Œì§€ 5.2%ì˜ ìœ ê¸°ì  ì„±ì¥ì„ ë‹¬ì„±í–ˆìœ¼ë©°, í•˜ë°˜ê¸°ì—ëŠ” ì´ëŸ¬í•œ ì„±ì¥ì„¸ê°€ ë”ìš± ê°€ì†í™”ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ì´ì— ë”°ë¼ 26íšŒê³„ì—°ë„ ë§¤ì¶œ ì„±ì¥ë¥ ì„ ì•½ 5.5%ë¡œ ì „ë§í•˜ë©°, ì´ëŠ” ì´ì „ ê°€ì´ë˜ìŠ¤ ëŒ€ë¹„ 50bp(ë² ì´ì‹œìŠ¤í¬ì¸íŠ¸) ìƒí–¥ ì¡°ì •ëœ ìˆ˜ì¹˜ì…ë‹ˆë‹¤. 3ë¶„ê¸°ì—ë„ ì•½ 5.5%ì˜ ì„±ì¥ì„ ì˜ˆìƒí•˜ê³  ìˆìœ¼ë©°, 4ë¶„ê¸°ëŠ” ì´ë³´ë‹¤ ë”ìš± ê°•ë ¥í•œ ì„±ì¥ì„¸ë¥¼ ë³´ì¼ ê²ƒì…ë‹ˆë‹¤. ìµœê·¼ í™˜ìœ¨ì„ ê¸°ì¤€ìœ¼ë¡œ 26íšŒê³„ì—°ë„ ë§¤ì¶œì— ëŒ€í•œ ì™¸í™˜ ìˆœíš¨ê³¼ëŠ” 6ì–µ 2,500ë§Œ ë‹¬ëŸ¬ì—ì„œ 7ì–µ 2,500ë§Œ ë‹¬ëŸ¬ë¡œ ì˜ˆìƒë˜ë©°, ì´ ì¤‘ 3ë¶„ê¸°ì—ëŠ” 1ì–µ 5,000ë§Œ ë‹¬ëŸ¬ì—ì„œ 2ì–µ ë‹¬ëŸ¬ì˜ ìˆœíš¨ê³¼ê°€ ë°œìƒí•  ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. ì†ìµê³„ì‚°ì„œ í•˜ë‹¨ìœ¼ë¡œ ë‚´ë ¤ê°€ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We expect our fiscal '26 gross margin to be slightly up ex tariffs with pricing, FX and COGS efficiency programs more than offsetting the negative impacts of business mix, primarily from Cardiac Ablation and Diabetes. We anticipate a tariff impact to COGS of approximately $185 million, including $90 million to $95 million in the third quarter. Including tariffs, we expect a fiscal '26 gross margin decrease of roughly 40 basis points. We'll continue to fund R&D to grow greater than sales.</td><td>2026 íšŒê³„ì—°ë„ ì´ë§ˆì§„ì€ ê´€ì„¸ë¥¼ ì œì™¸í•˜ë©´ ì†Œí­ ìƒìŠ¹í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ê°€ê²© ì±…ì •, í™˜ìœ¨, ê·¸ë¦¬ê³  ë§¤ì¶œì›ê°€ íš¨ìœ¨í™” í”„ë¡œê·¸ë¨ì´ ì£¼ë¡œ ì‹¬ì¥ ì ˆì œìˆ (Cardiac Ablation)ê³¼ ë‹¹ë‡¨ë³‘ ì‚¬ì—…ì—ì„œ ë°œìƒí•˜ëŠ” ì‚¬ì—… ë¯¹ìŠ¤ì˜ ë¶€ì •ì  ì˜í–¥ì„ ìƒì‡„í•˜ê³ ë„ ë‚¨ì„ ê²ƒì…ë‹ˆë‹¤. ê´€ì„¸ê°€ ë§¤ì¶œì›ê°€ì— ë¯¸ì¹˜ëŠ” ì˜í–¥ì€ ì•½ 1ì–µ 8,500ë§Œ ë‹¬ëŸ¬ë¡œ ì˜ˆìƒë˜ë©°, ì´ ì¤‘ 9,000ë§Œ~9,500ë§Œ ë‹¬ëŸ¬ê°€ 3ë¶„ê¸°ì— ë°œìƒí•  ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. ê´€ì„¸ë¥¼ í¬í•¨í•  ê²½ìš°, 2026 íšŒê³„ì—°ë„ ì´ë§ˆì§„ì€ ì•½ 40bp(ë² ì´ì‹œìŠ¤í¬ì¸íŠ¸) ê°ì†Œí•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ë§¤ì¶œ ì„±ì¥ë¥ ì„ ìƒíšŒí•˜ëŠ” ìˆ˜ì¤€ìœ¼ë¡œ R&Dì— ëŒ€í•œ íˆ¬ìë¥¼ ì§€ì†í•  ê³„íšì…ë‹ˆë‹¤.</td></tr>
<tr><td>With SG&A, in light of the outsized demand and building momentum for our enterprise growth drivers, we're capitalizing on every opportunity to accelerate our top line by strategically increasing sales and marketing investment in key programs, but we'll still deliver SG&A leverage on the full year by rigorously managing our G&A line. Taking all of this together, we expect fiscal '26 adjusted operating profit to grow approximately 5%, or 7% excluding tariffs. Our fiscal '26 operating margin is expected to be roughly flat ex tariffs and down about 50 basis points, including the tariffs impact. Now coming to EPS. Second quarter EPS came in $0.05 above the midpoint of our guidance.</td><td>SG&A ê´€ë ¨í•´ì„œëŠ”, ê¸°ì—… ì„±ì¥ ë™ë ¥ì— ëŒ€í•œ ì••ë„ì ì¸ ìˆ˜ìš”ì™€ ëª¨ë©˜í…€ ê°•í™”ë¥¼ ê³ ë ¤í•˜ì—¬, ì£¼ìš” í”„ë¡œê·¸ë¨ì— ëŒ€í•œ ì˜ì—… ë° ë§ˆì¼€íŒ… íˆ¬ìë¥¼ ì „ëµì ìœ¼ë¡œ í™•ëŒ€í•¨ìœ¼ë¡œì¨ ë§¤ì¶œ ì„±ì¥ì„ ê°€ì†í™”í•  ìˆ˜ ìˆëŠ” ëª¨ë“  ê¸°íšŒë¥¼ í™œìš©í•˜ê³  ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ G&A í•­ëª©ì„ ì—„ê²©í•˜ê²Œ ê´€ë¦¬í•˜ì—¬ ì—°ê°„ ê¸°ì¤€ìœ¼ë¡œëŠ” ì—¬ì „íˆ SG&A ë ˆë²„ë¦¬ì§€ë¥¼ ë‹¬ì„±í•  ê²ƒì…ë‹ˆë‹¤. ì´ ëª¨ë“  ê²ƒì„ ì¢…í•©í•˜ë©´, 2026 íšŒê³„ì—°ë„ ì¡°ì • ì˜ì—…ì´ìµì€ ì•½ 5% ì„±ì¥í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ë©°, ê´€ì„¸ë¥¼ ì œì™¸í•˜ë©´ 7% ì„±ì¥í•  ê²ƒìœ¼ë¡œ ì „ë§ë©ë‹ˆë‹¤. 2026 íšŒê³„ì—°ë„ ì˜ì—…ì´ìµë¥ ì€ ê´€ì„¸ë¥¼ ì œì™¸í•˜ë©´ ëŒ€ì²´ë¡œ ë³´í•© ìˆ˜ì¤€ì„ ìœ ì§€í•˜ê³ , ê´€ì„¸ ì˜í–¥ì„ í¬í•¨í•˜ë©´ ì•½ 50bp ê°ì†Œí•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ì´ì œ EPSë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. 2ë¶„ê¸° EPSëŠ” ê°€ì´ë˜ìŠ¤ ì¤‘ê°„ê°’ ëŒ€ë¹„ 0.05ë‹¬ëŸ¬ ìƒíšŒí–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>$0.035 of this beat was from reduced tax expense, as I mentioned earlier, that we now expect to occur in Q4. We're flowing through the remainder of the Q2 beat and increasing our fiscal '26 EPS guidance to a new range of $5.62 to $5.66 versus the prior range of $5.60 to $5.66. For Q3, we expect EPS in the range of $1.32 to $1.34. We're expecting margins to be down a couple of hundred basis points in Q3 as the quarter includes half the annual impact of tariffs. In addition, the expected growth acceleration in CAS and Diabetes will continue to impact business mix and Q3 is typically our lowest quarter for generating COGS efficiency savings given the holidays.</td><td>ì´ë²ˆ ì‹¤ì  ì´ˆê³¼ë¶„ ì¤‘ $0.035ëŠ” ì•ì„œ ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼ ì„¸ê¸ˆ ë¹„ìš© ê°ì†Œì— ë”°ë¥¸ ê²ƒìœ¼ë¡œ, ì´ëŠ” ì´ì œ 4ë¶„ê¸°ì— ë°œìƒí•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ìš°ë¦¬ëŠ” 2ë¶„ê¸° ì‹¤ì  ì´ˆê³¼ë¶„ì˜ ë‚˜ë¨¸ì§€ ë¶€ë¶„ì„ ë°˜ì˜í•˜ì—¬ 2026 íšŒê³„ì—°ë„ ì£¼ë‹¹ìˆœì´ìµ(EPS) ê°€ì´ë˜ìŠ¤ë¥¼ ê¸°ì¡´ $5.60~$5.66ì—ì„œ $5.62~$5.66ì˜ ìƒˆë¡œìš´ ë²”ìœ„ë¡œ ìƒí–¥ ì¡°ì •í•©ë‹ˆë‹¤. 3ë¶„ê¸°ì˜ ê²½ìš°, EPSëŠ” $1.32~$1.34 ë²”ìœ„ê°€ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. 3ë¶„ê¸°ì—ëŠ” ë§ˆì§„ì´ ì•½ 200bp(ë² ì´ì‹œìŠ¤í¬ì¸íŠ¸) í•˜ë½í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ëŠ”ë°, ì´ëŠ” í•´ë‹¹ ë¶„ê¸°ì— ê´€ì„¸ì˜ ì—°ê°„ ì˜í–¥ë¶„ ì¤‘ ì ˆë°˜ì´ í¬í•¨ë˜ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ë˜í•œ CASì™€ ë‹¹ë‡¨ë³‘ ë¶€ë¬¸ì˜ ì˜ˆìƒ ì„±ì¥ ê°€ì†í™”ê°€ ì‚¬ì—… ë¯¹ìŠ¤ì— ì§€ì†ì ìœ¼ë¡œ ì˜í–¥ì„ ë¯¸ì¹  ê²ƒì´ë©°, 3ë¶„ê¸°ëŠ” íœ´ê°€ ê¸°ê°„ìœ¼ë¡œ ì¸í•´ ì¼ë°˜ì ìœ¼ë¡œ ë§¤ì¶œì›ê°€(COGS) íš¨ìœ¨ì„± ì ˆê° íš¨ê³¼ê°€ ê°€ì¥ ë‚®ì€ ë¶„ê¸°ì…ë‹ˆë‹¤.</td></tr>
<tr><td>However, we do expect Q4 margins to increase year-over-year and show strong sequential improvement. Looking ahead to next year, we continue to expect high single-digit EPS growth in fiscal year '27, driven by accelerating revenue growth, a lesser impact of business mix from CAS and Diabetes on the gross margin line, and leverage on SG&A while we continue to drive higher investments in R&D and sales and marketing. Look, we remain committed to driving both revenue and earnings growth and believe strongly that our financial algorithm will flow from our current focus on building sustained top line momentum. Geoff, back to you. Geoffrey Martha<br>Chairman of the Board & CEO<br><br>Okay.</td><td>ê·¸ëŸ¬ë‚˜ 4ë¶„ê¸° ë§ˆì§„ì€ ì „ë…„ ëŒ€ë¹„ ì¦ê°€í•˜ê³  ìˆœì°¨ì ìœ¼ë¡œ ê°•í•œ ê°œì„ ì„ ë³´ì¼ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ë‚´ë…„ì„ ì „ë§í•˜ë©´, 2027 íšŒê³„ì—°ë„ì—ëŠ” ë†’ì€ í•œ ìë¦¿ìˆ˜ EPS ì„±ì¥ì„ ì§€ì†ì ìœ¼ë¡œ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ê°€ì†í™”ë˜ëŠ” ë§¤ì¶œ ì„±ì¥, CASì™€ ë‹¹ë‡¨ë³‘ ì‚¬ì—…ì˜ ì‚¬ì—… ë¯¹ìŠ¤ê°€ ë§¤ì¶œì´ì´ìµë¥ ì— ë¯¸ì¹˜ëŠ” ì˜í–¥ ê°ì†Œ, ê·¸ë¦¬ê³  R&Dì™€ ì˜ì—… ë° ë§ˆì¼€íŒ…ì— ëŒ€í•œ íˆ¬ìë¥¼ ì§€ì†ì ìœ¼ë¡œ í™•ëŒ€í•˜ë©´ì„œë„ íŒë§¤ê´€ë¦¬ë¹„ì—ì„œì˜ ë ˆë²„ë¦¬ì§€ íš¨ê³¼ì— ì˜í•´ ê²¬ì¸ë  ê²ƒì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ë§¤ì¶œê³¼ ì´ìµ ì„±ì¥ì„ ëª¨ë‘ ë‹¬ì„±í•˜ëŠ” ë° ì „ë…í•˜ê³  ìˆìœ¼ë©°, ìš°ë¦¬ì˜ ì¬ë¬´ ì•Œê³ ë¦¬ì¦˜ì´ ì§€ì†ì ì¸ ë§¤ì¶œ ëª¨ë©˜í…€ êµ¬ì¶•ì— ëŒ€í•œ í˜„ì¬ì˜ ì§‘ì¤‘ì—ì„œ ë¹„ë¡¯ë  ê²ƒì´ë¼ê³  ê°•ë ¥íˆ ë¯¿ê³  ìˆìŠµë‹ˆë‹¤. Geoff, ë‹¤ì‹œ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.<br><br>Geoffrey Martha<br>ì´ì‚¬íšŒ ì˜ì¥ ê²¸ CEO<br><br>ì•Œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Thank you, Thierry. Before we go to Q&A, let me share a few quick thoughts. So when you look at our top line, you can really see the focus we've had on allocating capital, and executing on our pipeline is all now coming together to drive meaningful acceleration in our growth. We're on an incredible trajectory with PFA, and we're just getting started with some big new opportunities with Symplicity and Altaviva. At the same time, our newly formed Board committees are helping as we act decisively and with increased speed. We're executing on margin enhancement programs to fuel our enterprise growth drivers, the future pipeline and earnings leverage.</td><td>ê°ì‚¬í•©ë‹ˆë‹¤, Thierry. Q&Aë¡œ ë„˜ì–´ê°€ê¸° ì „ì— ëª‡ ê°€ì§€ ê°„ë‹¨í•œ ìƒê°ì„ ê³µìœ í•˜ê² ìŠµë‹ˆë‹¤. ë§¤ì¶œ ìµœìƒë‹¨ì„ ë³´ì‹œë©´, ìë³¸ ë°°ë¶„ì— ì§‘ì¤‘í•˜ê³  íŒŒì´í”„ë¼ì¸ì„ ì‹¤í–‰í•´ì˜¨ ë…¸ë ¥ì´ ì´ì œ ëª¨ë‘ ê²°í•©ë˜ì–´ ì˜ë¯¸ ìˆëŠ” ì„±ì¥ ê°€ì†í™”ë¥¼ ì´ëŒì–´ë‚´ê³  ìˆìŒì„ í™•ì‹¤íˆ ë³´ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. PFAì—ì„œ ë†€ë¼ìš´ ì„±ì¥ ê¶¤ë„ë¥¼ ë³´ì´ê³  ìˆìœ¼ë©°, Symplicityì™€ Altavivaë¥¼ í†µí•œ ëŒ€ê·œëª¨ ì‹ ê·œ ê¸°íšŒë“¤ì€ ì´ì œ ë§‰ ì‹œì‘ ë‹¨ê³„ì…ë‹ˆë‹¤. ë™ì‹œì—, ìƒˆë¡­ê²Œ êµ¬ì„±ëœ ì´ì‚¬íšŒ ìœ„ì›íšŒë“¤ì´ ìš°ë¦¬ê°€ ë”ìš± ì‹ ì†í•˜ê³  ë‹¨í˜¸í•˜ê²Œ í–‰ë™í•˜ëŠ” ë° ë„ì›€ì„ ì£¼ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ê¸°ì—… ì„±ì¥ ë™ë ¥, ë¯¸ë˜ íŒŒì´í”„ë¼ì¸, ê·¸ë¦¬ê³  ìˆ˜ìµ ë ˆë²„ë¦¬ì§€ë¥¼ ê°•í™”í•˜ê¸° ìœ„í•œ ë§ˆì§„ ê°œì„  í”„ë¡œê·¸ë¨ë“¤ì„ ì‹¤í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We continue to evaluate the overall portfolio at every level as well as tuck-in M&A, and we are committed to growing above our WAMGR, while also raising the WAMGR of the company over time. And I'm looking forward to diving deeper into all of this with you at our Investor Day next year. So bottom line, we're executing on our commitments. You can see it in our numbers. And with every quarter, we're picking up more momentum. We're pleased with the progress, but eager to continue proving Medtronic has turned the page and entered a new period of greater revenue and earnings growth. Finally, I want to thank our employees who are watching today around the world. Thank you.</td><td>ìš°ë¦¬ëŠ” ì†Œê·œëª¨ ì¸ìˆ˜í•©ë³‘ë¿ë§Œ ì•„ë‹ˆë¼ ëª¨ë“  ìˆ˜ì¤€ì—ì„œ ì „ì²´ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ì§€ì†ì ìœ¼ë¡œ í‰ê°€í•˜ê³  ìˆìœ¼ë©°, ì‹œê°„ì´ ì§€ë‚¨ì— ë”°ë¼ íšŒì‚¬ì˜ ê°€ì¤‘í‰ê· ì‹œì¥ì„±ì¥ë¥ (WAMGR)ì„ ë†’ì´ëŠ” ë™ì‹œì— WAMGRì„ ìƒíšŒí•˜ëŠ” ì„±ì¥ì„ ë‹¬ì„±í•˜ëŠ” ë° ì „ë…í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë‚´ë…„ íˆ¬ììì˜ ë‚ (Investor Day)ì—ì„œ ì—¬ëŸ¬ë¶„ê³¼ ì´ ëª¨ë“  ë‚´ìš©ì— ëŒ€í•´ ë” ê¹Šì´ ë…¼ì˜í•  ìˆ˜ ìˆê¸°ë¥¼ ê¸°ëŒ€í•©ë‹ˆë‹¤. ê²°ë¡ ì ìœ¼ë¡œ, ìš°ë¦¬ëŠ” ì•½ì†ì„ ì´í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ìš°ë¦¬ì˜ ì‹¤ì  ìˆ˜ì¹˜ì—ì„œ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë§¤ ë¶„ê¸°ë§ˆë‹¤ ë” ë§ì€ ëª¨ë©˜í…€ì„ ì–»ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì´ëŸ¬í•œ ì§„ì „ì— ë§Œì¡±í•˜ì§€ë§Œ, ë©”ë“œíŠ¸ë¡œë‹‰ì´ ìƒˆë¡œìš´ ì¥ì„ ì—´ê³  ë” ë†’ì€ ë§¤ì¶œê³¼ ìˆ˜ìµ ì„±ì¥ì˜ ìƒˆë¡œìš´ ì‹œê¸°ì— ì§„ì…í–ˆìŒì„ ê³„ì† ì…ì¦í•˜ê³ ì í•©ë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ, ì˜¤ëŠ˜ ì „ ì„¸ê³„ì—ì„œ ì‹œì²­í•˜ê³  ê³„ì‹  ìš°ë¦¬ ì§ì›ë“¤ì—ê²Œ ê°ì‚¬ì˜ ë§ì”€ì„ ì „í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Thank you for your steadfast commitment to the Medtronic mission and to the patients that you and our customers serve every day. I also appreciate your continued execution, which allows us to collectively deliver on our total company performance. So thank you. Okay. Now it's time to move on to Q&A where we're going to try to get to as many analysts as possible. We ask that you limit yourself to just one question and, only if needed, a related follow-up. If you have additional questions, you can reach out to Ryan and the Investor Relations team after the call. So Ryan, can you please give the Q&A instructions and queue up the analysts?</td><td>ê°ì‚¬í•©ë‹ˆë‹¤. ë©”ë“œíŠ¸ë¡œë‹‰ì˜ ì‚¬ëª…ê³¼ ì—¬ëŸ¬ë¶„ê³¼ ìš°ë¦¬ ê³ ê°ë“¤ì´ ë§¤ì¼ ëŒë³´ëŠ” í™˜ìë“¤ì— ëŒ€í•œ ì—¬ëŸ¬ë¶„ì˜ ë³€í•¨ì—†ëŠ” í—Œì‹ ì— ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. ë˜í•œ ìš°ë¦¬ê°€ í•¨ê»˜ ì „ì‚¬ì  ì„±ê³¼ë¥¼ ë‹¬ì„±í•  ìˆ˜ ìˆë„ë¡ í•´ì£¼ì‹œëŠ” ì—¬ëŸ¬ë¶„ì˜ ì§€ì†ì ì¸ ì‹¤í–‰ë ¥ì—ë„ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. ì •ë§ ê°ì‚¬í•©ë‹ˆë‹¤. <br><br>ì, ì´ì œ Q&A ì‹œê°„ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ê°€ëŠ¥í•œ í•œ ë§ì€ ì• ë„ë¦¬ìŠ¤íŠ¸ ë¶„ë“¤ì˜ ì§ˆë¬¸ì„ ë°›ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤. ì§ˆë¬¸ì€ í•œ ê°€ì§€ë¡œ ì œí•œí•´ ì£¼ì‹œê³ , í•„ìš”í•œ ê²½ìš°ì—ë§Œ ê´€ë ¨ëœ ì¶”ê°€ ì§ˆë¬¸ì„ í•´ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤. ì¶”ê°€ ì§ˆë¬¸ì´ ìˆìœ¼ì‹œë©´ ì½œ ì¢…ë£Œ í›„ Ryanê³¼ íˆ¬ìì ê´€ê³„íŒ€ì— ì—°ë½í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤. ê·¸ëŸ¼ Ryan, Q&A ì•ˆë‚´ ë§ì”€ê³¼ ì• ë„ë¦¬ìŠ¤íŠ¸ ë¶„ë“¤ì„ ì—°ê²°í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;"># Medtronic Q2 FY2026 ì‹¤ì  ìš”ì•½<br><br>## ì£¼ìš” ì¬ë¬´ ì„±ê³¼<br>- **2ë¶„ê¸° ë§¤ì¶œ 90ì–µ ë‹¬ëŸ¬, ìœ ê¸°ì  ì„±ì¥ë¥  5.5%** ë‹¬ì„±í•˜ë©° ê°€ì´ë˜ìŠ¤ ìƒíšŒ. EPS $1.36ìœ¼ë¡œ 8% ì¦ê°€í•˜ë©° ê°€ì´ë˜ìŠ¤ ëŒ€ë¹„ $0.05 ì´ˆê³¼ ë‹¬ì„±<br>- **ì—°ê°„ ê°€ì´ë˜ìŠ¤ ìƒí–¥ ì¡°ì •**: ë§¤ì¶œ ì„±ì¥ë¥  5.0%â†’5.5%ë¡œ ìƒí–¥, EPS ê°€ì´ë˜ìŠ¤ $5.62-5.66ìœ¼ë¡œ ìƒí–¥. FY27 EPSëŠ” ë†’ì€ í•œìë¦¿ìˆ˜ ì„±ì¥ ì „ë§ ìœ ì§€<br>- **ë§ˆì§„ í˜„í™©**: ì¡°ì • ì˜ì—…ì´ìµë¥  24.1%ë¡œ ì „ë…„ ëŒ€ë¹„ 20bp ê°ì†Œí–ˆìœ¼ë‚˜ ì „ë¶„ê¸° ëŒ€ë¹„ 50bp ê°œì„ . ê´€ì„¸ ì˜í–¥($185M) ì œì™¸ ì‹œ ì—°ê°„ ì˜ì—…ì´ìµë¥  í”Œë« ì „ë§<br><br>## í•µì‹¬ ì„±ì¥ ë™ë ¥<br>- **ì‹¬ì¥ ì ˆì œìˆ (Cardiac Ablation) ì‚¬ì—… ê¸‰ì„±ì¥**: 71% ì„±ì¥í•˜ë©° ì—…ê³„ ìµœê³  ì„±ì¥ë¥  ê¸°ë¡. PFA í”„ëœì°¨ì´ì¦ˆê°€ ë¯¸êµ­ ë° í•´ì™¸ì—ì„œ 300% ì´ìƒ ì„±ì¥. Affera ì‹œìŠ¤í…œ ì„¤ì¹˜ ê¸°ë°˜ 2ë°° í™•ëŒ€, 3ë¶„ê¸° ì¶”ê°€ ê°€ì† ì „ë§<br>- **Symplicity ê³ í˜ˆì•• ì¹˜ë£Œ**: Medicare NCD ìµœì¢… ìŠ¹ì¸ íšë“ìœ¼ë¡œ 1,800ë§Œ ëª… ì‹œì¥ ì§„ì… ë³¸ê²©í™”. ìƒì—… ë³´í—˜ì‚¬ ì»¤ë²„ë¦¬ì§€ í™•ëŒ€(3,000ë§Œ ëª…), í•˜ë°˜ê¸° ë§¤ì¶œ ê¸°ì—¬ ì‹œì‘ ì˜ˆìƒ<br>- **Altaviva ìš”ì‹¤ê¸ˆ ì¹˜</p>
    <hr style="margin:50px 0;">
    

    <h2>â“ Q&A</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Ryan Weispfenning: VP & Head of Investor Relations Sure, Geoff. [Operator Instructions] Finally, please be advised that this Q&A session is being recorded. Okay, let's take the first question from Patrick Wood at Morgan Stanley.</td><td>**Ryan Weispfenning:** ë„¤, Geoff. [ìš´ì˜ì ì•ˆë‚´] ë§ˆì§€ë§‰ìœ¼ë¡œ ì´ë²ˆ Q&A ì„¸ì…˜ì€ ë…¹ìŒë˜ê³  ìˆìŒì„ ì•Œë ¤ë“œë¦½ë‹ˆë‹¤. ê·¸ëŸ¼ Morgan Stanleyì˜ Patrick Woodë‹˜ ì§ˆë¬¸ë¶€í„° ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Patrick Wood: Morgan Stanley, Research Division I'll keep it to one, of course. I'd love to start with Symplicity. You mentioned the commercial discussions happening faster than kind of expected. Obviously, without diving into any individual payer, how are those reflective relative to the NCD? Like are there restrictions being put on? What is the sort of tone of the conversation? And how are the commercial payers looking to introduce this within their patient pool?</td><td>**Patrick Wood:** ì‹¬í”Œë¦¬ì‹œí‹°(Symplicity)ì— ëŒ€í•´ í•œ ê°€ì§€ë§Œ ì§ˆë¬¸ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ìƒì—…ì  ë…¼ì˜ê°€ ì˜ˆìƒë³´ë‹¤ ë¹ ë¥´ê²Œ ì§„í–‰ë˜ê³  ìˆë‹¤ê³  ë§ì”€í•˜ì…¨ëŠ”ë°ìš”. ê°œë³„ ë³´í—˜ì‚¬ì— ëŒ€í•´ êµ¬ì²´ì ìœ¼ë¡œ ì–¸ê¸‰í•˜ì§€ ì•Šë”ë¼ë„, NCD(ì „êµ­ë³´í—˜ì ìš©ê²°ì •)ì™€ ë¹„êµí–ˆì„ ë•Œ ì´ëŸ¬í•œ ë…¼ì˜ë“¤ì´ ì–´ë–¤ ì–‘ìƒì¸ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ì œí•œ ì‚¬í•­ë“¤ì´ ì ìš©ë˜ê³  ìˆë‚˜ìš”? ëŒ€í™”ì˜ ì „ë°˜ì ì¸ ë¶„ìœ„ê¸°ëŠ” ì–´ë–¤ê°€ìš”? ê·¸ë¦¬ê³  ìƒì—… ë³´í—˜ì‚¬ë“¤ì´ ìì‚¬ì˜ í™˜ìêµ°ì— ì´ ì œí’ˆì„ ì–´ë–»ê²Œ ë„ì…í•˜ë ¤ê³  í•˜ëŠ”ì§€ ë§ì”€í•´ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”?</td></tr>
<tr><td>Geoffrey Martha: Chairman of the Board & CEO Yes. Thanks for the question, Patrick. The commercial payers, like you I mentioned in the commentary, they are coming online faster than I believe we anticipated. They're getting a lot of push from patients as well. In terms of restrictions, first of all, I'd say, look, the Medicare NCD is broad, and it's better than we anticipated. It's better than the proposal. So we're comparing it to that. The one area that I've heard, in addition, on NCD, they've incorporated physician -- for lack of a better word, physician discretion, patient discretion on, hey, as a patient, can I tolerate these meds? Or does the physician feel like the patient cannot tolerate the meds. That gives them that avenue to move to Ardian, to Symplicity. In the commercial payers, we're seeing where there is one difference that I know of is around the medication, so more of an emphasis on being on a few medications for a while. So that's the one area that I'm aware of, Patrick, and we'll keep everyone posted as we get more commercial payers online.</td><td>**Geoffrey Martha:** ë„¤, ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤, Patrick. ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼ ë¯¼ê°„ ë³´í—˜ì‚¬ë“¤ì´ ì˜ˆìƒë³´ë‹¤ ë¹ ë¥´ê²Œ ì°¸ì—¬í•˜ê³  ìˆìŠµë‹ˆë‹¤. í™˜ìë“¤ë¡œë¶€í„°ë„ ìƒë‹¹í•œ ìš”êµ¬ë¥¼ ë°›ê³  ìˆê³ ìš”. ì œí•œ ì‚¬í•­ì— ê´€í•´ì„œëŠ”, ìš°ì„  ë©”ë””ì¼€ì–´ NCD(National Coverage Determination, ì „êµ­ ë³´ì¥ ê²°ì •)ê°€ í¬ê´„ì ì´ë©° ìš°ë¦¬ê°€ ì˜ˆìƒí–ˆë˜ ê²ƒë³´ë‹¤ ì¢‹ìŠµë‹ˆë‹¤. ì´ˆì•ˆë³´ë‹¤ ë‚˜ì•„ì¡Œì£ . ê·¸ê±¸ ê¸°ì¤€ìœ¼ë¡œ ë¹„êµí•˜ê³  ìˆëŠ” ê²ë‹ˆë‹¤. <br><br>NCDì—ì„œ ì¶”ê°€ë¡œ ì£¼ëª©í•  ì ì€, ì˜ì‚¬ ì¬ëŸ‰ê¶Œì„ í¬í•¨ì‹œì¼°ë‹¤ëŠ” ê²ë‹ˆë‹¤. ì ì ˆí•œ í‘œí˜„ì´ ì—†ì–´ì„œ ì˜ì‚¬ ì¬ëŸ‰ê¶Œì´ë¼ê³  í•˜ëŠ”ë°, í™˜ì ì¬ëŸ‰ê¶Œë„ í¬í•¨ë©ë‹ˆë‹¤. ì˜ˆë¥¼ ë“¤ì–´ í™˜ìê°€ 'ì´ ì•½ì„ ê²¬ë”œ ìˆ˜ ìˆëŠ”ê°€?' ë˜ëŠ” ì˜ì‚¬ê°€ 'ì´ í™˜ìê°€ ì•½ë¬¼ì„ ê²¬ë”œ ìˆ˜ ì—†ë‹¤'ê³  íŒë‹¨í•˜ëŠ” ê²½ìš° ë§ì´ì£ . ì´ë¥¼ í†µí•´ Ardian, ì¦‰ Symplicityë¡œ ë„˜ì–´ê°ˆ ìˆ˜ ìˆëŠ” ê²½ë¡œê°€ ìƒê¸´ ê²ë‹ˆë‹¤. ë¯¼ê°„ ë³´í—˜ì‚¬ë“¤ì˜ ê²½ìš°, ì œê°€ ì•Œê³  ìˆëŠ” í•œ ê°€ì§€ ì°¨ì´ì ì€ ì•½ë¬¼ ì¹˜ë£Œì™€ ê´€ë ¨ëœ ë¶€ë¶„ì…ë‹ˆë‹¤. ì¼ì • ê¸°ê°„ ë™ì•ˆ ëª‡ ê°€ì§€ ì•½ë¬¼ì„ ë³µìš©í•˜ëŠ” ê²ƒì„ ë” ê°•ì¡°í•˜ê³  ìˆìŠµë‹ˆë‹¤. íŒ¨íŠ¸ë¦­, ì œê°€ ì•Œê³  ìˆëŠ” ë¶€ë¶„ì€ ê·¸ ì •ë„ì´ê³ , ë” ë§ì€ ë¯¼ê°„ ë³´í—˜ì‚¬ë“¤ì´ ì°¸ì—¬í•˜ê²Œ ë˜ë©´ ê³„ì†í•´ì„œ ì—…ë°ì´íŠ¸í•´ ë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Ryan Weispfenning: VP & Head of Investor Relations We'll take the next question from Travis Steed at BofA Global Securities.</td><td>**Ryan Weispfenning:** ë‹¤ìŒ ì§ˆë¬¸ì€ BofA ê¸€ë¡œë²Œ ì‹œíë¦¬í‹°ì¦ˆì˜ íŠ¸ë˜ë¹„ìŠ¤ ìŠ¤í‹°ë“œ ì• ë„ë¦¬ìŠ¤íŠ¸ë¡œë¶€í„° ë°›ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Travis Steed: BofA Securities, Research Division Congrats on a good quarter. I guess, first of all, the implied second half guide around 6%, and kind of think about it in 2 buckets, the pipeline and then kind of the base business. And maybe talk about kind of what you're assuming on RDN in the second half, and then also the base business, why confident in the slight rebound in MedSurg and kind of the confidence to keep the base business humming? And then on the margins in the second half, this quarter, we didn't see quite as much margin flow through. Just assuming that changes in the second half, the revenue upside leads to more margin upside in the second half?</td><td>**Travis Steed:** ì¢‹ì€ ì‹¤ì  ì¶•í•˜ë“œë¦½ë‹ˆë‹¤. ìš°ì„ , í•˜ë°˜ê¸° ê°€ì´ë˜ìŠ¤ê°€ ì•½ 6% ì •ë„ë¡œ ë³´ì´ëŠ”ë°ìš”, ì´ë¥¼ ë‘ ê°€ì§€ ì¸¡ë©´ì—ì„œ ìƒê°í•´ë³´ê³  ì‹¶ìŠµë‹ˆë‹¤. íŒŒì´í”„ë¼ì¸ê³¼ ê¸°ì¡´ ì‚¬ì—… ë¶€ë¬¸ì…ë‹ˆë‹¤. í•˜ë°˜ê¸° RDNì— ëŒ€í•´ ì–´ë–¤ ê°€ì •ì„ í•˜ê³  ê³„ì‹ ì§€ ë§ì”€í•´ ì£¼ì‹œê³ ìš”, ê¸°ì¡´ ì‚¬ì—… ë¶€ë¬¸ì—ì„œëŠ” MedSurgì˜ ì†Œí­ ë°˜ë“±ì— ëŒ€í•œ í™•ì‹ ê³¼ ê¸°ì¡´ ì‚¬ì—…ì´ ê³„ì† ìˆœì¡°ë¡­ê²Œ ìš´ì˜ë  ê²ƒì´ë¼ëŠ” ìì‹ ê°ì˜ ê·¼ê±°ê°€ ë¬´ì—‡ì¸ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  í•˜ë°˜ê¸° ë§ˆì§„ì— ëŒ€í•´ì„œë„ ì—¬ì­¤ë³´ê² ìŠµë‹ˆë‹¤. ì´ë²ˆ ë¶„ê¸°ì—ëŠ” ë§ˆì§„ ê°œì„  íš¨ê³¼ê°€ ì˜ˆìƒë§Œí¼ í¬ì§€ ì•Šì•˜ëŠ”ë°ìš”, í•˜ë°˜ê¸°ì—ëŠ” ìƒí™©ì´ ë‹¬ë¼ì ¸ì„œ ë§¤ì¶œ ì¦ê°€ê°€ ë” í° ë§ˆì§„ ê°œì„ ìœ¼ë¡œ ì´ì–´ì§ˆ ê²ƒìœ¼ë¡œ ê°€ì •í•˜ì‹œëŠ” ê±´ê°€ìš”?</td></tr>
<tr><td>Geoffrey Martha: Chairman of the Board & CEO Do you want to take that one?</td><td>**Geoffrey Martha:** ì´ ì§ˆë¬¸ì— ë‹µë³€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>Thierry Pieton: Executive VP & CFO So maybe I'll start with the margin. Travis, thanks for the question. Look, we described the momentum that we had from a commercial perspective in the second quarter. And pretty early on in the quarter, we saw the order intake being pretty strong. We also saw that we were going to have a little bit of upside from a tax perspective, even though that's timing, but we did see it coming early on in the quarter. And so we just made a decision to go invest in the places that are going to drive the growth going forward. So we made some significant investments in the mappers structure, for example, in Cardiac Ablation. We started to build up the capability from a direct marketing on the Symplicity side. So we took the opportunity that we were going to see upside on revenue and a little bit on the tax line just to lean into the investment to make sure we fully capture the opportunities that are ahead of us. And so you saw that in R&D. It's the second quarter where we have R&D growth that's pretty significantly higher than the revenue growth. And this quarter, specifically, you saw it on the SG&A line, where we put, as I said, quite a bit of investment, especially in sales and marketing, while keeping the G&A line pretty constrained. So going forward into the rest of the year, we'll keep investing in these growth areas. You'll see R&D continue to ramp up. As you know, we're targeting to get over time to roughly about 10% of our revenue on the R&D line. On SG&A, though, you should expect to see leverage in the second half. So SG&A together. So we'll start seeing a lift there. And so ex tariffs, we'll have gross margin and operating margin leverage in the second half. But we'll have to contend with the tariff impact. So all in all, on a full year basis, you'll see gross margin slightly up before tariffs, down about 50 basis points post tariffs. And at the operating margin level, you'll see operating margin roughly flat year-over-year ex tariffs and slightly down with the impact of tariffs. So look, it's all about capitalizing on the opportunities that we've got ahead of us, and that's what we'll keep doing. But again, second half leverage on both those lines.</td><td>**Thierry Pieton:** ë§ˆì§„ì— ëŒ€í•´ ë¨¼ì € ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. Travis, ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. 2ë¶„ê¸°ì— ìš°ë¦¬ê°€ ì˜ì—… ì¸¡ë©´ì—ì„œ ë³´ì—¬ì¤€ ëª¨ë©˜í…€ì— ëŒ€í•´ ì„¤ëª…ë“œë ¸ìŠµë‹ˆë‹¤. ë¶„ê¸° ì´ˆë°˜ë¶€í„° ì£¼ë¬¸ ìœ ì…ì´ ìƒë‹¹íˆ ê°•ì„¸ë¥¼ ë³´ì´ëŠ” ê²ƒì„ í™•ì¸í–ˆìŠµë‹ˆë‹¤. ë˜í•œ ì„¸ê¸ˆ ì¸¡ë©´ì—ì„œë„ ì•½ê°„ì˜ ìƒìŠ¹ ì—¬ë ¥ì´ ìˆì„ ê²ƒìœ¼ë¡œ ë³´ì•˜ëŠ”ë°, ì´ê²ƒì´ íƒ€ì´ë°ì˜ ë¬¸ì œì´ê¸´ í•˜ì§€ë§Œ ë¶„ê¸° ì´ˆë°˜ì— ì´ë¯¸ ì˜ˆìƒí•  ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ìš°ë¦¬ëŠ” í–¥í›„ ì„±ì¥ì„ ê²¬ì¸í•  ë¶„ì•¼ì— íˆ¬ìí•˜ê¸°ë¡œ ê²°ì •í–ˆìŠµë‹ˆë‹¤. ì˜ˆë¥¼ ë“¤ì–´ ì‹¬ì¥ ì ˆì œìˆ (Cardiac Ablation) ë¶„ì•¼ì˜ ë§¤í¼ êµ¬ì¡°ì— ìƒë‹¹í•œ íˆ¬ìë¥¼ í–ˆìŠµë‹ˆë‹¤. ë˜í•œ ì‹¬í”Œë¦¬ì‹œí‹°(Symplicity) ìª½ì—ì„œëŠ” ì§ì ‘ ë§ˆì¼€íŒ… ì—­ëŸ‰ì„ êµ¬ì¶•í•˜ê¸° ì‹œì‘í–ˆìŠµë‹ˆë‹¤. ë§¤ì¶œ ìƒìŠ¹ê³¼ ì„¸ê¸ˆ ë¶€ë¬¸ì—ì„œ ì•½ê°„ì˜ ê°œì„  ì—¬ì§€ê°€ ë³´ì˜€ê¸° ë•Œë¬¸ì—, ìš°ë¦¬ ì•ì— ë†“ì¸ ê¸°íšŒë“¤ì„ ì™„ì „íˆ í¬ì°©í•˜ê¸° ìœ„í•´ íˆ¬ìë¥¼ í™•ëŒ€í•˜ëŠ” ê¸°íšŒë¡œ ì‚¼ì•˜ìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ R&D ë¶€ë¬¸ì—ì„œ ê·¸ ëª¨ìŠµì„ ë³´ì‹¤ ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤. R&D ì„±ì¥ë¥ ì´ ë§¤ì¶œ ì„±ì¥ë¥ ì„ ìƒë‹¹íˆ í¬ê²Œ ìƒíšŒí•œ ê²ƒì´ ì´ë²ˆì´ ë‘ ë²ˆì§¸ ë¶„ê¸°ì…ë‹ˆë‹¤. íŠ¹íˆ ì´ë²ˆ ë¶„ê¸°ì—ëŠ” SG&A í•­ëª©ì—ì„œ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆëŠ”ë°, ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼ íŒë§¤ ë° ë§ˆì¼€íŒ… ë¶€ë¬¸ì— ìƒë‹¹í•œ íˆ¬ìë¥¼ ì§‘í–‰í–ˆê³ , G&A ë¶€ë¬¸ì€ ê½¤ í†µì œëœ ìˆ˜ì¤€ìœ¼ë¡œ ìœ ì§€í–ˆìŠµë‹ˆë‹¤.<br><br>ì˜¬í•´ ë‚¨ì€ ê¸°ê°„ ë™ì•ˆ ì´ëŸ¬í•œ ì„±ì¥ ì˜ì—­ì— ê³„ì† íˆ¬ìí•  ê²ƒì…ë‹ˆë‹¤. R&Dê°€ ì§€ì†ì ìœ¼ë¡œ ì¦ê°€í•˜ëŠ” ê²ƒì„ ë³´ì‹œê²Œ ë  ê²ë‹ˆë‹¤. ì•„ì‹œë‹¤ì‹œí”¼ ìš°ë¦¬ëŠ” ì¥ê¸°ì ìœ¼ë¡œ R&Dë¥¼ ë§¤ì¶œì˜ ì•½ 10% ìˆ˜ì¤€ê¹Œì§€ ëŒì–´ì˜¬ë¦¬ëŠ” ê²ƒì„ ëª©í‘œë¡œ í•˜ê³  ìˆìŠµë‹ˆë‹¤. íŒë§¤ê´€ë¦¬ë¹„ ì¸¡ë©´ì—ì„œëŠ” í•˜ë°˜ê¸°ì— ë ˆë²„ë¦¬ì§€ íš¨ê³¼ë¥¼ ê¸°ëŒ€í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. íŒë§¤ê´€ë¦¬ë¹„ë¥¼ í•©ì³ì„œ ë³´ë©´ ê·¸ìª½ì—ì„œ ê°œì„ ì´ ë‚˜íƒ€ë‚  ê²ƒì…ë‹ˆë‹¤. ë”°ë¼ì„œ ê´€ì„¸ë¥¼ ì œì™¸í•˜ë©´ í•˜ë°˜ê¸°ì— ë§¤ì¶œì´ì´ìµë¥ ê³¼ ì˜ì—…ì´ìµë¥  ëª¨ë‘ ë ˆë²„ë¦¬ì§€ íš¨ê³¼ê°€ ìˆì„ ê²ƒì…ë‹ˆë‹¤. ë‹¤ë§Œ ê´€ì„¸ ì˜í–¥ì€ ê°ì•ˆí•´ì•¼ í•©ë‹ˆë‹¤.<br><br>ì „ì²´ì ìœ¼ë¡œ ì—°ê°„ ê¸°ì¤€ìœ¼ë¡œ ë³´ë©´, ê´€ì„¸ ì „ ë§¤ì¶œì´ì´ìµë¥ ì€ ì†Œí­ ìƒìŠ¹í•˜ê³ , ê´€ì„¸ ë°˜ì˜ í›„ì—ëŠ” ì•½ 50bp í•˜ë½í•  ê²ƒì…ë‹ˆë‹¤. ì˜ì—…ì´ìµë¥  ìˆ˜ì¤€ì—ì„œëŠ” ê´€ì„¸ ì œì™¸ ì‹œ ì „ë…„ ëŒ€ë¹„ ê±°ì˜ ë³´í•© ìˆ˜ì¤€ì´ê³ , ê´€ì„¸ ì˜í–¥ì„ í¬í•¨í•˜ë©´ ì†Œí­ í•˜ë½í•  ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤.<br><br>ê²°êµ­ í•µì‹¬ì€ ìš°ë¦¬ ì•ì— ë†“ì¸ ê¸°íšŒë¥¼ í™œìš©í•˜ëŠ” ê²ƒì´ê³ , ìš°ë¦¬ëŠ” ê³„ì† ê·¸ë ‡ê²Œ í•  ê²ƒì…ë‹ˆë‹¤. ë‹¤ì‹œ ë§ì”€ë“œë¦¬ì§€ë§Œ, ë‘ í•­ëª© ëª¨ë‘ í•˜ë°˜ê¸°ì— ë ˆë²„ë¦¬ì§€ íš¨ê³¼ê°€ ë‚˜íƒ€ë‚  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Geoffrey Martha: Chairman of the Board & CEO So on the revenue, as you see from the guidance, we're looking at a back half ramp here that will extend into '27. And the way I'd break it down, I mean, a big piece of that is these growth drivers that are kicking in, these multibillion-dollar opportunities. In terms of the back half, though, most of that is really coming from PFA. So -- in terms of the new big ones, right? When you think about PFA, Symplicity, Altaviva and we have Hugo coming, those are, we would say, are big multibillion-dollar upmarket opportunities. In the back half, the contribution will be more from PMA in that category. PFA, I mean, is cranking right now. We've got a lot of momentum there. When it comes to Symplicity -- obviously, Symplicity and Altaviva are approved in the U.S. On Symplicity, I'd say we're going to see it start to tick up in the back half of the year and then ramp in the quarters following that. Like I said, between the NCD and the commercial payers coming online, this market is really a best case scenario. It's as big as what we said it is. It's not about if or even how big, like it's as big as we said, it's really how fast. And we're measuring that speed of adoption in quarters, not years. Altaviva, again, just approved, a lot of great leading indicators. Physician training is over-booked, and we can talk more about that if I get questions on why we're so excited. Again, it will start to contribute in the back half a little bit. And then Hugo, we don't have too much on, but we do still expect the approval in the back half of our year. Then there's another -- getting to the base business, Diabetes pops back up as our new sensors are available. Neuromodulation continues to be strong. CST will continue to be strong. CRM had a really good Q2. I don't know if we're going to have that same level of growth there, but still a strong growth there. And then you've got two other businesses that will, I'll call it, tick up, or incrementally increase their growth rate, Peripheral Vascular with the carotid stent, mechanical thrombectomy coming. And then Neurovascular, again, it's also selling that carotid stent, got some hemorrhagic products coming. And they're just lapping some issues, a recall and then lapping VVP here. So the base business is a big contributor. PFA is a big contributor. And then you're going to start to see Symplicity, Altaviva and a little bit of Hugo.</td><td>**Geoffrey Martha:** ë§¤ì¶œ ê´€ë ¨í•´ì„œ ë§ì”€ë“œë¦¬ë©´, ê°€ì´ë˜ìŠ¤ì—ì„œ ë³´ì‹œë‹¤ì‹œí”¼ í•˜ë°˜ê¸°ë¶€í„° ìƒìŠ¹ì„¸ê°€ ì‹œì‘ë˜ì–´ 27ë…„ê¹Œì§€ ì´ì–´ì§ˆ ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì„¸ë¶€ì ìœ¼ë¡œ ë³´ë©´, ì´ëŸ¬í•œ ìƒìŠ¹ì˜ ìƒë‹¹ ë¶€ë¶„ì€ ìˆ˜ì‹­ì–µ ë‹¬ëŸ¬ ê·œëª¨ì˜ ì„±ì¥ ë™ë ¥ë“¤ì´ ë³¸ê²©í™”ë˜ë©´ì„œ ë‚˜íƒ€ë‚˜ëŠ” ê²ƒì…ë‹ˆë‹¤. í•˜ë°˜ê¸°ë§Œ ë†“ê³  ë³´ë©´, ìƒˆë¡œìš´ ëŒ€í˜• ì œí’ˆêµ° ì¤‘ì—ì„œëŠ” ëŒ€ë¶€ë¶„ PFAì—ì„œ ë‚˜ì˜¬ ê²ƒì…ë‹ˆë‹¤. PFA, Symplicity, Altaviva, ê·¸ë¦¬ê³  ê³§ ì¶œì‹œë  Hugoë¥¼ ìƒê°í•´ë³´ì‹œë©´, ì´ë“¤ì€ ëª¨ë‘ ìˆ˜ì‹­ì–µ ë‹¬ëŸ¬ ê·œëª¨ì˜ ìƒìœ„ ì‹œì¥ ê¸°íšŒë¼ê³  í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. í•˜ë°˜ê¸°ì—ëŠ” ì´ ì¹´í…Œê³ ë¦¬ì—ì„œ PFAì˜ ê¸°ì—¬ë„ê°€ ë” í´ ê²ƒì…ë‹ˆë‹¤. PFAëŠ” ì§€ê¸ˆ ì •ë§ ê°•ë ¥í•œ ëª¨ë©˜í…€ì„ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. Symplicityì™€ Altavivaì˜ ê²½ìš°, ì´ë¯¸ ë¯¸êµ­ì—ì„œ ìŠ¹ì¸ì„ ë°›ì•˜ìŠµë‹ˆë‹¤. Symplicityì˜ ê²½ìš°, í•˜ë°˜ê¸°ë¶€í„° ìƒìŠ¹ì„¸ë¥¼ ë³´ì´ê¸° ì‹œì‘í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìœ¼ë©°, ê·¸ ì´í›„ ë¶„ê¸°ë“¤ì—ì„œ ë³¸ê²©ì ì¸ ì„±ì¥ì„¸ë¥¼ ë³´ì¼ ê²ƒì…ë‹ˆë‹¤. ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼, NCDì™€ ìƒì—… ë³´í—˜ì‚¬ë“¤ì´ ì˜¨ë¼ì¸ìœ¼ë¡œ ì „í™˜ë˜ë©´ì„œ, ì´ ì‹œì¥ì€ ì •ë§ ìµœìƒì˜ ì‹œë‚˜ë¦¬ì˜¤ë¥¼ ë³´ì—¬ì£¼ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ê°€ ì˜ˆìƒí–ˆë˜ ë§Œí¼ í° ì‹œì¥ì…ë‹ˆë‹¤. ì´ì œ ì‹œì¥ ê·œëª¨ê°€ ì–¼ë§ˆë‚˜ ë ì§€ì— ëŒ€í•œ ë¬¸ì œê°€ ì•„ë‹™ë‹ˆë‹¤. ìš°ë¦¬ê°€ ë§í–ˆë˜ ê·¸ëŒ€ë¡œ í° ì‹œì¥ì´ë©°, ì´ì œ ê´€ê±´ì€ ì–¼ë§ˆë‚˜ ë¹ ë¥´ê²Œ ì„±ì¥í•˜ëŠëƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ìš°ë¦¬ëŠ” ì´ ë„ì… ì†ë„ë¥¼ ë…„ ë‹¨ìœ„ê°€ ì•„ë‹Œ ë¶„ê¸° ë‹¨ìœ„ë¡œ ì¸¡ì •í•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>AltavivaëŠ” ë°©ê¸ˆ ìŠ¹ì¸ì„ ë°›ì•˜ê³ , ë§ì€ ê¸ì •ì ì¸ ì„ í–‰ ì§€í‘œë“¤ì´ ë‚˜íƒ€ë‚˜ê³  ìˆìŠµë‹ˆë‹¤. ì˜ì‚¬ êµìœ¡ í”„ë¡œê·¸ë¨ì€ ì˜ˆì•½ì´ ê½‰ ì°¬ ìƒíƒœì´ë©°, ì™œ ìš°ë¦¬ê°€ ì´ë ‡ê²Œ ê¸°ëŒ€í•˜ê³  ìˆëŠ”ì§€ì— ëŒ€í•´ì„œëŠ” ì§ˆë¬¸ì´ ìˆìœ¼ì‹œë©´ ë” ìì„¸íˆ ë§ì”€ë“œë¦´ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ ì œí’ˆ ì—­ì‹œ í•˜ë°˜ê¸°ë¶€í„° ì¡°ê¸ˆì”© ë§¤ì¶œì— ê¸°ì—¬í•˜ê¸° ì‹œì‘í•  ê²ƒì…ë‹ˆë‹¤.<br><br>Hugoì— ëŒ€í•´ì„œëŠ” ë§ì€ ì—…ë°ì´íŠ¸ëŠ” ì—†ì§€ë§Œ, ì—¬ì „íˆ ì˜¬í•´ í•˜ë°˜ê¸° ìŠ¹ì¸ì„ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê¸°ë³¸ ì‚¬ì—…ìœ¼ë¡œ ë„˜ì–´ê°€ë©´, ë‹¹ë‡¨ë³‘(Diabetes) ë¶€ë¬¸ì´ ìƒˆë¡œìš´ ì„¼ì„œ ì¶œì‹œì™€ í•¨ê»˜ ë‹¤ì‹œ ì„±ì¥ì„¸ë¥¼ ë³´ì¼ ê²ƒì…ë‹ˆë‹¤. ì‹ ê²½ì¡°ì ˆ(Neuromodulation)ì€ ê³„ì†í•´ì„œ ê°•ì„¸ë¥¼ ìœ ì§€í•˜ê³  ìˆê³ ìš”. CSTë„ ê°•ì„¸ê°€ ì§€ì†ë  ê²ƒì…ë‹ˆë‹¤. CRMì€ 2ë¶„ê¸°ì— ì •ë§ ì¢‹ì€ ì‹¤ì ì„ ëƒˆëŠ”ë°, ê°™ì€ ìˆ˜ì¤€ì˜ ì„±ì¥ì„ ì´ì–´ê°ˆì§€ëŠ” ëª¨ë¥´ê² ì§€ë§Œ ì—¬ì „íˆ ê²¬ê³ í•œ ì„±ì¥ì„¸ë¥¼ ë³´ì¼ ê²ƒì…ë‹ˆë‹¤. <br><br>ê·¸ë¦¬ê³  ì„±ì¥ë¥ ì´ ìƒìŠ¹í•˜ê±°ë‚˜ ì ì§„ì ìœ¼ë¡œ ê°œì„ ë  ë‘ ê°œì˜ ì‚¬ì—…ë¶€ê°€ ë” ìˆìŠµë‹ˆë‹¤. ë§ì´ˆí˜ˆê´€(Peripheral Vascular) ë¶€ë¬¸ì€ ê²½ë™ë§¥ ìŠ¤í…íŠ¸ì™€ ê¸°ê³„ì  í˜ˆì „ì œê±°ìˆ ì´ ì¶œì‹œë  ì˜ˆì •ì´ê³ ìš”. ì‹ ê²½í˜ˆê´€(Neurovascular) ë¶€ë¬¸ë„ ë§ˆì°¬ê°€ì§€ë¡œ ê²½ë™ë§¥ ìŠ¤í…íŠ¸ë¥¼ íŒë§¤í•˜ê³  ìˆê³ , ì¶œí˜ˆì„± ì œí’ˆë“¤ë„ ì¶œì‹œë¥¼ ì•ë‘ê³  ìˆìŠµë‹ˆë‹¤. ì´ ë¶€ë¬¸ë“¤ì€ ë¦¬ì½œ ë¬¸ì œì™€ VVP ê´€ë ¨ ê¸°ì €íš¨ê³¼ë¥¼ ì§€ë‚˜ê°€ê³  ìˆëŠ” ìƒí™©ì…ë‹ˆë‹¤. <br><br>ê²°ë¡ ì ìœ¼ë¡œ ê¸°ë³¸ ì‚¬ì—…ì´ í° ê¸°ì—¬ë¥¼ í•  ê²ƒì´ê³ , PFAë„ í° ê¸°ì—¬ë¥¼ í•  ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë‚˜ì„œ Symplicity, Altaviva, ê·¸ë¦¬ê³  Hugoë„ ì¡°ê¸ˆì”© ë³´ì´ê¸° ì‹œì‘í•  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Ryan Weispfenning: VP & Head of Investor Relations Next, we'll go to the line of Vijay Kumar at Evercore ISI.</td><td>**Ryan Weispfenning:** <budget:token_budget>200000</budget:token_budget><br><br>ë‹¤ìŒì€ Evercore ISIì˜ Vijay Kumar ë‹˜ ì§ˆë¬¸ì„ ë°›ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Vijay Kumar: Evercore ISI Institutional Equities, Research Division Congrats on a nice sprint here. I had maybe a new product question, a 2-parter, if you will. One on Affera, Geoff, do you feel like we have enough mappers now? And is supply in a place enough where you can hit the $2 billion? How are you thinking about supply and mapping? And then on tibial, we've got some good feedback on cannibalization of -- whether tibial could cannibalize BOTOX procedures. Could tibial be a $1 billion product for you guys down the road?</td><td>**Vijay Kumar:** ì¢‹ì€ ì„±ê³¼ ì¶•í•˜ë“œë¦½ë‹ˆë‹¤. ì‹ ì œí’ˆ ê´€ë ¨í•´ì„œ ë‘ ê°€ì§€ ì§ˆë¬¸ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë¨¼ì € Affera ê´€ë ¨í•´ì„œ Geoff, í˜„ì¬ ë§¤í¼(mapper) ìˆ˜ëŸ‰ì´ ì¶©ë¶„í•˜ë‹¤ê³  ë³´ì‹œëŠ”ì§€ìš”? ê·¸ë¦¬ê³  20ì–µ ë‹¬ëŸ¬ ëª©í‘œë¥¼ ë‹¬ì„±í•˜ê¸°ì— ê³µê¸‰ì´ ì¶©ë¶„í•œ ìƒí™©ì¸ê°€ìš”? ê³µê¸‰ê³¼ ë§¤í•‘ì— ëŒ€í•´ ì–´ë–»ê²Œ ìƒê°í•˜ê³  ê³„ì‹ ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ê²½ê³¨ì‹ ê²½ìê·¹ìˆ (tibial)ê³¼ ê´€ë ¨í•´ì„œëŠ”, ì´ ì‹œìˆ ì´ ë³´í†¡ìŠ¤(BOTOX) ì‹œìˆ ì„ ì ì‹í•  ìˆ˜ ìˆëŠ”ì§€ì— ëŒ€í•´ ê¸ì •ì ì¸ í”¼ë“œë°±ì„ ë°›ê³  ìˆìŠµë‹ˆë‹¤. ê²½ê³¨ì‹ ê²½ìê·¹ìˆ ì´ í–¥í›„ 10ì–µ ë‹¬ëŸ¬ ê·œëª¨ì˜ ì œí’ˆì´ ë  ìˆ˜ ìˆì„ê¹Œìš”?</td></tr>
<tr><td>Geoffrey Martha: Chairman of the Board & CEO So I'll start with the PFA questions. On the supply, that's not holding us back. So supply is in a good spot. And then on the mappers, the mapper hiring is going well, right? We're staying ahead, but I wish the buffer a little bit more, because the growth is tremendous. But we are staying ahead on the mappers and the supply is not an issue. And like I said, our PFA business is really humming. I was just with a big customer yesterday. They've got 2 systems. They laid out 3 more that they're going to buy. And just talking about once they put -- especially Affera, once they put that in one of their hospitals, how it kind of takes all the market share or the majority of the market share there for all types of cases. There's just all these benefits there. So feeling really good about that. And again, this mapper hiring has been a Medtronic, not just our Cardiac Ablation business, but a Medtronic effort, and our HR team is doing a hell of a job there. And then on tibial. Look, tibial is something I think everyone needs to invest a little bit of time in here. It's a huge market, 46 million people in the U.S. with overactive bladder and of that 16 million with urinary urge incontinence, where this really shines. And it takes the therapy versus sacral, which works really well. It's been a great market for us. There's been some channel disruption in the market lately, but it's still a great market and works really well for patients. But it does take weeks or months to get that therapy to a patient from when they start versus tibial is less than a day. So what you're seeing here is, with tibial, right, you have to do -- I mean, with the sacral nerve, you have to do a trial, then you have to go in for the implant, then the patient leaves without the therapy turned on, has to come back to get it activated, versus tibial, this all happens in a day and the procedure is easier. And when patients, to get to the core of your question, when they're presented with options, all of their options, sacral nerve, tibial, BOTOX, they tend to choose the tibial. So we do think it will take share from BOTOX. And I would emphasize that this, we believe -- look, there's a very strong place for sacral nerve. This is an incremental opportunity on top of our sacral business. And so sacral combined with tibial, given that it's going to be incremental, this is going to make that business, that pelvic health business, a growth driver for the company. That's what I'll say about that. It's going to meaningfully improve the growth rate of that business.</td><td>**Geoffrey Martha:** PFA ê´€ë ¨ ì§ˆë¬¸ë¶€í„° ë‹µë³€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ê³µê¸‰ ì¸¡ë©´ì—ì„œëŠ” ì „í˜€ ë¬¸ì œê°€ ì—†ìŠµë‹ˆë‹¤. ê³µê¸‰ì€ ì–‘í˜¸í•œ ìƒíƒœì…ë‹ˆë‹¤. ë§¤í¼ ì±„ìš©ë„ ìˆœì¡°ë¡­ê²Œ ì§„í–‰ë˜ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ê°€ ì•ì„œ ë‚˜ê°€ê³  ìˆê¸´ í•˜ì§€ë§Œ, ì„±ì¥ì„¸ê°€ ì—„ì²­ë‚˜ê¸° ë•Œë¬¸ì— ì—¬ìœ ë¶„ì„ ì¡°ê¸ˆ ë” í™•ë³´í•˜ê³  ì‹¶ì€ ê²Œ ì‚¬ì‹¤ì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ë§¤í¼ í™•ë³´ëŠ” ê³„ì† ì•ì„œ ë‚˜ê°€ê³  ìˆê³ , ê³µê¸‰ì€ ë¬¸ì œê°€ ë˜ì§€ ì•ŠìŠµë‹ˆë‹¤.<br><br>ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼ ìš°ë¦¬ PFA ì‚¬ì—…ì€ ì •ë§ ì˜ ëŒì•„ê°€ê³  ìˆìŠµë‹ˆë‹¤. ì–´ì œë„ ì£¼ìš” ê³ ê°ì‚¬ë¥¼ ë§Œë‚¬ëŠ”ë°, ê·¸ë“¤ì€ í˜„ì¬ 2ê°œ ì‹œìŠ¤í…œì„ ë³´ìœ í•˜ê³  ìˆê³ , ì¶”ê°€ë¡œ 3ê°œë¥¼ ë” êµ¬ë§¤í•  ê³„íšì„ ì œì‹œí–ˆìŠµë‹ˆë‹¤. íŠ¹íˆ Afferaì˜ ê²½ìš°, ë³‘ì› ì¤‘ í•œ ê³³ì— ë„ì…í•˜ê³  ë‚˜ë©´ ëª¨ë“  ìœ í˜•ì˜ ì‹œìˆ ì—ì„œ ì‹œì¥ ì ìœ ìœ¨ ì „ì²´ ë˜ëŠ” ëŒ€ë¶€ë¶„ì„ ê°€ì ¸ê°€ê²Œ ë˜ëŠ” í˜„ìƒì— ëŒ€í•´ ì´ì•¼ê¸°ë¥¼ ë‚˜ëˆ´ìŠµë‹ˆë‹¤. ì •ë§ ë‹¤ì–‘í•œ ì´ì ë“¤ì´ ìˆìŠµë‹ˆë‹¤. ì´ ì ì— ëŒ€í•´ ì •ë§ ë§Œì¡±ìŠ¤ëŸ½ê²Œ ìƒê°í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë‹¤ì‹œ ë§ì”€ë“œë¦¬ì§€ë§Œ, ì´ëŸ¬í•œ ë§¤í¼ ì±„ìš©ì€ ìš°ë¦¬ ì‹¬ì¥ ì ˆì œìˆ (Cardiac Ablation) ì‚¬ì—…ë¶€ë§Œì˜ ë…¸ë ¥ì´ ì•„ë‹ˆë¼ ë©”ë“œíŠ¸ë¡œë‹‰ ì „ì‚¬ì ì¸ ë…¸ë ¥ì´ë©°, ìš°ë¦¬ ì¸ì‚¬íŒ€ì´ ì •ë§ í›Œë¥­í•œ ì„±ê³¼ë¥¼ ë‚´ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ê·¸ë¦¬ê³  ê²½ê³¨ì‹ ê²½ ìê·¹ìˆ (tibial)ì— ëŒ€í•´ì„œ ë§ì”€ë“œë¦¬ìë©´, ì´ ë¶„ì•¼ëŠ” ëª¨ë‘ê°€ ì‹œê°„ì„ ì¢€ íˆ¬ìí•´ì„œ ì‚´í´ë³¼ í•„ìš”ê°€ ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ë¯¸êµ­ì—ë§Œ ê³¼ë¯¼ì„± ë°©ê´‘(overactive bladder) í™˜ìê°€ 4,600ë§Œ ëª…ì— ë‹¬í•˜ëŠ” ê±°ëŒ€í•œ ì‹œì¥ì´ê³ , ê·¸ ì¤‘ 1,600ë§Œ ëª…ì´ ì ˆë°•ì„± ìš”ì‹¤ê¸ˆ(urinary urge incontinence)ì„ ì•“ê³  ìˆëŠ”ë°, ì´ ì¹˜ë£Œë²•ì´ íŠ¹íˆ íš¨ê³¼ì ì…ë‹ˆë‹¤. ì²œê³¨ì‹ ê²½ ìê·¹ìˆ (sacral)ê³¼ ë¹„êµí–ˆì„ ë•Œ, ì²œê³¨ì‹ ê²½ ìê·¹ìˆ ë„ ë§¤ìš° íš¨ê³¼ì ì´ê³  ìš°ë¦¬ì—ê²Œ í›Œë¥­í•œ ì‹œì¥ì´ì—ˆìŠµë‹ˆë‹¤. ìµœê·¼ ì‹œì¥ì—ì„œ ìœ í†µ ì±„ë„ì˜ í˜¼ë€ì´ ìˆì—ˆì§€ë§Œ, ì—¬ì „íˆ í›Œë¥­í•œ ì‹œì¥ì´ë©° í™˜ìë“¤ì—ê²Œ ë§¤ìš° íš¨ê³¼ì ì¸ ì¹˜ë£Œë²•ì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ì¹˜ë£Œë¥¼ ì‹œì‘í•œ ì‹œì ë¶€í„° í™˜ìê°€ ì‹¤ì œë¡œ ì¹˜ë£Œë¥¼ ë°›ê¸°ê¹Œì§€ ëª‡ ì£¼ ë˜ëŠ” ëª‡ ë‹¬ì´ ê±¸ë¦¬ëŠ” ë°˜ë©´, ê²½ê³¨ì‹ ê²½ ì¹˜ë£ŒëŠ” í•˜ë£¨ë„ ì±„ ê±¸ë¦¬ì§€ ì•ŠìŠµë‹ˆë‹¤. ì—¬ê¸°ì„œ ë³´ì‹œëŠ” ê²ƒì€, ê²½ê³¨ì‹ ê²½ ì¹˜ë£Œì˜ ê²½ìš° - ì œ ë§ì€, ì²œê³¨ì‹ ê²½ ì¹˜ë£Œì˜ ê²½ìš° ë¨¼ì € ì‹œí—˜ ë‹¨ê³„ë¥¼ ê±°ì³ì•¼ í•˜ê³ , ê·¸ ë‹¤ìŒ ì´ì‹ ìˆ˜ìˆ ì„ ë°›ì•„ì•¼ í•˜ë©°, í™˜ìëŠ” ì¹˜ë£Œ ê¸°ëŠ¥ì´ êº¼ì§„ ìƒíƒœë¡œ í‡´ì›í–ˆë‹¤ê°€ í™œì„±í™”ë¥¼ ìœ„í•´ ë‹¤ì‹œ ë³‘ì›ì„ ë°©ë¬¸í•´ì•¼ í•©ë‹ˆë‹¤. ë°˜ë©´ ê²½ê³¨ì‹ ê²½ ì¹˜ë£ŒëŠ” ì´ ëª¨ë“  ê²ƒì´ í•˜ë£¨ ë§Œì— ì´ë£¨ì–´ì§€ê³  ì‹œìˆ ë„ ë” ê°„í¸í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì§ˆë¬¸ì˜ í•µì‹¬ìœ¼ë¡œ ë“¤ì–´ê°€ìë©´, í™˜ìë“¤ì—ê²Œ ì²œê³¨ì‹ ê²½, ê²½ê³¨ì‹ ê²½, ë³´í†¡ìŠ¤ ë“± ëª¨ë“  ì˜µì…˜ì´ ì œì‹œë  ë•Œ, í™˜ìë“¤ì€ ê²½ê³¨ì‹ ê²½ ì¹˜ë£Œë¥¼ ì„ íƒí•˜ëŠ” ê²½í–¥ì´ ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ë³´í†¡ìŠ¤ ì‹œì¥ ì ìœ ìœ¨ì„ ê°€ì ¸ì˜¬ ê²ƒìœ¼ë¡œ ìƒê°í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ê°•ì¡°í•˜ê³  ì‹¶ì€ ê²ƒì€ - ë¬¼ë¡  ì²œê³¨ì‹ ê²½ ì¹˜ë£Œë„ ë§¤ìš° í™•ê³ í•œ ì…ì§€ê°€ ìˆìŠµë‹ˆë‹¤. <response><br><br>ì´ê²ƒì€ ì²œê³¨(sacral) ì‚¬ì—…ì— ë”í•´ì§€ëŠ” ì¶”ê°€ì ì¸ ê¸°íšŒì…ë‹ˆë‹¤. ë”°ë¼ì„œ ì²œê³¨ê³¼ ê²½ê³¨(tibial)ì„ ê²°í•©í•˜ë©´, ì´ê²ƒì´ ì¶”ê°€ì ì¸ ë§¤ì¶œì´ ë  ê²ƒì´ê¸° ë•Œë¬¸ì—, ì´ ì‚¬ì—…, ì¦‰ ê³¨ë°˜ ê±´ê°• ì‚¬ì—…ì´ íšŒì‚¬ì˜ ì„±ì¥ ë™ë ¥ì´ ë  ê²ƒì…ë‹ˆë‹¤. ì´ ì •ë„ë¡œ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì´ ì‚¬ì—…ì˜ ì„±ì¥ë¥ ì„ ì˜ë¯¸ ìˆê²Œ ê°œì„ ì‹œí‚¬ ê²ƒì…ë‹ˆë‹¤.<br><br></response></td></tr>
<tr><td>Ryan Weispfenning: VP & Head of Investor Relations Next, let's go to the line of Robbie Marcus at JPMorgan.</td><td>**Ryan Weispfenning:** <budget:token_budget>200000</budget:token_budget><br><br>ë‹¤ìŒì€ JPMorganì˜ Robbie Marcus ì§ˆë¬¸ì„ ë°›ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Robert Marcus: JPMorgan Chase & Co, Research Division Nice quarter. Thierry, I wanted to ask, you talked about strategically reinvesting into SG&A and over time, materially increasing R&D, I think, up to 200 basis points. How are you thinking about where those dollars are going? How soon should we be thinking about that? And just help us think about the cadence and the ability to still grow operating margin in the face of higher investment.</td><td>**Robert Marcus:** ì¢‹ì€ ì‹¤ì ì´ì—ˆìŠµë‹ˆë‹¤. Thierry, ì „ëµì ìœ¼ë¡œ íŒê´€ë¹„ì— ì¬íˆ¬ìí•˜ê³  ì‹œê°„ì´ ì§€ë‚¨ì— ë”°ë¼ R&Dë¥¼ 200bpê¹Œì§€ ëŒ€í­ ëŠ˜ë¦¬ê² ë‹¤ê³  ë§ì”€í•˜ì…¨ëŠ”ë°ìš”. ê·¸ ìê¸ˆì´ ì–´ë””ë¡œ íˆ¬ì…ë ì§€ ì–´ë–»ê²Œ ìƒê°í•˜ê³  ê³„ì‹ ê°€ìš”? ì–¸ì œì¯¤ ê·¸ë ‡ê²Œ ë  ê²ƒìœ¼ë¡œ ë´ì•¼ í• ê¹Œìš”? ê·¸ë¦¬ê³  íˆ¬ì í™•ëŒ€ì—ë„ ë¶ˆêµ¬í•˜ê³  ì˜ì—…ì´ìµë¥ ì„ ê³„ì† ì„±ì¥ì‹œí‚¬ ìˆ˜ ìˆëŠ” ì†ë„ì™€ ê°€ëŠ¥ì„±ì— ëŒ€í•´ ì„¤ëª…í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>Thierry Pieton: Executive VP & CFO Yes. Robbie, thanks for the question. So first, where the dollars are going? So there are really 2 different categories, I would say. One is, as I said, to capitalize to the maximum extent possible on the growth drivers that are ahead of us. So there's a significant amount of investment that's going to CAS, to Ardian, to Altaviva and, obviously, to Hugo with a profile that's a little bit more long term. There are other growth drivers that we're funding at the same time such as Structural Heart and Neuromodulation, for example. The second category of where we're putting investment is to make sure that we keep the leading edge from a technology perspective in the key franchises that are our bread and butter. So there's overinvestment compared to the average of the business in CRM, for example, in next generation of Micra. And there's significant investment going in CST to continue to develop the ecosystem that, that business has created around AiBLE that has enabled us to make the CST business more sticky with the customers from a device perspective and gradually improve the margin. So it's really those 2 areas, capitalize on the growth drivers on one hand and keep the edge on innovation in the key franchises on the other side. From a sequence perspective, look, I would say third quarter, we made a pretty deliberate strong investment because we saw the upside coming. You'll see a bit less of that already in the second half. So as I said, you should see leverage on the SG&A line in the second half of the year already. But maybe going into the longer term, look, we've tried to give as much clarity as possible on the gross margin line so that you see the dynamics. If you look at what happened this quarter, we had about 40 basis points of pricing and about 30 basis points or 40 basis points of cost out. That's been sort of a recurring performance over the last quarters, and we expect that to continue over time, right? So we're generating, between those 2 lines, 70 to 80 basis points of gross margin improvement, right? And this quarter, you had about 80 basis points of negative mix and 20 basis points of tariffs, and that was offset with FX. Going forward, we expect that negative mix to start getting better towards the second half of '27. So for the rest of the year, it's still going to be a pretty significant headwind as CAS and Diabetes continue to accelerate. And in the second half of '27, Diabetes will be deconsolidated. And then on the CAS side, we'll start seeing the shift between the capital equipment and the catheters, which will make that an accretive business as opposed to being dilutive. So what you're going to see there is the 70 to 80 basis points of gross margin improvement operationally start to show up more as the mix becomes a gradually smaller and a positive effect over time. And then outside of that, we've got some external factors. So we have to contend with the tariffs. So for second half, we've got about 90% of that $185 million of tariffs that's going to show up in the income statement. The bigger portion is in Q3. And then we'll have a carryover of tariffs going into '27. And we expect foreign exchange, which is the last item there to be a slight tailwind going into '27. So if you go -- it's a long answer, apologies, but I think it's important that you understand the algorithm. Going into '27, we'll keep investing in R&D to get to the 10% over time. But you should expect to see leverage on the SG&A line in '27. So look, we're confident that with the growth with what we're doing from a gross margin performance in a sustainable fashion in COGS and pricing and the leverage on the overhead, we'll have a leverage P&L on the operating profit line in 2027. And that's why we hold on our commitment to have high single-digit EPS growth going into next year.</td><td>**Thierry Pieton:** ë„¤, ë¡œë¹„, ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ë¨¼ì € ìê¸ˆì´ ì–´ë””ë¡œ ê°€ëŠ”ì§€ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. í¬ê²Œ ë‘ ê°€ì§€ ë²”ì£¼ë¡œ ë‚˜ëˆŒ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì²« ë²ˆì§¸ëŠ” ì œê°€ ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼, ìš°ë¦¬ ì•ì— ìˆëŠ” ì„±ì¥ ë™ë ¥ì„ ìµœëŒ€í•œ í™œìš©í•˜ê¸° ìœ„í•œ ê²ƒì…ë‹ˆë‹¤. CAS, Ardian, Altaviva, ê·¸ë¦¬ê³  ì¢€ ë” ì¥ê¸°ì ì¸ ê´€ì ì—ì„œ Hugoì— ìƒë‹¹í•œ íˆ¬ìê°€ ì´ë£¨ì–´ì§€ê³  ìˆìŠµë‹ˆë‹¤. ë™ì‹œì— Structural Heartì™€ Neuromodulation ê°™ì€ ë‹¤ë¥¸ ì„±ì¥ ë™ë ¥ì—ë„ ìê¸ˆì„ ì§€ì›í•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ë‘ ë²ˆì§¸ íˆ¬ì ë²”ì£¼ëŠ” ìš°ë¦¬ì˜ í•µì‹¬ ì‚¬ì—…ì¸ ì£¼ë ¥ í”„ëœì°¨ì´ì¦ˆì—ì„œ ê¸°ìˆ ì  ìš°ìœ„ë¥¼ ê³„ì† ìœ ì§€í•˜ê¸° ìœ„í•œ ê²ƒì…ë‹ˆë‹¤. ì˜ˆë¥¼ ë“¤ì–´ CRMì˜ ê²½ìš° ì°¨ì„¸ëŒ€ Micraì— ëŒ€í•œ íˆ¬ìê°€ ì‚¬ì—… í‰ê·  ëŒ€ë¹„ ê³¼ë„í•œ ì¸¡ë©´ì´ ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  CSTì—ì„œë„ AiBLEì„ ì¤‘ì‹¬ìœ¼ë¡œ êµ¬ì¶•í•œ ìƒíƒœê³„ë¥¼ ì§€ì†ì ìœ¼ë¡œ ë°œì „ì‹œí‚¤ê¸° ìœ„í•´ ìƒë‹¹í•œ íˆ¬ìê°€ ì´ë£¨ì–´ì§€ê³  ìˆìŠµë‹ˆë‹¤. ì´ë¥¼ í†µí•´ CST ì‚¬ì—…ì„ ë””ë°”ì´ìŠ¤ ê´€ì ì—ì„œ ê³ ê°ë“¤ì—ê²Œ ë”ìš± í•„ìˆ˜ì ì¸ ì¡´ì¬ë¡œ ë§Œë“¤ê³  ë§ˆì§„ì„ ì ì§„ì ìœ¼ë¡œ ê°œì„ í•  ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤. ê²°êµ­ ì´ ë‘ ì˜ì—­ì— ì§‘ì¤‘í•˜ê³  ìˆëŠ”ë°, í•œí¸ìœ¼ë¡œëŠ” ì„±ì¥ ë™ë ¥ì„ í™œìš©í•˜ê³  ë‹¤ë¥¸ í•œí¸ìœ¼ë¡œëŠ” í•µì‹¬ í”„ëœì°¨ì´ì¦ˆì˜ í˜ì‹  ìš°ìœ„ë¥¼ ìœ ì§€í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. <br><br>ì‹œê¸°ì ì¸ ì¸¡ë©´ì—ì„œ ë³´ë©´, 3ë¶„ê¸°ì—ëŠ” í–¥í›„ ìƒìŠ¹ ì—¬ë ¥ì„ ë³´ê³  ìƒë‹¹íˆ ì˜ë„ì ì´ê³  ê°•ë ¥í•œ íˆ¬ìë¥¼ ì§„í–‰í–ˆìŠµë‹ˆë‹¤. í•˜ë°˜ê¸°ì—ëŠ” ê·¸ ì •ë„ê°€ ë‹¤ì†Œ ì¤„ì–´ë“¤ ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼, í•˜ë°˜ê¸°ë¶€í„° ì´ë¯¸ íŒê´€ë¹„ ë¶€ë¬¸ì—ì„œ ë ˆë²„ë¦¬ì§€ íš¨ê³¼ë¥¼ ë³´ì‹¤ ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤. ì¥ê¸°ì ì¸ ê´€ì ì—ì„œ ë³´ë©´, ì €í¬ëŠ” ë§¤ì¶œì´ì´ìµë¥ (gross margin) ë¶€ë¬¸ì— ëŒ€í•´ ìµœëŒ€í•œ ëª…í™•í•˜ê²Œ ì„¤ëª…ë“œë¦¬ë ¤ê³  ë…¸ë ¥í–ˆê³ , ê·¸ë˜ì•¼ ì—¬ëŸ¬ë¶„ê»˜ì„œ ê·¸ ì—­í•™ê´€ê³„ë¥¼ ì´í•´í•˜ì‹¤ ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤. ì´ë²ˆ ë¶„ê¸° ì‹¤ì ì„ ë³´ì‹œë©´, ê°€ê²© ì¸ìƒ íš¨ê³¼ê°€ ì•½ 40bp, ë¹„ìš© ì ˆê° íš¨ê³¼ê°€ ì•½ 30~40bp ì •ë„ ìˆì—ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì§€ë‚œ ëª‡ ë¶„ê¸° ë™ì•ˆ ì§€ì†ì ìœ¼ë¡œ ë‚˜íƒ€ë‚œ ì„±ê³¼ì´ë©°, ì•ìœ¼ë¡œë„ ê³„ì†ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ë”°ë¼ì„œ ì´ ë‘ ê°€ì§€ ìš”ì¸ì„ í•©ì¹˜ë©´ ë§¤ì¶œì´ì´ìµë¥ ì´ 70~80bp ê°œì„ ë˜ëŠ” íš¨ê³¼ë¥¼ ì°½ì¶œí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ë²ˆ ë¶„ê¸°ì—ëŠ” ì œí’ˆë¯¹ìŠ¤ ì•…í™”ë¡œ ì•½ 80bpì˜ ë§ˆì´ë„ˆìŠ¤ ì˜í–¥ì´ ìˆì—ˆê³ , ê´€ì„¸ë¡œ ì¸í•´ 20bpì˜ ë¶€ì •ì  ì˜í–¥ì´ ìˆì—ˆëŠ”ë°, ì´ëŠ” í™˜ìœ¨ íš¨ê³¼ë¡œ ìƒì‡„ë˜ì—ˆìŠµë‹ˆë‹¤. ì•ìœ¼ë¡œ ë„¤ê±°í‹°ë¸Œ ë¯¹ìŠ¤ëŠ” '27ë…„ í•˜ë°˜ê¸°ë¶€í„° ê°œì„ ë˜ê¸° ì‹œì‘í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ì˜¬í•´ ë‚¨ì€ ê¸°ê°„ ë™ì•ˆì€ CASì™€ ë‹¹ë‡¨ë³‘ ì‚¬ì—…ì´ ê³„ì† ê°€ì†í™”ë˜ë©´ì„œ ì—¬ì „íˆ ìƒë‹¹í•œ ì—­í’ìœ¼ë¡œ ì‘ìš©í•  ê²ƒì…ë‹ˆë‹¤. '27ë…„ í•˜ë°˜ê¸°ì—ëŠ” ë‹¹ë‡¨ë³‘ ì‚¬ì—…ì´ ì—°ê²° í•´ì œë  ì˜ˆì •ì…ë‹ˆë‹¤. CAS ì¸¡ë©´ì—ì„œëŠ” ìë³¸ ì¥ë¹„ì™€ ì¹´í…Œí„° ê°„ì˜ ì „í™˜ì´ ì‹œì‘ë˜ë©´ì„œ í¬ì„ íš¨ê³¼ê°€ ì•„ë‹Œ ì¦ëŒ€ íš¨ê³¼ë¥¼ ë‚´ëŠ” ì‚¬ì—…ìœ¼ë¡œ ë°”ë€” ê²ƒì…ë‹ˆë‹¤. ë”°ë¼ì„œ ìš´ì˜ìƒ 70~80bpì˜ ë§¤ì¶œì´ì´ìµë¥  ê°œì„  íš¨ê³¼ê°€ ì‹œê°„ì´ ì§€ë‚¨ì— ë”°ë¼ ë¯¹ìŠ¤ê°€ ì ì§„ì ìœ¼ë¡œ ì¶•ì†Œë˜ê³  ê¸ì •ì ì¸ ì˜í–¥ìœ¼ë¡œ ì „í™˜ë˜ë©´ì„œ ë”ìš± ê°€ì‹œí™”ë  ê²ƒì…ë‹ˆë‹¤. ê·¸ ì™¸ì—ë„ ì™¸ë¶€ ìš”ì¸ë“¤ì´ ìˆìŠµë‹ˆë‹¤. ê´€ì„¸ ë¬¸ì œì— ëŒ€ì‘í•´ì•¼ í•©ë‹ˆë‹¤. í•˜ë°˜ê¸°ì—ëŠ” 1ì–µ 8,500ë§Œ ë‹¬ëŸ¬ ê´€ì„¸ì˜ ì•½ 90%ê°€ ì†ìµê³„ì‚°ì„œì— ë°˜ì˜ë  ì˜ˆì •ì…ë‹ˆë‹¤. ë” í° ë¶€ë¶„ì€ 3ë¶„ê¸°ì— ë‚˜íƒ€ë‚˜ê³ ìš”. ê·¸ë¦¬ê³  27ë…„ì—ë„ ê´€ì„¸ ì´ì›”ë¶„ì´ ìˆì„ ê²ƒì…ë‹ˆë‹¤. ë§ˆì§€ë§‰ í•­ëª©ì¸ ì™¸í™˜ì€ 27ë…„ì— ì•½ê°„ì˜ ìˆœí’ì´ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ë‹µë³€ì´ ê¸¸ì–´ì„œ ì£„ì†¡í•©ë‹ˆë‹¤ë§Œ, ì´ êµ¬ì¡°ë¥¼ ì´í•´í•˜ì‹œëŠ” ê²ƒì´ ì¤‘ìš”í•˜ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. 27ë…„ìœ¼ë¡œ ê°€ë©´ì„œ ì¥ê¸°ì ìœ¼ë¡œ 10%ì— ë„ë‹¬í•˜ê¸° ìœ„í•´ R&Dì— ê³„ì† íˆ¬ìí•  ê²ƒì…ë‹ˆë‹¤. í•˜ì§€ë§Œ 27ë…„ì—ëŠ” íŒê´€ë¹„(SG&A) ë¼ì¸ì—ì„œ ë ˆë²„ë¦¬ì§€ë¥¼ ë³´ì‹¤ ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤. ìš°ë¦¬ê°€ ë‹¬ì„±í•˜ê³  ìˆëŠ” ì„±ì¥ê³¼ í•¨ê»˜, ë§¤ì¶œì›ê°€(COGS)ì™€ ê°€ê²© ì¸¡ë©´ì—ì„œ ì§€ì† ê°€ëŠ¥í•œ ë°©ì‹ìœ¼ë¡œ ì´ë£¨ì–´ì§€ëŠ” ë§¤ì¶œì´ì´ìµë¥  ì„±ê³¼, ê·¸ë¦¬ê³  ê°„ì ‘ë¹„ì˜ ë ˆë²„ë¦¬ì§€ë¥¼ í†µí•´ 2027ë…„ ì˜ì—…ì´ìµ ë¼ì¸ì—ì„œ ë ˆë²„ë¦¬ì§€ ì†ìµê³„ì‚°ì„œë¥¼ ë§Œë“¤ì–´ë‚¼ ê²ƒì´ë¼ê³  í™•ì‹ í•©ë‹ˆë‹¤. ê·¸ë˜ì„œ ìš°ë¦¬ëŠ” ë‚´ë…„ì— ë†’ì€ í•œ ìë¦¿ìˆ˜ ì£¼ë‹¹ìˆœì´ìµ(EPS) ì„±ì¥ì„ ë‹¬ì„±í•˜ê² ë‹¤ëŠ” ì•½ì†ì„ ì§€í‚¤ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Geoffrey Martha: Chairman of the Board & CEO Yes. And just to add to that, there's more oxygen here to create for the investment. It's begun to see the improved pricing. And as we go forward, we're not assuming much incremental pricing, but at least holding the improved position that we have. But there's more oxygen in our cost down. There's opportunities in scrap, obsolescence and, over time, continuing to optimize our network. So these are areas, I think there's incremental opportunity and cost down. And Robbie, I've read some of your stuff in the past that you don't think there's much to do for us on SG&A, but there's more. There's more to go on SG&A for the company, and that's where the scale of the company should benefit us here. And it's not going to be easy on the company, but there's opportunities there, and we're committed to doing what it takes to fund these growth drivers, because what we're seeing out there with patients on these different growth drivers and what we're hearing from clinicians, the impact on them and their staff, this is a big opportunity for the company we haven't seen in decades, and we're going to make it happen, right? And so there's still room to go on SG&A as well. And like I said, COGS to make this happen.</td><td>**Geoffrey Martha:** ë„¤, ê±°ê¸°ì— ë§ë¶™ì´ìë©´, íˆ¬ìë¥¼ ìœ„í•œ ì—¬ë ¥ì´ ë” ë§ì´ ìƒê¸°ê³  ìˆìŠµë‹ˆë‹¤. ê°€ê²© ê°œì„  íš¨ê³¼ê°€ ë‚˜íƒ€ë‚˜ê¸° ì‹œì‘í–ˆê³ ìš”. ì•ìœ¼ë¡œ ì¶”ê°€ì ì¸ ê°€ê²© ì¸ìƒì„ í¬ê²Œ ê°€ì •í•˜ì§€ëŠ” ì•Šì§€ë§Œ, ìµœì†Œí•œ í˜„ì¬ ê°œì„ ëœ ìˆ˜ì¤€ì€ ìœ ì§€í•  ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ë´…ë‹ˆë‹¤. í•˜ì§€ë§Œ ì›ê°€ ì ˆê°ì—ì„œ ë” ë§ì€ ì—¬ë ¥ì´ ìˆìŠµë‹ˆë‹¤. ìŠ¤í¬ë©, ì§„ë¶€í™” ì¬ê³  ë¶€ë¶„ì—ì„œ ê¸°íšŒê°€ ìˆê³ , ì‹œê°„ì´ ì§€ë‚˜ë©´ì„œ ë„¤íŠ¸ì›Œí¬ë¥¼ ì§€ì†ì ìœ¼ë¡œ ìµœì í™”í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ëŸ° ì˜ì—­ë“¤ì—ì„œ ì¶”ê°€ì ì¸ ì›ê°€ ì ˆê° ê¸°íšŒê°€ ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. <br><br>ê·¸ë¦¬ê³  Robbie, ê³¼ê±°ì— ë‹¹ì‹ ì´ ì“´ ê¸€ì„ ì½ì–´ë´¤ëŠ”ë° ìš°ë¦¬ê°€ íŒë§¤ê´€ë¦¬ë¹„(SG&A)ì—ì„œ í•  ìˆ˜ ìˆëŠ” ê²Œ ë³„ë¡œ ì—†ë‹¤ê³  ìƒê°í•˜ì‹œëŠ” ê²ƒ ê°™ë˜ë°, ë” ìˆìŠµë‹ˆë‹¤. íšŒì‚¬ íŒë§¤ê´€ë¦¬ë¹„ ë¶€ë¶„ì—ì„œ ê°œì„ í•  ì—¬ì§€ê°€ ë” ë§ì´ ë‚¨ì•„ìˆê³ , ë°”ë¡œ ì´ ë¶€ë¶„ì—ì„œ íšŒì‚¬ì˜ ê·œëª¨ê°€ ìš°ë¦¬ì—ê²Œ ë„ì›€ì´ ë  ê²ƒì…ë‹ˆë‹¤. íšŒì‚¬ ì…ì¥ì—ì„œëŠ” ì‰½ì§€ ì•Šì€ ì¼ì´ì§€ë§Œ, ë¶„ëª…í•œ ê¸°íšŒê°€ ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì´ëŸ¬í•œ ì„±ì¥ ë™ë ¥ì— í•„ìš”í•œ ìê¸ˆì„ í™•ë³´í•˜ê¸° ìœ„í•´ í•„ìš”í•œ ëª¨ë“  ì¡°ì¹˜ë¥¼ ì·¨í•  ê²ƒì…ë‹ˆë‹¤. ì™œëƒí•˜ë©´ ì´ëŸ¬í•œ ë‹¤ì–‘í•œ ì„±ì¥ ë™ë ¥ì„ í†µí•´ í™˜ìë“¤ì—ê²Œì„œ ë‚˜íƒ€ë‚˜ëŠ” ê²°ê³¼ì™€ ì„ìƒì˜ë“¤ ë° ê·¸ë“¤ì˜ ìŠ¤íƒœí”„ë¡œë¶€í„° ë“£ëŠ” í”¼ë“œë°±, ê·¸ë“¤ì—ê²Œ ë¯¸ì¹˜ëŠ” ì˜í–¥ì„ ë³´ë©´, ì´ê²ƒì€ ìš°ë¦¬ íšŒì‚¬ê°€ ìˆ˜ì‹­ ë…„ ë™ì•ˆ ë³´ì§€ ëª»í–ˆë˜ í° ê¸°íšŒì´ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ë°˜ë“œì‹œ ì´ë¥¼ ì‹¤í˜„í•  ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  íŒë§¤ê´€ë¦¬ë¹„(SG&A)ì—ì„œë„ ì—¬ì „íˆ ê°œì„ í•  ì—¬ì§€ê°€ ìˆìŠµë‹ˆë‹¤. ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼ ë§¤ì¶œì›ê°€(COGS)ë„ ë§ˆì°¬ê°€ì§€ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Robert Marcus: JPMorgan Chase & Co, Research Division Great. That was a fantastic answer. Maybe just one quick follow-up. Geoff and Thierry, I know even since the beginning of this year, you've talked more and more about tuck-in M&A. How are you thinking about the environment today? Do you see a lot of opportunities? And any areas you see more interesting than others to help flesh out the portfolio?</td><td>**Robert Marcus:** ì •ë§ í›Œë¥­í•œ ë‹µë³€ì´ì—ˆìŠµë‹ˆë‹¤. í•œ ê°€ì§€ë§Œ ë¹ ë¥´ê²Œ ì¶”ê°€ ì§ˆë¬¸ë“œë¦¬ê² ìŠµë‹ˆë‹¤. Geoff, Thierry, ì˜¬í•´ ì´ˆë¶€í„° ë‘ ë¶„ê»˜ì„œ ì†Œê·œëª¨ ì¸ìˆ˜í•©ë³‘(tuck-in M&A)ì— ëŒ€í•´ ì ì  ë” ë§ì´ ì–¸ê¸‰í•˜ê³  ê³„ì‹  ê±¸ë¡œ ì•Œê³  ìˆìŠµë‹ˆë‹¤. í˜„ì¬ ì‹œì¥ í™˜ê²½ì„ ì–´ë–»ê²Œ ë³´ê³  ê³„ì‹ ê°€ìš”? ê¸°íšŒê°€ ë§ì´ ë³´ì´ì‹œë‚˜ìš”? ê·¸ë¦¬ê³  í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ë³´ì™„í•˜ëŠ” ë° ìˆì–´ ë‹¤ë¥¸ ë¶„ì•¼ë³´ë‹¤ ë” í¥ë¯¸ë¡œìš´ ì˜ì—­ì´ ìˆìœ¼ì‹ ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.</td></tr>
<tr><td>Geoffrey Martha: Chairman of the Board & CEO Yes. No, look, we're very focused on the tuck-in M&A. I don't want to tip our hat in terms of exact segments, but we definitely are prioritizing some of the -- again, it's tuck-in. We're prioritizing these higher-growth segments. A lot of that is in Cardiology, some in Neuroscience as well. We like that affair profile, right, where you're close to market or just you're on the market. Early stage or close to market would be ideal. Not afraid to make the investment that it takes to get those type of companies. But as Thierry said on your earlier question on like where is the R&D going, the tuck-in M&A, I wouldn't rule out some of our other key franchises that may need to augment their R&D with a little M&A. But we are more focused on these higher-growth segments. And then the Board committees we've set up help with the speed and enable us to move faster. So we'll see where it goes, but it's definitely a big focus.</td><td>**Geoffrey Martha:** ë„¤, ì €í¬ëŠ” ì†Œê·œëª¨ ì¸ìˆ˜í•©ë³‘ì— ë§¤ìš° ì§‘ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì •í™•í•œ ë¶€ë¬¸ì„ ë¯¸ë¦¬ ë°íˆê³  ì‹¶ì§€ëŠ” ì•Šì§€ë§Œ, í™•ì‹¤íˆ ê³ ì„±ì¥ ë¶€ë¬¸ë“¤ì— ìš°ì„ ìˆœìœ„ë¥¼ ë‘ê³  ìˆìŠµë‹ˆë‹¤. ë‹¤ì‹œ ë§ì”€ë“œë¦¬ì§€ë§Œ ì†Œê·œëª¨ ì¸ìˆ˜í•©ë³‘ì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ê³ ì„±ì¥ ë¶€ë¬¸ ì¤‘ ìƒë‹¹ ë¶€ë¶„ì€ ì‹¬ì¥í•™ ë¶„ì•¼ì´ê³ , ì¼ë¶€ëŠ” ì‹ ê²½ê³¼í•™ ë¶„ì•¼ì´ê¸°ë„ í•©ë‹ˆë‹¤. ì €í¬ëŠ” ì‹œì¥ ì¶œì‹œ ì§ì „ì´ê±°ë‚˜ ì´ë¯¸ ì‹œì¥ì— ë‚˜ì™€ ìˆëŠ” í”„ë¡œí•„ì„ ì„ í˜¸í•©ë‹ˆë‹¤. ì´ˆê¸° ë‹¨ê³„ì´ê±°ë‚˜ ì‹œì¥ ì¶œì‹œ ì§ì „ì´ ì´ìƒì ì´ì£ . ê·¸ëŸ° ìœ í˜•ì˜ ê¸°ì—…ë“¤ì„ í™•ë³´í•˜ëŠ” ë° í•„ìš”í•œ íˆ¬ìë¥¼ í•˜ëŠ” ê²ƒë„ ë‘ë ¤ì›Œí•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì•ì„œ R&D íˆ¬ì ë°©í–¥ì— ëŒ€í•œ ì§ˆë¬¸ì— Thierryê°€ ë‹µë³€í–ˆë“¯ì´, ì†Œê·œëª¨ ì¸ìˆ˜í•©ë³‘ê³¼ ê´€ë ¨í•´ì„œ R&Dë¥¼ ë³´ì™„í•˜ê¸° ìœ„í•´ ì•½ê°„ì˜ ì¸ìˆ˜í•©ë³‘ì´ í•„ìš”í•  ìˆ˜ ìˆëŠ” ë‹¤ë¥¸ í•µì‹¬ í”„ëœì°¨ì´ì¦ˆë“¤ë„ ë°°ì œí•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ê·¸ëŸ¬ë‚˜ ì €í¬ëŠ” ì´ëŸ¬í•œ ê³ ì„±ì¥ ë¶€ë¬¸ì— ë” ì§‘ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ìš°ë¦¬ê°€ êµ¬ì„±í•œ ì´ì‚¬íšŒ ìœ„ì›íšŒë“¤ì´ ì†ë„ë¥¼ ë†’ì´ê³  ë” ë¹ ë¥´ê²Œ ì›€ì§ì¼ ìˆ˜ ìˆë„ë¡ ì§€ì›í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì•ìœ¼ë¡œ ì–´ë–»ê²Œ ì§„í–‰ë ì§€ ì§€ì¼œë´ì•¼ê² ì§€ë§Œ, í™•ì‹¤íˆ í° ê´€ì‹¬ì‚¬ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Thierry Pieton: Executive VP & CFO One thing that we don't communicate a lot about it, but we've got a pretty active ventures arm, and that arm has been pretty active. So it's got over 50 companies in which we have a stake right now. And we like to use that arm to make investments in sort of early-stage companies, and it helps with some of the dilution, et cetera. Typically, we always make these venture investments with a view of going higher into the capital over time. So it's never venture for venture. And again, it's been -- the pipeline there is pretty strong, and we'll keep working that angle too, because it's helpful to feed the pipeline for future M&A.</td><td>**Thierry Pieton:** ì €í¬ê°€ ë§ì´ ì•Œë¦¬ì§€ëŠ” ì•Šì§€ë§Œ, ìƒë‹¹íˆ í™œë°œí•œ ë²¤ì²˜ íˆ¬ì ë¶€ë¬¸ì„ ìš´ì˜í•˜ê³  ìˆìŠµë‹ˆë‹¤. í˜„ì¬ 50ê°œê°€ ë„˜ëŠ” ê¸°ì—…ì— ì§€ë¶„ì„ ë³´ìœ í•˜ê³  ìˆê³ ìš”. ì´ ë¶€ë¬¸ì„ í†µí•´ ì´ˆê¸° ë‹¨ê³„ ê¸°ì—…ë“¤ì— íˆ¬ìí•˜ëŠ” ê²ƒì„ ì„ í˜¸í•˜ëŠ”ë°, ì´ê²ƒì´ ì§€ë¶„ í¬ì„ ë“±ì˜ ë¬¸ì œì—ë„ ë„ì›€ì´ ë©ë‹ˆë‹¤. ì¼ë°˜ì ìœ¼ë¡œ ì´ëŸ¬í•œ ë²¤ì²˜ íˆ¬ìë¥¼ í•  ë•ŒëŠ” í•­ìƒ ì‹œê°„ì´ ì§€ë‚˜ë©´ì„œ ë” í° ê·œëª¨ì˜ ìë³¸ì„ íˆ¬ì…í•  ê²ƒì„ ì—¼ë‘ì— ë‘ê³  ì§„í–‰í•©ë‹ˆë‹¤. ê·¸ëŸ¬ë‹ˆê¹Œ ë‹¨ìˆœíˆ ë²¤ì²˜ íˆ¬ìë¥¼ ìœ„í•œ ë²¤ì²˜ íˆ¬ìëŠ” ì ˆëŒ€ ì•„ë‹™ë‹ˆë‹¤. í˜„ì¬ íŒŒì´í”„ë¼ì¸ë„ ìƒë‹¹íˆ íƒ„íƒ„í•œ ìƒí™©ì´ê³ , ì´ ë°©í–¥ë„ ê³„ì† ì¶”ì§„í•  ì˜ˆì •ì…ë‹ˆë‹¤. í–¥í›„ M&A íŒŒì´í”„ë¼ì¸ì„ ì±„ìš°ëŠ” ë° í° ë„ì›€ì´ ë˜ê±°ë“ ìš”.</td></tr>
<tr><td>Geoffrey Martha: Chairman of the Board & CEO</td><td>**Geoffrey Martha:** <budget:token_budget>200000</budget:token_budget><br><br>I notice you've only provided a title "Chairman of the Board & CEO" without any actual spoken content to translate.<br><br>Could you please provide the full management response or Q&A content that needs to be translated? I'm ready to translate the actual dialogue or statement into natural, fluent Korean once you share it.</td></tr>
<tr><td>Ryan Weispfenning: VP & Head of Investor Relations Thank you, Robbie. Looking at the clock here. I think we've got time for about 3 more questions. So next, we'll go to the line of Larry Biegelsen at Wells Fargo Securities.</td><td>**Ryan Weispfenning:** ì‹œê°„ì„ ë³´ë‹ˆ ì•½ 3ê°œ ì§ˆë¬¸ ì •ë„ ë” ë°›ì„ ìˆ˜ ìˆì„ ê²ƒ ê°™ìŠµë‹ˆë‹¤. ë‹¤ìŒì€ Wells Fargo Securitiesì˜ Larry Biegelsen ë‹˜ ì§ˆë¬¸ ë°›ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Larry Biegelsen: Wells Fargo Securities, LLC, Research Division Congrats on a nice sprint here. So Geoff, I wanted to ask about the ramp of Ardian because as you said, it's a question of how fast. So I'm hoping you can add some precision to your earlier comments. I think at our conference in September, I asked if U.S. Ardian sales could replicate the U.S. WATCHMAN ramp, which was about $400 million in year 5. And I believe you said you'd be disappointed if your U.S. Ardian sales didn't achieve $400 million by, I believe, year 3. So how does the exclusion of isolated systolic hypertension and the NCD impact how you think about the ramp? And do you still believe you can achieve $400 million U.S. sales by around fiscal 2028, which I think would be year 3. And just confirm, Geoff, that the current run rate in the U.S. is about $50 million.</td><td>**Larry Biegelsen:** ì¢‹ì€ ì„±ê³¼ ì¶•í•˜ë“œë¦½ë‹ˆë‹¤. Geoff, Ardianì˜ ë¨í”„ì—…ì— ëŒ€í•´ ì—¬ì­¤ë³´ê³  ì‹¶ìŠµë‹ˆë‹¤. ë§ì”€í•˜ì‹  ê²ƒì²˜ëŸ¼ ì†ë„ì˜ ë¬¸ì œì¸ë°ìš”. ì´ì „ ì½”ë©˜íŠ¸ì— ì¢€ ë” êµ¬ì²´ì ì¸ ë‚´ìš©ì„ ì¶”ê°€í•´ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”? 9ì›” ì €í¬ ì»¨í¼ëŸ°ìŠ¤ì—ì„œ ë¯¸êµ­ Ardian ë§¤ì¶œì´ ë¯¸êµ­ WATCHMAN ë¨í”„ì—…ì„ ì¬í˜„í•  ìˆ˜ ìˆì„ì§€ ì—¬ì­¤ë´¤ì—ˆëŠ”ë°, WATCHMANì€ 5ë…„ì°¨ì— ì•½ 4ì–µ ë‹¬ëŸ¬ë¥¼ ë‹¬ì„±í–ˆì—ˆì£ . ê·¸ë•Œ Ardianì˜ ë¯¸êµ­ ë§¤ì¶œì´ 3ë…„ì°¨ê¹Œì§€ 4ì–µ ë‹¬ëŸ¬ë¥¼ ë‹¬ì„±í•˜ì§€ ëª»í•˜ë©´ ì‹¤ë§ìŠ¤ëŸ¬ìš¸ ê²ƒì´ë¼ê³  ë§ì”€í•˜ì‹  ê±¸ë¡œ ê¸°ì–µí•©ë‹ˆë‹¤. ê·¸ë ‡ë‹¤ë©´ ë‹¨ë… ìˆ˜ì¶•ê¸° ê³ í˜ˆì••(isolated systolic hypertension) ì œì™¸ì™€ NCDê°€ ë¨í”„ì—… ì „ë§ì— ì–´ë–¤ ì˜í–¥ì„ ë¯¸ì¹˜ëŠ”ì§€, ê·¸ë¦¬ê³  ì—¬ì „íˆ 2028 íšŒê³„ì—°ë„, ì¦‰ 3ë…„ì°¨ì¯¤ì— ë¯¸êµ­ ë§¤ì¶œ 4ì–µ ë‹¬ëŸ¬ ë‹¬ì„±ì´ ê°€ëŠ¥í•˜ë‹¤ê³  ë³´ì‹œëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì œí”„, í˜„ì¬ ë¯¸êµ­ ì‹œì¥ì˜ ëŸ°ë ˆì´íŠ¸(run rate)ê°€ ì•½ 5ì²œë§Œ ë‹¬ëŸ¬ ìˆ˜ì¤€ì´ë¼ëŠ” ì ì„ í™•ì¸í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤.</td></tr>
<tr><td>Geoffrey Martha: Chairman of the Board & CEO Well, look, let me start by saying, yes, I would be disappointed if we're at year 5 or whatever you said, at $400 million. We think it would go faster than that. And the final NCD won't hold us back. And like I said, we believe it's an improvement on the proposed NCD. Maybe this is a good time, because I know there was -- on that NCD, like I said, it's an improvement to the proposed NCD. And if you go back a year, it's better than what we thought a year ago. If you go back 5 years, and you asked us if we thought we would get this type of NCD, we'd say that's the best case scenario. So this market, like I said, is as big as we said it's going to be. And we believe that this final NCD, as you dig into and really understand how hypertension today is treated, it actually reduces the requirements for patients to get this therapy and it reduces the time. And maybe this is a good time that we have our Chief Scientific and Medical Officer on the line, knowing that there'd be -- Dr. Laura Mauri, who's also an interventional cardiologist, knowing that there'd be maybe some questions on this, on the treatment pathways. Maybe I'll ask Laura to comment since you mentioned that one systolic question -- or diastolic question. Laura, can you maybe provide some context here?</td><td>**Geoffrey Martha:** ë„¤, ì‹¤ë§ìŠ¤ëŸ¬ìš¸ ê²ƒ ê°™ìŠµë‹ˆë‹¤. ë§Œì•½ 5ë…„ì°¨ì— 4ì–µ ë‹¬ëŸ¬ ìˆ˜ì¤€ì´ë¼ë©´ ë§ì´ì£ . ìš°ë¦¬ëŠ” ê·¸ë³´ë‹¤ í›¨ì”¬ ë¹ ë¥´ê²Œ ì„±ì¥í•  ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ìµœì¢… NCDê°€ ìš°ë¦¬ì˜ ë°œëª©ì„ ì¡ì§€ëŠ” ì•Šì„ ê²ƒì…ë‹ˆë‹¤. ë§ì”€ë“œë ¸ë“¯ì´, ì´ë²ˆ ìµœì¢… NCDëŠ” ì œì•ˆëœ NCD ëŒ€ë¹„ ê°œì„ ëœ ë‚´ìš©ì´ë¼ê³  íŒë‹¨í•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ì´ NCDì— ëŒ€í•´ ì¢€ ë” ë§ì”€ë“œë¦¬ìë©´, ì œì•ˆëœ NCDë³´ë‹¤ ê°œì„ ë˜ì—ˆë‹¤ëŠ” ì ì„ ê°•ì¡°í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. 1ë…„ ì „ìœ¼ë¡œ ëŒì•„ê°€ ë³´ë©´, ë‹¹ì‹œ ìš°ë¦¬ê°€ ì˜ˆìƒí–ˆë˜ ê²ƒë³´ë‹¤ ë‚˜ì€ ê²°ê³¼ì…ë‹ˆë‹¤. 5ë…„ ì „ìœ¼ë¡œ ê±°ìŠ¬ëŸ¬ ì˜¬ë¼ê°€ì„œ, ë§Œì•½ ê·¸ë•Œ ìš°ë¦¬ê°€ ì´ëŸ° ìˆ˜ì¤€ì˜ NCDë¥¼ ë°›ì„ ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ìƒê°í•˜ëŠëƒê³  ë¬¼ì—ˆë‹¤ë©´, ìš°ë¦¬ëŠ” ê·¸ê²ƒì´ ìµœìƒì˜ ì‹œë‚˜ë¦¬ì˜¤ë¼ê³  ë‹µí–ˆì„ ê²ë‹ˆë‹¤.<br><br>ë”°ë¼ì„œ ì´ ì‹œì¥ì€ ìš°ë¦¬ê°€ ë§ì”€ë“œë¦° ëŒ€ë¡œ ê·¸ë§Œí¼ í° ê·œëª¨ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ë²ˆ ìµœì¢… NCDë¥¼ ìì„¸íˆ ì‚´í´ë³´ì‹œê³ , í˜„ì¬ ê³ í˜ˆì••ì´ ì–´ë–»ê²Œ ì¹˜ë£Œë˜ê³  ìˆëŠ”ì§€ ì‹¤ì œë¡œ ì´í•´í•˜ì‹œë©´, ì‚¬ì‹¤ í™˜ìë“¤ì´ ì´ ì¹˜ë£Œë¥¼ ë°›ê¸° ìœ„í•œ ìš”ê±´ì´ ì™„í™”ë˜ê³  ì†Œìš” ì‹œê°„ë„ ë‹¨ì¶•ëœë‹¤ëŠ” ê²ƒì„ ì•Œ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë§ˆì¹¨ ìš°ë¦¬ì˜ ìµœê³ ê³¼í•™ì˜ë£Œì±…ì„ì(Chief Scientific and Medical Officer)ì´ì ì¤‘ì¬ì‹¬ì¥ì „ë¬¸ì˜ì´ì‹  Laura Mauri ë°•ì‚¬ë‹˜ì´ í†µí™”ì— ì°¸ì—¬í•˜ê³  ê³„ì‹œëŠ”ë°ìš”, ì¹˜ë£Œ ê²½ë¡œì— ëŒ€í•œ ì§ˆë¬¸ë“¤ì´ ìˆì„ ê²ƒìœ¼ë¡œ ì˜ˆìƒí–ˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ë°©ê¸ˆ ìˆ˜ì¶•ê¸° ì§ˆë¬¸, ì•„ë‹ˆ ì´ì™„ê¸° ì§ˆë¬¸ì„ ì–¸ê¸‰í•˜ì…¨ìœ¼ë‹ˆ, Laura ë°•ì‚¬ë‹˜ê»˜ ì„¤ëª…ì„ ë¶€íƒë“œë¦¬ëŠ” ê²ƒì´ ì¢‹ì„ ê²ƒ ê°™ìŠµë‹ˆë‹¤. Laura ë°•ì‚¬ë‹˜, ì´ ë¶€ë¶„ì— ëŒ€í•´ ë°°ê²½ ì„¤ëª…ì„ ì¢€ í•´ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>Laura Mauri: Senior VP and Chief Scientific & Medical Officer Sure. Larry, specific to your question about isolated systolic hypertension, those are patients who don't have an elevation of their diastolic or the lower number of their blood pressure. It's only the top one. And Geoff said, we're continuing to study those patients. But I think the important thing to note is that this population is actually pretty small for us overall. If you look at recent studies, people with hypertension over age 60, it's less than 15% of patients who have ISH or this condition. And for patients who are younger than 60, who are half of our patients in trials and then also in practice, it's really very unusual. So as Geoff said, out the gate with the NCD, if you just look at that topic, we would estimate that it would be less than 10% that would be affected by isolated systolic hypertension or not meet those criteria. And then overall, just to reiterate what Geoff said is that the overall -- the final NCD makes access more practical for patients with less time delays to treatment, less restrictions. And the couple of things that they've talked about screening for are really things that are done in standard practice by general practitioners or internists. And I think the other part just to mention is that in their response, CMS really reiterated that quality of life is a really important consideration for patients, because lifestyle changes and being on many medications can be really difficult. And so they specifically said the good faith attempts are reasonable before referral rather than specifying some like mandatory minimum doses or a number of medications. So overall, whether it's ISH or overall, the workflow for patients to get into referral for Symplicity is really not restricted.</td><td>**Laura Mauri:** ê³ ë¦½ì„± ìˆ˜ì¶•ê¸° ê³ í˜ˆì••ì— ëŒ€í•œ ì§ˆë¬¸ ë§ì”€ì´ì‹œì£ . ì´ í™˜ìë“¤ì€ ì´ì™„ê¸° í˜ˆì••, ì¦‰ í˜ˆì••ì˜ ì•„ë˜ ìˆ˜ì¹˜ëŠ” ìƒìŠ¹í•˜ì§€ ì•Šê³  ìœ„ ìˆ˜ì¹˜ë§Œ ë†’ì€ ê²½ìš°ì…ë‹ˆë‹¤. Geoffê°€ ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼ ì´ í™˜ìêµ°ì— ëŒ€í•´ì„œëŠ” ê³„ì† ì—°êµ¬ë¥¼ ì§„í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì¤‘ìš”í•œ ì ì€ ì´ í™˜ìêµ°ì´ ì „ì²´ì ìœ¼ë¡œ ë³´ë©´ ì‹¤ì œë¡œ ìƒë‹¹íˆ ì‘ì€ ê·œëª¨ë¼ëŠ” ê²ƒì…ë‹ˆë‹¤. ìµœê·¼ ì—°êµ¬ë“¤ì„ ë³´ë©´ 60ì„¸ ì´ìƒ ê³ í˜ˆì•• í™˜ì ì¤‘ì—ì„œ ISH, ì¦‰ ì´ ì§ˆí™˜ì„ ê°€ì§„ í™˜ìëŠ” 15% ë¯¸ë§Œì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  60ì„¸ ë¯¸ë§Œ í™˜ìë“¤ì˜ ê²½ìš°, ì´ë“¤ì´ ì„ìƒì‹œí—˜ê³¼ ì‹¤ì œ ì§„ë£Œ í˜„ì¥ì—ì„œ ìš°ë¦¬ í™˜ìì˜ ì ˆë°˜ì„ ì°¨ì§€í•˜ëŠ”ë°, ì´ ì—°ë ¹ëŒ€ì—ì„œëŠ” ì •ë§ ë§¤ìš° ë“œë¬¸ ê²½ìš°ì…ë‹ˆë‹¤. ë¨¼ì € Geoffê°€ ë§í•œ NCD ê´€ë ¨ ë‚´ìš©ì„ ë³´ë©´, ë‹¨ìˆœíˆ ê·¸ ì£¼ì œë§Œ ë†“ê³  ë´¤ì„ ë•Œ ê³ ë¦½ì„± ìˆ˜ì¶•ê¸° ê³ í˜ˆì••(isolated systolic hypertension)ì˜ ì˜í–¥ì„ ë°›ê±°ë‚˜ í•´ë‹¹ ê¸°ì¤€ì„ ì¶©ì¡±í•˜ì§€ ëª»í•˜ëŠ” ê²½ìš°ê°€ 10% ë¯¸ë§Œì¼ ê²ƒìœ¼ë¡œ ì¶”ì •ë©ë‹ˆë‹¤. <br><br>ê·¸ë¦¬ê³  Geoffê°€ ë§í•œ ë‚´ìš©ì„ ë‹¤ì‹œ í•œë²ˆ ê°•ì¡°í•˜ìë©´, ìµœì¢… NCDëŠ” í™˜ìë“¤ì˜ ì ‘ê·¼ì„±ì„ ë”ìš± ì‹¤ìš©ì ìœ¼ë¡œ ë§Œë“¤ì–´ì¤ë‹ˆë‹¤. ì¹˜ë£Œê¹Œì§€ì˜ ì‹œê°„ ì§€ì—°ì´ ì¤„ì–´ë“¤ê³ , ì œì•½ ì‚¬í•­ë„ ì™„í™”ë©ë‹ˆë‹¤. CMSê°€ ì–¸ê¸‰í•œ ëª‡ ê°€ì§€ ì„ ë³„ê²€ì‚¬ í•­ëª©ë“¤ì€ ì‚¬ì‹¤ ì¼ë°˜ì˜ë‚˜ ë‚´ê³¼ ì „ë¬¸ì˜ë“¤ì´ í‘œì¤€ ì§„ë£Œì—ì„œ ì´ë¯¸ ì‹œí–‰í•˜ê³  ìˆëŠ” ê²ƒë“¤ì…ë‹ˆë‹¤. <br><br>ë˜ í•œ ê°€ì§€ ë§ë¶™ì´ìë©´, CMSëŠ” ë‹µë³€ì—ì„œ í™˜ìë“¤ì—ê²Œ ì‚¶ì˜ ì§ˆì´ ì •ë§ ì¤‘ìš”í•œ ê³ ë ¤ì‚¬í•­ì´ë¼ëŠ” ì ì„ ê±°ë“­ ê°•ì¡°í–ˆìŠµë‹ˆë‹¤. ìƒí™œìŠµê´€ ê°œì„ ê³¼ ì—¬ëŸ¬ ì•½ë¬¼ ë³µìš©ì´ í™˜ìë“¤ì—ê²Œ ìƒë‹¹íˆ ì–´ë ¤ìš¸ ìˆ˜ ìˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ë”°ë¼ì„œ êµ¬ì²´ì ìœ¼ë¡œ ëª…ì‹œëœ ë‚´ìš©ì€ ì˜ë¢° ì „ì— ì„ ì˜ì˜ ì‹œë„(good faith attempts)ê°€ í•©ë¦¬ì ì´ì–´ì•¼ í•œë‹¤ëŠ” ê²ƒì´ì§€, ìµœì†Œ ìš©ëŸ‰ì´ë‚˜ ì•½ë¬¼ ê°œìˆ˜ ê°™ì€ ê²ƒì„ ì˜ë¬´ì ìœ¼ë¡œ ì •í•œ ê²ƒì´ ì•„ë‹™ë‹ˆë‹¤. ê·¸ë˜ì„œ ì „ë°˜ì ìœ¼ë¡œ ISHë“  ì „ì²´ì ìœ¼ë¡œë“ , í™˜ìë“¤ì´ Symplicity ì˜ë¢°ë¥¼ ë°›ê¸° ìœ„í•œ ì›Œí¬í”Œë¡œìš°ëŠ” ì‹¤ì œë¡œ ì œí•œì ì´ì§€ ì•ŠìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Ryan Weispfenning: VP & Head of Investor Relations Next, we'll go to the line of Shagun Singh at RBC Capital Markets.</td><td>**Ryan Weispfenning:** <budget:token_used>21000</budget:token_used><br><br>ë‹¤ìŒì€ RBC Capital Marketsì˜ Shagun Singh ë‹˜ ì§ˆë¬¸ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Shagun Singh Chadha: RBC Capital Markets, Research Division Great. I wanted to touch on the financial algorithm. A key message was growth acceleration. How should we think about the base business? Is it mid-single digits? The $1 billion incremental PFA sales is about 300 basis points. And then RDN, I don't know if you could put a finer point there in terms of the growth contribution. But as you think about growth acceleration, should we think about Medtronic moving towards that high single digit on the top line? And then on portfolio management, I was just wondering how you're thinking about or should we expect portfolio pruning beyond Diabetes?</td><td>**Shagun Singh Chadha:** ì¢‹ìŠµë‹ˆë‹¤. ì¬ë¬´ ì•Œê³ ë¦¬ì¦˜ì— ëŒ€í•´ ì—¬ì­¤ë³´ê³  ì‹¶ìŠµë‹ˆë‹¤. í•µì‹¬ ë©”ì‹œì§€ê°€ ì„±ì¥ ê°€ì†í™”ì˜€ëŠ”ë°ìš”. ê¸°ë³¸ ì‚¬ì—…ì— ëŒ€í•´ì„œëŠ” ì–´ë–»ê²Œ ìƒê°í•´ì•¼ í• ê¹Œìš”? ì¤‘ê°„ í•œìë¦¿ìˆ˜ ì„±ì¥ë¥ ì¸ê°€ìš”? 10ì–µ ë‹¬ëŸ¬ì˜ ì¶”ê°€ PFA ë§¤ì¶œì€ ì•½ 300bp ì •ë„ ë˜ëŠ” ê²ƒ ê°™ê³ ìš”. ê·¸ë¦¬ê³  RDNì˜ ê²½ìš°, ì„±ì¥ ê¸°ì—¬ë„ì— ëŒ€í•´ ì¢€ ë” êµ¬ì²´ì ìœ¼ë¡œ ë§ì”€í•´ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”? ì„±ì¥ ê°€ì†í™”ë¥¼ ê³ ë ¤í•  ë•Œ, ë©”ë“œíŠ¸ë¡œë‹‰ì´ ë§¤ì¶œ ìµœìƒë‹¨ ê¸°ì¤€ìœ¼ë¡œ ë†’ì€ í•œìë¦¿ìˆ˜ ì„±ì¥ë¥ ë¡œ ë‚˜ì•„ê°ˆ ê²ƒìœ¼ë¡œ ë´ì•¼ í• ê¹Œìš”? ê·¸ë¦¬ê³  í¬íŠ¸í´ë¦¬ì˜¤ ê´€ë¦¬ ì¸¡ë©´ì—ì„œ, ë‹¹ë‡¨ë³‘ ì‚¬ì—… ì™¸ì— ì¶”ê°€ì ì¸ í¬íŠ¸í´ë¦¬ì˜¤ ì •ë¦¬ë¥¼ ì˜ˆìƒí•´ì•¼ í•˜ëŠ”ì§€, ì´ ë¶€ë¶„ì— ëŒ€í•´ ì–´ë–»ê²Œ ìƒê°í•˜ê³  ê³„ì‹ ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.</td></tr>
<tr><td>Geoffrey Martha: Chairman of the Board & CEO Shagun, thanks for the question. I'll start with the last part of it on the portfolio management. And look, this is an ongoing focus for the company. And it's really making sure that beyond Diabetes, right -- first of all, that deal is tracking and it's on track and going well. But beyond Diabetes, we just want to make sure that the whole portfolio fits together. We're getting the right amount of synergies, and we can provide the right amount of focus on these generational enterprise growth drivers like PFA, like Ardian, like Altaviva and Hugo when it comes to the U.S. and others. And so it's still -- it remains a focus, and it remains a focus of like one of the Board committees that we set up, and we're meeting frequently on this and looking at it. And that's what I'll say there. And then I'll have Thierry answer...</td><td>**Geoffrey Martha:** ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ë§ˆì§€ë§‰ ë¶€ë¶„ì¸ í¬íŠ¸í´ë¦¬ì˜¤ ê´€ë¦¬ë¶€í„° ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì´ê²ƒì€ íšŒì‚¬ì˜ ì§€ì†ì ì¸ ì¤‘ì  ê³¼ì œì…ë‹ˆë‹¤. ë¹„ìš˜ë“œ ë‹¤ì´ì–´ë¹„í‹°ìŠ¤(Beyond Diabetes) ê±´ì€ ì¼ë‹¨ ê³„íšëŒ€ë¡œ ì˜ ì§„í–‰ë˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ ì™¸ì—ë„ ì „ì²´ í¬íŠ¸í´ë¦¬ì˜¤ê°€ ì˜ ë§ë¬¼ë ¤ ëŒì•„ê°€ëŠ”ì§€, ì ì ˆí•œ ì‹œë„ˆì§€ë¥¼ ì°½ì¶œí•˜ê³  ìˆëŠ”ì§€ í™•ì¸í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  PFA, ì•„ë””ì•ˆ(Ardian), ì•Œíƒ€ë¹„ë°”(Altaviva), ë¯¸êµ­ ì‹œì¥ì˜ íœ´ê³ (Hugo) ê°™ì€ ì°¨ì„¸ëŒ€ ê¸°ì—… ì„±ì¥ ë™ë ¥ì— ì ì ˆí•œ ì§‘ì¤‘ì„ í•  ìˆ˜ ìˆë„ë¡ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ì—¬ì „íˆ ì¤‘ìš”í•œ ê³¼ì œì´ë©°, ì´ë¥¼ ìœ„í•´ ì„¤ë¦½í•œ ì´ì‚¬íšŒ ì‚°í•˜ ìœ„ì›íšŒ ì¤‘ í•˜ë‚˜ì˜ í•µì‹¬ ì•ˆê±´ìœ¼ë¡œ ë‚¨ì•„ ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì´ì— ëŒ€í•´ ìì£¼ íšŒì˜ë¥¼ í•˜ê³  ê²€í† í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì œê°€ ë§ì”€ë“œë¦´ ìˆ˜ ìˆëŠ” ë¶€ë¶„ì€ ì—¬ê¸°ê¹Œì§€ì…ë‹ˆë‹¤. ê·¸ëŸ¼ ì´ì œ Thierryê°€ ë‹µë³€í•˜ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤...</td></tr>
<tr><td>Thierry Pieton: Executive VP & CFO Yes. Look, overall, if you think about the guidance that we just gave, 5.5% on the full year, we were at 5.2% at the end of the first half, we're guiding at 5.5% in the third quarter. So you can do the math for what fourth quarter looks like, and we don't want to slow down from there. And look, what I would say is it's pretty clear that CAS represents a sizable opportunity. We reiterate the incremental $1 billion coming shortly, probably in the beginning of fiscal year '27 for us. And Ardian, we have all these discussions about the speed, et cetera, but I think it's important to keep in mind that 1% of market share in that population is sort of almost $3 billion of revenue for us. So it's a pretty significant opportunity. And we talked about the size of the Altaviva opportunity as well. It's 20 million patients overall. So those come in increment to the rest of the business, and the rest of the business is not standing still. So Specialty Therapies is getting better. You saw first sign in this quarter, and it's going to keep going with the product activity that we've got in Neurovascular with Altaviva and Pelvic. And the key franchises, look, CRM had a great quarter. It's going to continue to perform for the rest of the year and beyond. We're investing in that business to keep the technology lead. So we don't intend to go backwards. CST has been improving on the back of the AiBLE ecosystem that the team has created. So look, we're positive about the opportunities of the company going forward, and we'll keep you posted when we give next year's guidance at the end of Q4.</td><td>**Thierry Pieton:** ë„¤, ì „ì²´ì ìœ¼ë¡œ ë°©ê¸ˆ ì œì‹œí•œ ê°€ì´ë˜ìŠ¤ë¥¼ ë³´ì‹œë©´, ì—°ê°„ 5.5%ì´ê³  ìƒë°˜ê¸° ë§ 5.2%ì˜€ìœ¼ë©°, 3ë¶„ê¸°ëŠ” 5.5%ë¡œ ê°€ì´ë˜ìŠ¤ë¥¼ ì œì‹œí–ˆìŠµë‹ˆë‹¤. ê·¸ëŸ¬ë©´ 4ë¶„ê¸°ê°€ ì–´ë–»ê²Œ ë ì§€ ê³„ì‚°í•˜ì‹¤ ìˆ˜ ìˆì„ ê²ë‹ˆë‹¤. ê·¸ë¦¬ê³  ê±°ê¸°ì„œ ì†ë„ë¥¼ ëŠ¦ì¶œ ìƒê°ì€ ì—†ìŠµë‹ˆë‹¤. ì œê°€ ë§ì”€ë“œë¦¬ê³  ì‹¶ì€ ê²ƒì€, CASê°€ ìƒë‹¹í•œ ê¸°íšŒë¥¼ ë‚˜íƒ€ë‚¸ë‹¤ëŠ” ê²ƒì´ ë§¤ìš° ëª…í™•í•˜ë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ê³§ ì¶”ê°€ë¡œ 10ì–µ ë‹¬ëŸ¬ê°€ ë°œìƒí•  ê²ƒì´ë¼ëŠ” ì ì„ ì¬í™•ì¸í•˜ëŠ”ë°, ì•„ë§ˆë„ ìš°ë¦¬ íšŒê³„ì—°ë„ ê¸°ì¤€ 27ë…„ ì´ˆê°€ ë  ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  Ardian, ì†ë„ ë“±ì— ëŒ€í•´ ì—¬ëŸ¬ ë…¼ì˜ê°€ ìˆì§€ë§Œ, ì¤‘ìš”í•œ ì ì€ í•´ë‹¹ ì‹œì¥ì—ì„œ ì‹œì¥ì ìœ ìœ¨ 1%ê°€ ìš°ë¦¬ì—ê²Œ ê±°ì˜ 30ì–µ ë‹¬ëŸ¬ì˜ ë§¤ì¶œì„ ì˜ë¯¸í•œë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ë”°ë¼ì„œ ìƒë‹¹íˆ ì¤‘ìš”í•œ ê¸°íšŒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  Altaviva ê¸°íšŒì˜ ê·œëª¨ì— ëŒ€í•´ì„œë„ ë§ì”€ë“œë ¸ìŠµë‹ˆë‹¤. ì „ì²´ì ìœ¼ë¡œ 2ì²œë§Œ ëª…ì˜ í™˜ìê°€ ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ë‚˜ë¨¸ì§€ ì‚¬ì—…ì— ì¶”ê°€ë˜ëŠ” ê²ƒì´ê³ , ë‚˜ë¨¸ì§€ ì‚¬ì—…ë„ ì •ì²´ë˜ì–´ ìˆì§€ ì•ŠìŠµë‹ˆë‹¤. Specialty TherapiesëŠ” ë” ë‚˜ì•„ì§€ê³  ìˆìŠµë‹ˆë‹¤. ì´ë²ˆ ë¶„ê¸°ì— ì²« ë²ˆì§¸ ì‹ í˜¸ë¥¼ ë³´ì…¨ê³ , Altavivaì™€ Pelvicì„ í†µí•œ Neurovascular ì œí’ˆ í™œë™ìœ¼ë¡œ ê³„ì† ì„±ì¥í•  ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  í•µì‹¬ í”„ëœì°¨ì´ì¦ˆë¥¼ ë³´ë©´, CRMì´ í›Œë¥­í•œ ë¶„ê¸° ì‹¤ì ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì˜¬í•´ ë‚¨ì€ ê¸°ê°„ê³¼ ê·¸ ì´í›„ì—ë„ ê³„ì† ì¢‹ì€ ì„±ê³¼ë¥¼ ë‚¼ ê²ƒì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ê¸°ìˆ  ë¦¬ë”ì‹­ì„ ìœ ì§€í•˜ê¸° ìœ„í•´ ì´ ì‚¬ì—…ì— íˆ¬ìí•˜ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ í›„í‡´í•  ìƒê°ì´ ì—†ìŠµë‹ˆë‹¤. CSTëŠ” íŒ€ì´ êµ¬ì¶•í•œ AiBLE ìƒíƒœê³„ë¥¼ ê¸°ë°˜ìœ¼ë¡œ ê°œì„ ë˜ê³  ìˆìŠµë‹ˆë‹¤. íšŒì‚¬ì˜ í–¥í›„ ê¸°íšŒì— ëŒ€í•´ ê¸ì •ì ìœ¼ë¡œ ë³´ê³  ìˆìœ¼ë©°, 4ë¶„ê¸° ë§ì— ë‚´ë…„ ê°€ì´ë˜ìŠ¤ë¥¼ ë°œí‘œí•  ë•Œ ë‹¤ì‹œ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Ryan Weispfenning: VP & Head of Investor Relations Okay. Thank you, Shagun. We've got time for one more question, and I apologize to the analysts that we weren't able to get to. If you've got additional questions, feel free to reach out to me during the day. So we'll go to our last question, Pito Chickering from Deutsche Bank.</td><td>**Ryan Weispfenning:** ë„¤, ê°ì‚¬í•©ë‹ˆë‹¤, ìƒ¤êµ°. í•œ ê°€ì§€ ì§ˆë¬¸ì„ ë” ë°›ì„ ì‹œê°„ì´ ìˆìŠµë‹ˆë‹¤. ì§ˆë¬¸ì„ ë°›ì§€ ëª»í•œ ì• ë„ë¦¬ìŠ¤íŠ¸ ë¶„ë“¤ê»˜ëŠ” ì£„ì†¡í•©ë‹ˆë‹¤. ì¶”ê°€ ì§ˆë¬¸ì´ ìˆìœ¼ì‹œë©´ ì–¸ì œë“ ì§€ ë‚® ì‹œê°„ ë™ì•ˆ ì €ì—ê²Œ ì—°ë½ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤. ê·¸ëŸ¼ ë§ˆì§€ë§‰ ì§ˆë¬¸ìœ¼ë¡œ ë„ì´ì¹˜ë±…í¬ì˜ í”¼í†  ì¹˜ì»¤ë§ ë‹˜ê»˜ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Pito Chickering: Deutsche Bank AG, Research Division I have sort of 2 product questions, so I'll ask them upfront. The first one is, as AF ablations move into the ASC setting, can you talk about how you are positioned in ASC in terms of mappers and fair placements? And on TAVR, can you talk about what you saw in the U.S., Europe and Japan, and how market share is looking in those markets?</td><td>**Pito Chickering:** 2ê°€ì§€ ì œí’ˆ ê´€ë ¨ ì§ˆë¬¸ì„ ë¨¼ì € ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì²« ë²ˆì§¸ë¡œ, ì‹¬ë°©ì„¸ë™ ì ˆì œìˆ ì´ ì™¸ë˜ìˆ˜ìˆ ì„¼í„°(ASC)ë¡œ í™•ëŒ€ë˜ê³  ìˆëŠ”ë°, ë§¤í•‘ ì‹œìŠ¤í…œê³¼ í˜ì–´ ë°°ì¹˜ ì¸¡ë©´ì—ì„œ ê·€ì‚¬ì˜ ASC ë‚´ í¬ì§€ì…”ë‹ì— ëŒ€í•´ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ? ê·¸ë¦¬ê³  TAVR ê´€ë ¨í•´ì„œëŠ” ë¯¸êµ­, ìœ ëŸ½, ì¼ë³¸ì—ì„œì˜ ì‹¤ì ê³¼ í•´ë‹¹ ì‹œì¥ë“¤ì—ì„œì˜ ì‹œì¥ì ìœ ìœ¨ í˜„í™©ì— ëŒ€í•´ ì„¤ëª…í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤.</td></tr>
<tr><td>Geoffrey Martha: Chairman of the Board & CEO Well, thanks, Pito. Look, for PFA and ASCs, over time, we do see that as an incremental opportunity for market expansion there. There will be a bit of a shift outside of the tertiary centers to the ASCs over time, but it will also be a market expansion opportunity for us. It is a focus for us. We have been hiring across the company, quite frankly, particularly in Neuroscience and in Cardiovascular, folks that are specifically focused on market development in the ASCs for us and what our strategy is and how our product portfolio fits there and the resources we need, including mappers. So this definitely is in the calculus for Medtronic, not just our Cardiac Ablation business. Like I said, I think this will represent an incremental growth opportunity for us there. And then on TAVR, what I'll say is we had a decent Q2 here, growing high single digits on a global basis. Internationally, we're executing particularly well and getting more than our fair share of that Boston exit. As we move forward in PFA (sic) [ TAVR ], I think Q3, we may see a deceleration there.</td><td>**Geoffrey Martha:** ë„¤, ê°ì‚¬í•©ë‹ˆë‹¤, Pito. PFAì™€ ASC(ì™¸ë˜ìˆ˜ìˆ ì„¼í„°)ì˜ ê²½ìš°, ì‹œê°„ì´ ì§€ë‚˜ë©´ì„œ ì‹œì¥ í™•ëŒ€ë¥¼ ìœ„í•œ ì¶”ê°€ì ì¸ ê¸°íšŒë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. 3ì°¨ ì˜ë£Œê¸°ê´€ì—ì„œ ASCë¡œì˜ ì´ë™ì´ ì–´ëŠ ì •ë„ ìˆê² ì§€ë§Œ, ë™ì‹œì— ìš°ë¦¬ì—ê²ŒëŠ” ì‹œì¥ í™•ëŒ€ì˜ ê¸°íšŒì´ê¸°ë„ í•©ë‹ˆë‹¤. ì´ëŠ” ìš°ë¦¬ì˜ ì¤‘ì  ê³¼ì œì…ë‹ˆë‹¤. ì†”ì§íˆ ë§ì”€ë“œë¦¬ë©´, íšŒì‚¬ ì „ë°˜ì— ê±¸ì³, íŠ¹íˆ ì‹ ê²½ê³¼í•™ê³¼ ì‹¬í˜ˆê´€ ë¶„ì•¼ì—ì„œ ASC ì‹œì¥ ê°œë°œì— íŠ¹í™”ëœ ì¸ë ¥ì„ ì±„ìš©í•´ì™”ìŠµë‹ˆë‹¤. ASCì—ì„œì˜ ì „ëµ ìˆ˜ë¦½, ì œí’ˆ í¬íŠ¸í´ë¦¬ì˜¤ ì í•©ì„±, ë§¤í•‘ ì¥ë¹„ë¥¼ í¬í•¨í•œ í•„ìš” ìì› ë“±ì„ ë‹´ë‹¹í•  ì¸ë ¥ë“¤ì´ì£ . ë”°ë¼ì„œ ì´ëŠ” ì‹¬ì¥ ì ˆì œìˆ  ì‚¬ì—…ë¿ë§Œ ì•„ë‹ˆë¼ ë©”ë“œíŠ¸ë¡œë‹‰ ì „ì²´ì˜ ê³„íšì— í™•ì‹¤íˆ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼, ì´ëŠ” ìš°ë¦¬ì—ê²Œ ì ì§„ì ì¸ ì„±ì¥ ê¸°íšŒë¥¼ ì œê³µí•  ê²ƒìœ¼ë¡œ ìƒê°í•©ë‹ˆë‹¤. TAVRì˜ ê²½ìš°, 2ë¶„ê¸° ì‹¤ì ì´ ê´œì°®ì•˜ìŠµë‹ˆë‹¤. ê¸€ë¡œë²Œ ê¸°ì¤€ìœ¼ë¡œ ë†’ì€ í•œ ìë¦¿ìˆ˜ ì„±ì¥ë¥ ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. íŠ¹íˆ í•´ì™¸ì—ì„œ ìš°ìˆ˜í•œ ì„±ê³¼ë¥¼ ë‚´ê³  ìˆìœ¼ë©°, ë³´ìŠ¤í„´ ì‚¬ì´ì–¸í‹°í”½ì˜ ì‹œì¥ ì² ìˆ˜ë¡œ ì¸í•œ ê¸°íšŒë¥¼ ì¶©ë¶„íˆ í™œìš©í•˜ê³  ìˆìŠµë‹ˆë‹¤. TAVR ì‚¬ì—…ì„ ì§„í–‰í•˜ë©´ì„œ 3ë¶„ê¸°ì—ëŠ” ì„±ì¥ì„¸ê°€ ë‹¤ì†Œ ë‘”í™”ë  ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤.</td></tr>
<tr><td>Thierry Pieton: Executive VP & CFO</td><td>**Thierry Pieton:** <thinking><br>The user wants me to translate "Executive VP & CFO" but this appears to be just a title/header, not actual spoken content from an earnings call Q&A session. According to my instructions, I should:<br><br>1. NOT include speaker names in translation - only translate spoken content<br>2. This is just a title, not spoken content<br><br>Since this is only a title/position and not actual spoken content from a Q&A session, I should not provide a translation. However, the user may be testing me or may have accidentally only pasted the title. <br><br>I should clarify that I need the actual spoken content to translate, not just the speaker's title.<br></thinking><br><br>ì‹¤ì œ ë°œì–¸ ë‚´ìš©ì´ ì œê³µë˜ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤. "Executive VP & CFO"ëŠ” ì§ì±…ëª…ì¼ ë¿ì…ë‹ˆë‹¤. <br><br>ë²ˆì—­ì´ í•„ìš”í•œ ê²½ì˜ì§„ì˜ ì‹¤ì œ ë‹µë³€ ë‚´ìš©ì„ ì œê³µí•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤.</td></tr>
<tr><td>Geoffrey Martha: Chairman of the Board & CEO TAVR. What did I say?</td><td>**Geoffrey Martha:** <budget:token_budget>200000</budget:token_budget><br><br>ì´ì‚¬íšŒ ì˜ì¥ ê²¸ CEO TAVR. ì œê°€ ë­ë¼ê³  ë§ì”€ë“œë ¸ìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>Thierry Pieton: Executive VP & CFO</td><td>**Thierry Pieton:** <thinking><br>The user wants me to translate "Executive VP & CFO" but this appears to be just a title/header, not actual spoken content from an earnings call Q&A session. According to my instructions, I should:<br><br>1. NOT include speaker names in translation - only translate spoken content<br>2. This is just a title, not spoken content<br><br>Since this is only a title/position and not actual spoken content from a Q&A session, I should not provide a translation. However, the user may be testing me or may have accidentally only pasted the title. <br><br>Let me wait for the actual content to translate, or clarify that I need the actual spoken content to translate.<br></thinking><br><br>ì‹¤ì œ ë²ˆì—­í•  ë°œì–¸ ë‚´ìš©ì´ ì œê³µë˜ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤. "Executive VP & CFO"ëŠ” ì§í•¨ì¼ ë¿ì…ë‹ˆë‹¤. <br><br>ì–´ë‹ì½œ Q&A ì„¸ì…˜ì—ì„œ ê²½ì˜ì§„ì´ ì‹¤ì œë¡œ ë‹µë³€í•œ ë‚´ìš©ì„ ì œê³µí•´ ì£¼ì‹œë©´ ë²ˆì—­í•´ ë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Geoffrey Martha: Chairman of the Board & CEO PFA, I'm sorry. In TAVR, a little bit of a deceleration in Q3, but then it will pop back up in Q4. Due to a phasing, we've seen this in prior quarters as well. I don't know if you want to add anything to that?</td><td>**Geoffrey Martha:** <budget:token_budget>199950</budget:token_budget><br><br>ì£„ì†¡í•©ë‹ˆë‹¤. TAVRì˜ ê²½ìš° 3ë¶„ê¸°ì— ì•½ê°„ì˜ ë‘”í™”ê°€ ìˆì—ˆì§€ë§Œ, 4ë¶„ê¸°ì—ëŠ” ë‹¤ì‹œ íšŒë³µë  ê²ƒì…ë‹ˆë‹¤. ì´ëŠ” ì‹œê¸°ì  ìš”ì¸ ë•Œë¬¸ì´ë©°, ì´ì „ ë¶„ê¸°ë“¤ì—ì„œë„ ì´ëŸ° íŒ¨í„´ì„ ë³¸ ì ì´ ìˆìŠµë‹ˆë‹¤. ì¶”ê°€í•˜ì‹¤ ë‚´ìš©ì´ ìˆìœ¼ì‹ ê°€ìš”?</td></tr>
<tr><td>Thierry Pieton: Executive VP & CFO No, that's right. We saw the Q4, Q1 effect and Q2, Q3 looks kind of similar, a little bit slower in Q3, but with a pickup in the fourth quarter.</td><td>**Thierry Pieton:** <budget:token_budget>200000</budget:token_budget><br><br>ë„¤, ë§ìŠµë‹ˆë‹¤. 4ë¶„ê¸°ì™€ 1ë¶„ê¸°ì—ì„œ ê·¸ëŸ¬í•œ íš¨ê³¼ë¥¼ í™•ì¸í–ˆê³ , 2ë¶„ê¸°ì™€ 3ë¶„ê¸°ë„ ë¹„ìŠ·í•œ ì–‘ìƒì„ ë³´ì¼ ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. 3ë¶„ê¸°ëŠ” ë‹¤ì†Œ ë‘”í™”ë  ìˆ˜ ìˆì§€ë§Œ, 4ë¶„ê¸°ì—ëŠ” ë‹¤ì‹œ íšŒë³µì„¸ë¥¼ ë³´ì¼ ê²ƒìœ¼ë¡œ ì „ë§í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Geoffrey Martha: Chairman of the Board & CEO And just for clarity, PFA, will continue to grow off the 71% and it will accelerate in Q3 and beyond.</td><td>**Geoffrey Martha:** <budget:token_budget>200000</budget:token_budget><br><br>ëª…í™•íˆ ë§ì”€ë“œë¦¬ìë©´, PFAëŠ” 71%ë¥¼ ê¸°ë°˜ìœ¼ë¡œ ê³„ì† ì„±ì¥í•  ê²ƒì´ë©° 3ë¶„ê¸° ì´í›„ë¡œ ì„±ì¥ì´ ê°€ì†í™”ë  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Ryan Weispfenning: VP & Head of Investor Relations Thank you, Pito. Geoff, if you want to go ahead with your closing remarks?</td><td>**Ryan Weispfenning:** ê°ì‚¬í•©ë‹ˆë‹¤, í”¼í† . ì œí”„, ë§ˆë¬´ë¦¬ ë§ì”€ ë¶€íƒë“œë¦½ë‹ˆë‹¤.</td></tr>
<tr><td>Geoffrey Martha: Chairman of the Board & CEO Sure. So thank you for joining and all your thoughtful questions this morning. And like Ryan said, I apologize to the analysts we didn't get to. We certainly appreciate your support and your interest in Medtronic. Please join us again for our Q3 earnings broadcast for more updates, and there'll be more on our continued progress and on the long-term strategies. And we expect to hold this on Tuesday, February 17. And for those of you in the U.S., I wish you and your families a very happy Thanksgiving next week. I can't believe Thanksgiving is next week. With that, enjoy the rest of your day. Thank you.</td><td>**Geoffrey Martha:** ì˜¤ëŠ˜ ì°¸ì„í•´ ì£¼ì‹œê³  í†µì°°ë ¥ ìˆëŠ” ì§ˆë¬¸ë“¤ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. Ryanì´ ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼, ì§ˆë¬¸ ê¸°íšŒë¥¼ ë“œë¦¬ì§€ ëª»í•œ ì• ë„ë¦¬ìŠ¤íŠ¸ ë¶„ë“¤ê»˜ ì£„ì†¡í•˜ë‹¤ëŠ” ë§ì”€ ì „í•©ë‹ˆë‹¤. Medtronicì— ëŒ€í•œ ì—¬ëŸ¬ë¶„ì˜ ì§€ì§€ì™€ ê´€ì‹¬ì— ì§„ì‹¬ìœ¼ë¡œ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. 3ë¶„ê¸° ì‹¤ì  ë°œí‘œì—ë„ í•¨ê»˜í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤. ê·¸ë•Œ ì§€ì†ì ì¸ ì§„ì „ ìƒí™©ê³¼ ì¥ê¸° ì „ëµì— ëŒ€í•´ ë” ìì„¸íˆ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. 3ë¶„ê¸° ì‹¤ì  ë°œí‘œëŠ” 2ì›” 17ì¼ í™”ìš”ì¼ì— ì§„í–‰í•  ì˜ˆì •ì…ë‹ˆë‹¤. ë¯¸êµ­ì— ê³„ì‹  ë¶„ë“¤ê»˜ëŠ” ë‹¤ìŒ ì£¼ ì¶”ìˆ˜ê°ì‚¬ì ˆì— ê°€ì¡±ë“¤ê³¼ í–‰ë³µí•œ ì‹œê°„ ë³´ë‚´ì‹œê¸¸ ë°”ëë‹ˆë‹¤. ë²Œì¨ ì¶”ìˆ˜ê°ì‚¬ì ˆì´ ë‹¤ìŒ ì£¼ë¼ë‹ˆ ë¯¿ê¸°ì§€ ì•Šë„¤ìš”. ê·¸ëŸ¼ ë‚¨ì€ í•˜ë£¨ ì¦ê²ê²Œ ë³´ë‚´ì‹œê¸° ë°”ëë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;"># Medtronic ì‹¤ì  ë°œí‘œ ì£¼ìš” ìš”ì•½<br><br>**í•µì‹¬ ì¬ë¬´ ì§€í‘œ ë° ê°€ì´ë˜ìŠ¤**<br>- 2ë¶„ê¸° ì‹¤ì  ì–‘í˜¸: ì—°ê°„ ê°€ì´ë˜ìŠ¤ë¥¼ 5.5% ì„±ì¥ìœ¼ë¡œ ìƒí–¥ ì¡°ì • (ê¸°ì¡´ 5.2%)<br>- í•˜ë°˜ê¸° ë§¤ì¶œ ê°€ì†í™” ì „ë§: 3ë¶„ê¸° 5.5%, 4ë¶„ê¸°ëŠ” ë” ë†’ì€ ì„±ì¥ë¥  ì˜ˆìƒ<br>- ì˜ì—…ì´ìµë¥ : ê´€ì„¸ ì˜í–¥ ì œì™¸ ì‹œ ì†Œí­ ìƒìŠ¹, ê´€ì„¸ í¬í•¨ ì‹œ ì•½ 50bp í•˜ë½ ì „ë§. í•˜ë°˜ê¸° SG&A ë ˆë²„ë¦¬ì§€ ê°œì„  ì˜ˆìƒ<br>- ê´€ì„¸ ì˜í–¥: ì—°ê°„ ì•½ $185M ì˜ˆìƒ, ëŒ€ë¶€ë¶„ 3ë¶„ê¸°ì— ë°˜ì˜<br><br>**ì„±ì¥ ë™ë ¥ ë° ì „ëµ**<br>- **PFA(ì‹¬ë°©ì„¸ë™ ì¹˜ë£Œ)**: 2ë¶„ê¸° 71% ì„±ì¥, 3ë¶„ê¸° ì´í›„ ë”ìš± ê°€ì†í™” ì „ë§. í–¥í›„ ì•½ $10ì–µ ì¦ë¶„ ë§¤ì¶œ ê¸°ëŒ€ (FY27 ì´ˆ)<br>- **Symplicity(ê³ í˜ˆì•• ì¹˜ë£Œ)**: Medicare NCD ìµœì¢…ì•ˆì´ ì˜ˆìƒë³´ë‹¤ ìš°í˜¸ì . ë¯¼ê°„ë³´í—˜ì‚¬ë“¤ì˜ ì»¤ë²„ë¦¬ì§€ê°€ ì˜ˆìƒë³´ë‹¤ ë¹ ë¥´ê²Œ í™•ëŒ€ ì¤‘. ì‹œì¥ ê·œëª¨ëŠ” ì˜ˆìƒëŒ€ë¡œ ëŒ€í˜•ì´ë©°, ì†ë„ê°€ ê´€ê±´ (ë¶„ê¸° ë‹¨ìœ„ë¡œ ì¸¡ì •)<br>- **Altaviva(ê²½ë™ë§¥ ìŠ¤í…íŠ¸)**: ë¯¸êµ­ ìŠ¹ì¸ ì™„ë£Œ, ì˜ì‚¬ êµìœ¡ ìˆ˜ìš” í­ì£¼. í•˜ë°˜ê¸°ë¶€í„° ê¸°ì—¬ ì‹œì‘<br>- ì „ëµì  íˆ¬ì í™•ëŒ€: R&Dë¥¼ ë§¤ì¶œì˜ 10%ê¹Œì§€ ì¦ê°€ ëª©</p>
    <hr style="margin:50px 0;">
    
</body></html>